Drug Resistance in Cancer Cells
Kapil Mehta · Zahid H. Siddik Editors
Drug Resistance in Cancer Cells
Foreword by Susan E. Bates
123
Editors Kapil Mehta Department of Experimental Therapeutics M.D. Anderson Cancer Center University of Texas 1515 Holcombe Blvd. Houston TX 77030 USA
[email protected]
ISBN 978-0-387-89444-7 DOI 10.1007/978-0-387-89445-4
Zahid H. Siddik Department of Experimental Therapeutics M.D. Anderson Cancer Center University of Texas 1515 Holcombe Blvd. Houston TX 77030 USA
[email protected]
e-ISBN 978-0-387-89445-4
Library of Congress Control Number: 2009927661 c Springer Science+Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper springer.com
Foreword
It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosis and 565,650 individuals would die of cancer (Jemal et al. 2008). Since the vast majority of patients dying of cancer will have had anticancer therapy, both conventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of multidrug resistance is a worn out idea, stemming from disappointment with the drug resistance reversal strategies that were carried out in the 1990s using pump inhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger definition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence cannot be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original definition of multidrug resistance as simply the resistance to multiple agents that occurs in the course of normal cancer progression. This resistance is likely to be mediated by many factors. Figure 1 presents a schematic that is meant to represent the complexity of our current understanding of drug resistance. At this, the schematic is still an oversimplification. The multifactorial nature of drug resistance is unquestioned now, but there was a time when a major goal of cancer investigation was to identify a single mechanism of resistance. Today, we can think of drug resistance in two classes: target-specific and target-nonspecific. These are very closely aligned with the older terms: acquired and intrinsic. Target-specific mechanisms relate to the development of resistance mechanisms that are specific to the drug target. These resistance mechanisms are often acquired – whether due to a new event or to selection of pre-existing events. An example of this type of resistance is found in the subset of breast cancers demonstrating loss of estrogen receptor following emergence of tamoxifen resistance (Clarke et al. 2003). Another excellent example is the development of BcrAbl kinase domain mutations such as the T315I, which renders chronic myelogenous leukemia (CML) cells resistant to
v
vi
Foreword
Cellular Mechanisms of Drug Resistance: Too Numerous to Count?
Drug Uptake
RFC
Damage Repair
Drug
Drug Metabolism
R P1
hEN T
M
1 TR hC
CN T
Drug Target P GSH bcr-abl GSH P bcr-abl GST GS-Drug
MMR Proteins
OAT
Drug
Pgp
Topo-II Survival p53 Topo -I
2
AB CA 2
Glu-Drug
UGT Drug Drug
Metabolism
Tubulin
G2 ABC
Glu Glu
MRP
Drug Efflux
Fig. 1 Cellular mechanisms of drug resistance: too numerous to count? Six categories of resistance mechanisms are depicted: Drug Uptake, Drug Efflux, Drug Metabolism, Drug Target, Damage Repair, and Survival. The broken arrows indicate impaired drug binding to target such as might occur with an acquired mutation in Bcr-Abl, reduced levels of topoisomerase, or altered isotype composition in tubulin
imatinib (Gorre et al. 2001). Similarly, the T790M EGFR mutation renders NSCLC resistant to gefitinib (Pao et al. 2005). Turning to in vitro model systems, increased expression and a markedly increased phosphorylation of EGFR has been observed in trastuzumab resistant breast cancer cells (Ritter et al. 2007). The converse has also been demonstrated – upregulation of HER2 following suppression of EGFR with cetuximab suggests an alternate proliferative pathway for cancer maintenance (Wheeler et al. 2008). These target-specific mechanisms are difficult to predict in advance, and a single “fix” cannot be identified that would circumvent this type of resistance. Target-nonspecific mechanisms, on the other hand, are often intrinsic or constitutive – that is, they are present a priori and may be expropriated to promote drug resistance. They include those general mechanisms that were identified beginning in studies of resistance to “cytotoxic” agents, and they are often upregulated or preferentially selected after exposure to anticancer agents. These include p21-, p27-, or p53-induced cell cycle arrest; reduction in cell proliferation through cell adhesion signaling; upregulation of Bcl-2 or other pro-survival molecules; upregulation of enzymes that increase metabolic inactivation, such as glucuronidation or glutathione
Foreword
vii
conjugation; upregulation of drug efflux transporters; and downregulation of drug influx transporters (Mellor and Callaghan 2008). However, it would be a mistake to characterize every drug failure as drug resistance. Consider a clear and obvious example, the use of trastuzumab in HER2+ breast cancer. Early clinical trials in breast cancer demonstrated the activity of trastuzumab in the subset of patients whose cancers expressed high levels of HER2. Enrichment of patients with overexpressing cancers demonstrated a clinical benefit that may have been missed had the drug been developed in the entire patient population. The response rate in patients with breast cancer staining 2+ for HER2 was 6%, while it was 18% in patients with breast cancers staining 3+ for HER2 (Cobleigh et al. 1999). A later study suggested that immunohistochemical assessment incorrectly classified some of the patients. Among patients found to have cancers positive by fluorescence in situ hybridization (FISH), which documents amplification of HER2, responses were noted in 20%, relative to the absence of responses noted in FISH-negative tumors (Baselga 2001). Beyond the use of biomarkers to indicate that tumors are either HER2 positive or not, genomic analysis demonstrated that gene expression profiles can be used to cluster invasive breast cancers into six different subtypes, with HER2 positive tumors representing one distinct subtype (Sorlie et al. 2001). This suggests that there is not only HER2 overexpression but also that distinctive downstream signaling events result from activation of HER2. Tumors of this subtype are dependent on HER2 signaling for maintenance of the malignant phenotype. The remaining subtypes are equally distinctive but do not cluster with cells exhibiting HER2 overexpression. Do we then classify the cancers without HER2 expression as being “drug resistant?” In these tumors, the target is absent. Herceptin will not work in these tumors, and only confusion would result if investigators began to study mechanisms of resistance to Herceptin in such tumors. Thus, we need to be careful about defining a tumor as drug resistant. Are the 60–70% of renal cell cancers that do not achieve a partial remission with sunitinib drug resistant (Motzer et al. 2007)? Sorafenib, which at its FDA-approved dose appears to be a less potent TKI in comparison to sunitinib, achieves partial remissions in less than 10% of cases (Escudier et al. 2007). Are these tumors drug resistant? Similarly, gefitinib was found to be more tolerable than erlotinib, perhaps because a lower effective dose was selected for development (Lorusso 2003; Soulieres et al. 2004). As with the sorafenib/sutent pairing, it would be hard to argue that a tumor responding to erlotinib and not to gefitinib was indeed drug resistant. A strong argument could be made for a definition of drug resistance in the era of novel-targeted agents that requires presence of the target and effective drug concentrations. While an “effective drug concentration” may be related to a drug and its potency, another aspect that should be considered is interpatient variability in drug activation, absorption (for oral drugs), drug metabolism, and drug excretion. The expanding field of pharmacogenomics has already lent considerable insights into the potential impact of single nucleotide polymorphisms in altering drug clearance. As one example, tamoxifen is hydroxylated by cytochrome P450 (CYP) 2D6 to the potent
viii
Foreword
metabolites 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam). Carriers of CYP2D6 alleles with reduced enzyme activity metabolize tamoxifen more poorly and have lower levels of active metabolites. These alleles have been associated with a poorer outcome to tamoxifen therapy (Goetz et al. 2007). Inhibitors of CYP 2D6 have been shown to have similar effects. Together with the presence of other tamoxifen metabolizing pathways, these findings further increase the complexity of “personalized medicine”. Low drug concentrations due to impaired activation or low plasma levels due to rapid clearance generate pharmacologic drug resistance, a problem deserving intensive study in oncology. Trough levels of imatinib above 1002 ng/ml have been associated with better and deeper responses to treatment in CML (Picard et al. 2007). The genotypes involved in mediating differences in imatinib levels have not been worked out in detail, some have postulated a role for the multidrug transporter ABCB1. Similarly, a polymorphic variant in the multidrug transporter ABCG2 that results in impaired transport has been related to increased gefitinib levels and toxicity (Cusatis et al. 2006; Li et al. 2007). These studies to date have been carried out on a small scale, and the impact of this variant on efficacy is not known. However, it will not come as a great surprise to find greater efficacy in patients carrying the variant. Finally, just as in the early 1990s, an overly simplistic view of multidrug resistance led to numerous ill-conceived trials attempting to overcome drug resistance (see Sakacs et al. in this book), so it would be overly simplistic to now consider resistance to gefitinib or to imatinib or to any other targeted agent as due solely to a single mechanism (Engelman and Janne 2008). Rather, it will be important to evaluate tumor samples for multiple mechanisms of drug resistance. Just as the field has set as its goal personalized approaches to cancer therapy (hoping to avoid intrinsic drug resistance by selecting appropriate therapies at the start), so we should develop strategies to identify individual mechanisms, or sets of mechanisms, of drug resistance. Table 1 lists some examples of multiple mechanisms of drug resistance that have been identified in the setting of both traditional agents and novel targeted agents. This list for each drug is not exhaustive – rather the emphasis is on unique mechanisms that have been identified. General pro-survival mechanisms such as cell cycle arrest allowing time for repair of damage have not been included here. Since it will not be possible to clinically address every possible mechanism of drug resistance for a given agent, the personalized medicine of the future will need to order the resistance mechanisms in terms of importance. For example, the secondary BCR-ABL mutation T315I, which renders CML cells more than 20-fold resistant to imatinib, is all that is needed to provoke clinical imatinib failure (Apperley 2007). However, BcrAbl mutations that render CML cells only 2–3-fold resistant to imatinib will need to coexist with another mechanism of resistance, in order to provoke clinical failure. In medicine, we attempt to distill a group of patient symptoms into a single diagnosis, and skilled diagnosticians are prized. Yet, in considering drug resistance as a diagnosis, we must function in a counterintuitive fashion. The phenotype is simple –
Foreword
ix Table 1 Multiple mechanisms of drug resistance Imatinib in CML: BCR-ABL kinase domain mutation BCR-ABL gene amplification Interindividual variation: Trough levels <1000 ng/ml ABCB1/Pgp ABCG2/BCRP Tamoxifen in Breast Cancer: Estrogen Receptor loss Low Cytochrome 2A6 expression and failure to generate active metabolite Gefitinib in NSCLC: Lower potency Lack of activating EGFR mutation Secondary EGFR T790M mutation Increased PI3K pathway and downstream survival signaling MET amplification ABCG2/BCRP Cisplatin: Metallothionines Decreased uptake transporters Increased DNA repair Increased glutathione conjugation Doxorubicin: Decreased topoisomerase II levels Increased oxygen radical scavenging Increased glutathione conjugation Increased ABCB1/Pgp expression
the drug fails to provide clinical benefit. But the underlying pathways to drug resistance are manifold and complex and very likely dependent on cell context. Rather than having a form of “stage migration” as one newly identified drug resistance mechanism subverts another in our collective imaginations, it will be important to begin to catalogue them all and to determine how to identify those operating in a particular tumor type. This book is an effort to describe in one place the array of drug resistance mechanisms confronting clinical oncologists today. Susan E. Bates National Cancer Institute Bethesda, MD, USA
References Apperley, J. F. 2007. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8: 1116–1128. Baselga, J. 2001. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology. 61 Suppl 2: 14–21.
x
Foreword Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O’Brien, K., Wang, Y. and Hilakivi-Clarke, L. A. 2003. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 22: 7316–7339. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G. and Slamon, D. J. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639–2648. Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R. G., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M., Sparreboom, A. and Baker, S. D. 2006. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 98: 1739–1742. Engelman, J. A. and Janne, P. A. 2008. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14: 2895–2899. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R. and Bukowski, R. M. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356: 125–134. Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Weinshilboum, R. M., Fritcher, E. G., Nibbe, A. M., Desta, Z., Nguyen, A., Flockhart, D. A., Perez, E. A. and Ingle, J. N. 2007. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101: 113–121. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N. and Sawyers, C. L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293: 876–880. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M. J. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58: 71–96. Li, J., Cusatis, G., Brahmer, J., Sparreboom, A., Robey, R. W., Bates, S. E., Hidalgo, M. and Baker, S. D. 2007. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 6: 432–438. Lorusso, P. M. 2003. Phase I studies of ZD1839 in patients with common solid tumors. Semin. Oncol. 30: 21–29. Mellor, H. R. and Callaghan, R. 2008. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology. 81: 275–300. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M. and Figlin, R. A. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356: 115–124. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G. and Varmus, H. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2: e73. Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M. A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., Moore, N., Molimard, M. and Mahon, F. X. 2007. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 109: 3496–3499. Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A. and Arteaga, C. L. 2007. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13: 4909–4919. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O.,
Foreword
xi
Botstein, D., Eystein Lonning, P. and Borresen-Dale, A. L. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci., U S A. 98: 10869–10874. Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S. and Siu, L. L. 2004. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22: 77–85. Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V., Hsu, K. T. and Harari, P. M. 2008. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 27: 3944–3956.
Contents
1 Multidrug Resistance Mediated by MDR-ABC Transporters . . . . . . . . Gergely Szak´acs, Kenneth Kin Wah To, Orsolya Polg´ar, Robert W. Robey, and Susan E. Bates
1
2 Metastasis and Drug Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Dominic Fan, Sun-Jin Kim, Robert L. Langley, and Isaiah J. Fidler 3 The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 Tomohisa Yokoyama, Yasuko Kondo, Oliver B¨ogler, and Seiji Kondo 4 Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors . . . 73 Stacey J. Baker and E. Premkumar Reddy 5 Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 Kapil Mehta and Jansina Y. Fok 6 Extracellular Matrix-Mediated Drug Resistance . . . . . . . . . . . . . . . . . . . 115 P.S. Hodkinson and Tariq Sethi 7 Oxidative Stress and Drug Resistance in Cancer . . . . . . . . . . . . . . . . . . . 137 Dunyaporn Trachootham, Wan Zhang, and Peng Huang 8 Nuclear Factor-κB and Chemoresistance: How Intertwined Are They? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177 Ajaikumar B. Kunnumakkara, Preetha Anand, and Bharat B. Aggarwal 9 Drug Resistance and the Tumor Suppressor p53: The Paradox of Wild-Type Genotype in Chemorefractory Cancers . . . . . . . . . . . . . . . 209 Zahid H. Siddik xiii
xiv
Contents
10
Resistance to Differentiation Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233 Bulent Ozpolat
11
MicroRNAs and Drug Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257 Elisa Barbarotto and George A. Calin
12
Molecular Signatures of Drug Resistance . . . . . . . . . . . . . . . . . . . . . . . . . 271 Melissa A. Troester, Jason I. Herschkowitz, and Katherine A. Hoadley
13
Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295 Natalie Charnley, Catharine West, and Pat Price
14
Overcoming Drug Resistance by Phytochemicals . . . . . . . . . . . . . . . . . . . 315 Marion M. Chan and Dunne Fong
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
Contributors
Bharat B. Aggarwal Department of Experimental Therapeutics, Unit 0143, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Preetha Anand Department of Experimental Therapeutics, Unit 0143, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Stacey J. Baker Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, PA 19140, USA Elisa Barbarotto Department of Experimental Therapeutics–Unit 36, The University of Texas M. D. Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA Susan E. Bates National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA Oliver B¨ogler Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA George A. Calin Department of Experimental Therapeutics–Unit 36, The University of Texas M. D. Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA Marion M. Chan Department of Microbiology and Immunology, Temple University School of Medicine, 3400 North Broad Street, Philadelphia, PA 19140, USA Natalie Charnley Academic Department of Radiation Oncology, Christie Hospital, Withington, Manchester M20 4BX, UK Dominic Fan Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Isaiah J. Fidler Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
xv
xvi
Contributors
Jansina Y. Fok Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd. – Unit 362, Houston, TX 77030, USA Dunne Fong Department of Cell Biology and Neuroscience, Rutgers University, 604 Allison Road, Piscataway, NJ 08854, USA Jason I. Herschkowit Department of Cell Biology – Rosen, Baylor College of Medicine, Houston, TX 77030, USA Katherine A. Hoadley Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA P.S. Hodkinson Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK Peng Huang Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Sun-Jin Kim Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Seiji Kondo Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Yasuko Kondo Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Ajaikumar B. Kunnumakkara Department of Experimental Therapeutics, Unit 0143, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Robert L. Langley Department of Cancer Biology, Cancer Metastasis Research Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Kapil Mehta Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd. – Unit 362, Houston, TX 77030, USA Bulent Ozpolat Department of Experimental Therapeutics, Unit 422, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA Orsolya Polg´ar National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA Pat Price Academic Department of Radiation Oncology, Christie Hospital, Withington, Manchester M20 4BX, UK
Contributors
xvii
E. Premkumar Reddy Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, PA 19140, USA Robert W. Robey National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA Tariq Sethi Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK Zahid H. Siddik Department of Experimental Therapeutics – Unit 353, The University of Texas M. D. Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA Gergely Szak´acs Institute of Enzymology, Hungarian Academy of Sciences, H-1113 Budapest, Hungary Dunyaporn Trachootham Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Kenneth K. To Wah National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA Melissa A. Troester Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, USA Catharine West Academic Department of Radiation Oncology, Christie Hospital, Withington, Manchester M20 4BX, UK Tomohisa Yokoyama Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA Wan Zhang Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Chapter 1
Multidrug Resistance Mediated by MDR-ABC Transporters Gergely Szak´acs, Kenneth Kin Wah To, Orsolya Polg´ar, Robert W. Robey, and Susan E. Bates
Abstract Cancer cells are constantly being selected for survival and proliferation. During this process, tumor cells often co-opt basic physiological mechanisms to protect themselves from toxic chemotherapy. Of these mechanisms, the one that is most commonly encountered in laboratory studies is the increased cellular efflux of a broad class of cytotoxic drugs that is mediated by a family of energy-dependent transporters, known as ATP-binding cassette (ABC) proteins. Although 48 human ABC transporters have been described, only a handful are likely to be involved in drug resistance. These include P-glycoprotein (Pgp), the multidrug resistance associated protein (MRP), and the breast cancer resistance protein (BCRP), also termed ABCG2. In this chapter, we will provide an overview of the general structural and mechanistic features of the human ABC transporters thought to be involved in multidrug resistance in cancer cells. These transporters can no longer be understood only as candidate drug targets for overcoming multidrug resistance. Rather, these transporters are involved in multiple normal tissues in protection from drugs and xenobiotics. These include the blood brain barrier, oral bioavailability of drugs and xenobiotics through expression of transporters in the GI tract, drug disposition, and fetal protection through expression at the maternal–fetal barrier. We describe emerging information related to their potential role in drug and xenobiotic resistance and argue that studies of this drug resistance mechanism should continue in the laboratory and in the clinic. Keywords ABC transporter · P-glycoprotein · ABCG2 · Drug resistance · Drug transporters
S.E. Bates (B) Medical Oncology Branch, Bldg 10 Rm 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA e-mail:
[email protected]
K. Mehta, Z.H. Siddik (eds.), Drug Resistance in Cancer Cells, C Springer Science+Business Media, LLC 2009 DOI 10.1007/978-0-387-89445-4 1,
1
2
G. Szak´acs et al.
Introduction Cancer cells are constantly being selected for survival and proliferation. During this process, tumor cells often co-opt basic physiological mechanisms to protect themselves from toxic chemotherapy. Drug resistance can be the result of a variety of cellular and pharmacological mechanisms that are detailed in the chapters of this volume. Of these mechanisms, the one that is most commonly encountered in the laboratory is the increased efflux of a broad class of cytotoxic drugs that is mediated by a family of energy-dependent transporters, known as ATP-binding cassette (ABC) transporters. ABC transporters translocate a wide range of structurally unrelated compounds across biological membranes, including most of the routinely used agents of the current chemotherapy regimens. While several ABC transporters, particularly in the ABCC family, have been shown to transport certain drug substrates, three in particular have been studied for their role in drug disposition and in multidrug resistance. The three major multidrug resistance (MDR) proteins include members of the ABCB (ABCB1/MDR1/P-glycoprotein), the ABCC (ABCC1/MRP1), and the ABCG (ABCG2/MXR/BCRP) subfamilies. In this chapter, we will provide an overview of the general structural and mechanistic features of the human MDR-ABC transporters. We will also describe emerging information related to their potential role in drug and xenobiotic resistance and argue that studies of this drug resistance mechanism should continue in the laboratory and in the clinic.
Mechanistic Aspects of ABC Transporters ABC transporters are present in all living organisms from bacteria to humans and are of great importance to various cellular functions. Forty-eight ABC transporters are identified in the human genome, grouped into seven subfamilies (ABCA– ABCG) based on phylogenetic analysis (Dean et al. 2001). Several human ABC transporter genes have been associated with inheritable diseases, including cystic fibrosis (ABCC7), Dubin–Johnson syndrome (ABCC2), adrenoleukodystrophy (ABCD1), and sitosterolemia (ABCG5/ABCG8) (Borst and Elferink 2002). ABC transporters are large membrane-bound proteins built of two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs). The NBDs contain the conserved Walker A and B motifs, found in all ATP-binding proteins, as well as the C signature motif that distinguishes the superfamily from other ATPases. A subset of these ABC proteins has been shown to be drug transporters. The drug translocation pathway is formed by the transmembrane domains, which typically contain 12 (2×6) membrane-spanning alpha helices (TMs). This structural organization is either encoded in a single gene (a full transporter) in the case of P-glycoprotein (ABCB1) or MRP (ABCC1) or is achieved through the homo-, or heterodimerization of two half-transporters, containing a single TMD and NBD, in the case of the breast cancer resistance protein (ABCG2). Unfortunately, crystallization has, so far, not been accomplished for these transporters to a resolution sufficient for proper insight into how the pumps might actually
1 ABC Transporters in Drug Resistance
3
work. Crystallization of membrane-embedded proteins remains a very difficult task. Currently, crystal structures of approximately 160 transmembrane proteins ˚ while the number of available are available to a resolution greater than 4 A, structures for soluble proteins is in the thousands. There are seven ABC transporter structures solved, all found in bacteria (Locher et al. 2002, Dawson and Locher 2006, Hvorup et al. 2007, Hollenstein et al. 2007, Pinkett et al. 2007, Ward et al. 2007, Oldham et al. 2007). Of these, Sav1866 from Staphylococcus aureus likely resembles the most the three major human multidrug resistance transporters. Indeed, all three have already been modeled using the Sav1866 structure as a template and tested to some extent using data derived from mutagenesis (O’Mara and Tieleman 2007, DeGorter et al. 2008, Hazai and Bikadi 2008). As noted above, Pgp, MRP1, and ABCG2 have several common structural features; on the other hand, they differ significantly in some aspects. Pgp and MRP1 are so-called full transporters, composed of a tandem repeat of transmembrane and nucleotide-binding domains (TMD–NBD–TMD–NBD). ABCG2 has only one NBD and a single TMD, and it requires dimerization in order to be functional. There is compelling evidence supporting homodimerization of ABCG2 (Ozvegy et al. 2001, Henriksen et al. 2005, Kage et al. 2002). In addition to being a half-transporter, the domain organization of ABCG2 is reversed when compared to Pgp, MRP1, or Sav1866, with an N-terminal NBD and a C-terminal TMD. The importance of this reverse orientation, if any, has yet to be determined, nevertheless, it makes it even harder to predict the structure of ABCG2 in the absence of a crystal structure. In addition to a Pgp-like core, MRP1 has an extra transmembrane domain with five membrane-spanning alpha helices, termed TMD0 connected to TMD1 via an intracellular loop (L0 ), present in several other ABCC subfamily members. TMD0 could not be modeled based on Sav1866 which has only 12 TMs. Interestingly, deletion of TMD0 did not prevent the transport function and proper membrane localization of MRP1 (Bakos et al. 2000). However, certain mutations introduced to TMD0 had structural and functional consequences (Yang et al. 2002). There are no such striking differences between the ATP-binding sites of the three transporters, although the two sites demonstrate less symmetry in MRP1 than in Pgp. Upon binding and hydrolysis of ATP, conformational changes are presumed to occur that are transmitted to the TMDs, ultimately resulting in the translocation of the substrate from one side of the membrane to the other. Based on the observations from multiple bacterial NBD structures, the two ATP-binding sites are thought to form a “sandwich dimer”, in which the Walker A and B motifs from one subunit bind ATP together with the C signature sequence of the other subunit (Hollenstein et al. 2007)
MDR-ABC Transporters Based on a great deal of clinical and experimental work, it has been established that the MDR-ABC proteins recognize and transport a very wide range of drug substrates. This is relevant to their presumed normal role in human physiology in
4
G. Szak´acs et al.
regulating the GI absorption and normal tissue exposure of xenobiotics. Although recognized substrates are mostly hydrophobic compounds, MDR pumps can also extrude amphipathic anions and cations. As discussed in detail below, ABCB1 preferentially extrudes large hydrophobic molecules, while ABCC1 and ABCG2 can transport both hydrophobic drugs and large anionic compounds, e.g., drug conjugates. This “promiscuous” character and the additional overlapping substrate recognition by the three major classes of the MDR-ABC transporters provide an amazing network of drug resistance capacity in cancer cells (Sarkadi et al. 2006). These transporters were initially described in multidrug-resistant cancer cell lines (Juliano and Ling 1976, Cole et al. 1992, Doyle et al. 1998, Allikmets et al. 1998, Miyake et al. 1999); therefore, the first substrates identified were chemotherapeutic agents. Later, a wide variety of transported compounds unrelated to cancer therapy have been recognized, leading to an emerging role of these pumps in protection against xenobiotics and most recently in pharmacokinetics and pharmacogenomics. Although Pgp, the first of the three transporters, was identified more than 30 years ago, we have yet a long way to go before fully understanding the exact nature of their mechanism of action, and the role these pumps play in normal physiology and clinical multidrug resistance.
Transported Substrates The list of compounds transported by Pgp, MRP1, and ABCG2 is rapidly expanding and demonstrates significant overlaps. Many of the substrates are structurally dissimilar, while certain trends for favored compounds for each transporter can be established (Table 1.1) Pgp, similarly to ABCG2, preferentially transports large, hydrophobic, positively charged molecules. Its substrates include a wide variety of clinically relevant compounds, including anticancer drugs, human immunodeficiency virus (HIV)-protease inhibitors, immunosuppressive agents, antiarrhythmics, antihistamines, H-2 receptor blockers, antiemetics, steroids, cardiac glycosides, antibiotics, antihelmintics, antidepressants, antiepileptics, and analgesics. Among the chemotherapeutic agents transported by Pgp are anthracyclines (daunorubicin, doxorubicin, epirubicin), anthracenes (bisantrene, mitoxantrone), vinca alkaloids (vinblastine, vincristine, vinorelbine, vindesine), camptothecins (topotecan), taxanes (paclitaxel, docetaxel), and epipodophyllotoxins (etoposide, teniposide). Steroid hormones, phospholipids, and cytokines are among the potential physiological substrates of Pgp. Besides effluxing mostly neutral hydrophobic compounds, MRP1 is capable of transporting organic anions, such as molecules conjugated to glutathione (GSH), glucuronate, and sulfate. Among these conjugates are the compounds considered as endogenous substrates of the protein, e.g., GSH conjugates of leukotriene C4, leukotriene D4, leukotriene E4, prostaglandin A2, glucoronide conjugates of estradiol, and sulfate conjugates of estrone and dehydroepiandrosterone. Interestingly, GSH itself is a substrate for the pump. MRP1 also transports drugs currently used in the clinic, such as HIV-protease inhibitors,
1 ABC Transporters in Drug Resistance
5
ABCG2
ABCC1
ABCB1
Table 1.1 Clinically relevant substrates of the MDR-ABC transporters (Szakacs et al. 2006)
Vinblastine Vincristine Daunorubicin Anthracyclines Doxorubicin Epirubicin Epipodophyllotoxins Etoposide Teniposide Docetaxel Taxanes Paclitaxel Gleevec Kinase inhibitors Flavopiridol Irinotecan (CPT-11) Campthotecins SN-38 Topotecan 6-Mercaptopurine Thiopurines 6-Thioguanine 5-FU Bisantrene Other Cisplatin Arsenite Colchicine Estramustine Methotrexate Mitoxantrone Saquinivir PMEA Actinomycin-D AZT Digoxin Vinca alkaloids
antibiotics, antiandrogens, and chemotherapeutic agents. The latter group includes anthracyclines (doxorubicin, daunorubicin), vinca alkaloids (vinblastine, vincristine), epipodophyllotoxins (etoposide, teniposide), camptothecins (topotecan, irinotecan), and methotrexate (Bakos and Homolya 2007). The manner in which MRP1 handles its substrates is rather complex. Transport of certain hydrophobic compounds, such as vincristine, was shown to be stimulated by GSH. In addition, vincristine transport was suggested to be dependent on physiological concentrations of GSH (Loe et al. 1998). These observations have led to the assumption that the two molecules are cotransported, but the question is complicated by the fact that efflux of some compounds, such as daunorubicin, is stimulated by GSH, while they themselves have no effect on GSH transport (Renes et al. 1999). In contrast, verapamil, which is not a substrate of MRP1, stimulates GSH transport. Cotransport could be envisioned with
6
G. Szak´acs et al.
two separate substrate-binding sites or with a single larger site that can accommodate the two molecules at the same time. The existence of an allosteric site that modulates the affinity of the substrate site is also possible. A third possibility is that some compounds alter the membrane environment which in turn has an effect on the affinity for certain substrates (Borst et al. 2006). Of the three multidrug resistance transporters, ABCG2 is the most recently described, nevertheless, it also has a long list of established substrates comparable to that of Pgp and MRP1. ABCG2, as mentioned above, primarily transports large, hydrophobic, positively charged molecules, among which are flavonoids, porphyrins, antibiotics, HMG-CoA reductase inhibitors, antivirals, H-2 receptor blockers, antihypertensive agents, vitamins, and folic acid. A substantial number of chemotherapeutic agents are also effluxed by ABCG2, including mitoxantrone, flavopiridol, campthotecins (e.g., topotecan, irinotecan, SN-38), indolocarbazoles, antifolates, tyrosine kinase inhibitors (e.g., imatinib, gefitinib, erlotonib, nelotinib). Besides the anticancer and other clinically important drugs, it is worth mentioning that several fluorescent compounds are transported by Pgp, MRP1, and ABCG2, such as Hoechst 33342 (Pgp, ABCG2), rhodamine 123 (Pgp), calcein (MRP1), calcein-AM (Pgp). These molecules proved to be excellent tools in studying these transporters in the laboratory.
Gene Regulation P-glycoprotein is constitutively expressed in many normal tissues including the adrenal gland, liver, kidney, intestinal mucosa, muscle, and the endothelial cells of the blood–brain barrier and blood–testes barrier (Cordon-Cardo et al. 1990). The human MDR1 gene is located on chromosome 7, band p21–21.1, and it extends over more than 100 kb containing 28 exons. The transcriptional regulation of MDR1 has been extensively studied. The MDR1 gene, as is true for all of the human multidrug transporters examined to date, has a “TATA-less” promoter. Activation of MDR1 occurs rapidly in response to a variety of cellular stresses and stimuli ranging from DNA injury to serum starvation, linking Pgp to a general anti-apoptotic mechanism. Interestingly, signals from these stimuli were shown to converge on a common region of the MDR1 promoter referred to as the “MDR1 enhanceosome” (Jin and Scotto 1998). This region contains an inverted CCAAT and a GC-rich element, which serve as binding sites for the trimeric transcription factor NF-Y and the Sp family of GC-binding transcription factors. Upon DNA binding, these transcription factors recruit histone-acetyl transferase PCAF to the MDR1 promoter, resulting in regional histone modification followed by further chromatin remodeling and subsequent gene activation (Hu et al. 2000). In addition, the MDR1 promoter has been reported as susceptible to mulitple other regulatory mechanisms: the orphan nuclear receptor (SXR/PXR), steroid receptor, and the xenobiotic receptor may directly bind and activate the promoter (Cerveny et al. 2007, Song et al. 2004, Synold et al. 2001). Similarly, HIF-1α activates the MDR1 promoter through a
1 ABC Transporters in Drug Resistance
7
consensus-binding sequence (5’-GCGTG-3’) (Comerford et al. 2002). GC-binding protein Sp1 may be involved in the hypoxic response. Mutant p53 proteins have been shown to transactivate the MDR1 promoter (Sampath et al. 2001). It has been shown that random chromosomal rearrangements could trap MDR1 in close proximity to a constitutively active heterologous promoter, resulting in aberrant activation of the MDR1 gene in drug-resistant cell lines and in a subset of drug refractory acute lymphocytic leukemias (Huff et al. 2006). MDR1 expression can also be regulated at the epigenetic level. Methylation of the MDR1 promoter has been shown to silence basal MDR1 expression in cell line models and clinical samples (El-Osta et al. 2002, Harikrishnan et al. 2005). It has been suggested that the upregulation of MDR1 expression in cancer cells following chemotherapy treatment may in some settings be attributable to a loss of MDR1 promoter methylation (Nakayama et al. 1998, Tada et al. 2000). In related studies, drug-induced upregulation of MDR1 was associated with increase in histone H3 acteylation and induction of methylated H3K4 within discrete regions of the MDR1 locus (Baker et al. 2005). More recently, the posttranscriptional regulation of MDR1 has been reported. In a drug-resistant variant of K562 cells, the presence of an additional 5’ untranslated fragment in the MDR1 mRNA was shown to greatly improve the translational efficiency of the mRNA, leading to overexpression of Pgp (GomezMartinez et al. 2007). Another study demonstrated that two microRNAs miR-27a and miR-451 are involved in the activation of MDR1 expression and the multidrugresistance phenotype (Zhu et al. 2008). MicroRNAs are known to have the ability to reduce protein expression by causing translational inhibition or degradation of the target mRNA. The effects of the microRNAs appear to be indirect and are likely mediated through inhibiting expression of some transcriptional factors involved in suppressing MDR1 activation. The human MRP1 gene maps to chromosome 16p13.11–p13.12 and comprises 31 exons, spanning 200 kb. MRP1 was found to be amplified in various anti-tumor drug-resistant cell lines (Cole et al. 1992, Paul et al. 1996), but its increased transcription can also occur without gene amplification. The basal promoter activity was localized to a GC-rich region of the MRP1 gene between nucleotides –91 to +103. The binding of Sp1 to some putative binding sites in this GC-rich region was shown to be important for optimal MRP1 transcriptional activity (Zhu and Center 1994, 1996). Although the MRP1 promoter does not contain a p53 consensus sequence, it has been shown that wild type p53 may repress MRP1 by reducing the binding of Sp1 (Wang and Beck 1998). A putative AP1 site at the MRP1 promoter that can be bound by a complex containing c-jun and junD is also important for MRP1 transcription (Kurz et al. 2001). Decreased expression of MRP1 has been reported in cells transfected with mutant c-jun (Cripe et al. 2002). ABCG2 is constitutively expressed in many normal tissues, including liver, placenta, brain, hematopoietic stem cells, and putatively other types of stem cells. The human ABCG2 gene is located on chromosome 4q21–4q22, and it extends over 66 kb, containing 16 exons and 15 introns. The molecular mechanisms regulating ABCG2 expression are not well understood. The ABCG2 promoter lacks a consensus TATA box found on many protein-encoding genes and instead contains numerous
8
G. Szak´acs et al.
Sp1, AP1, AP2 sites and a CCAAT box, presumably important for initiation of transcription. A basal ABCG2 promoter has been identified at about 312 bp directly upstream from the transcriptional start site (Bailey-Dell et al. 2001). ABCG2 has a putative CpG island located within its promoter. To date, most studies examining the regulation of ABCG2 under physiological conditions are focused at the transcriptional level. Two functional cis elements in the ABCG2 promoter, namely the estrogen and hypoxia (Krishnamurthy et al. 2004) response elements, and a peroxisome proliferator-activated receptor γ (PPARγ ) response element, upstream of the ABCG2 gene (Szatmari et al. 2006), have been identified and validated by electrophoretic mobility shift analysis. Ebert and colleagues proposed that aryl hydrocarbon receptor (AhR) upregulates ABCG2 expression, but the responsive element has not been identified (Ebert et al. 2005). Conflicting data have been reported for the effect of the sex hormones estrogen, progesterone, and testosterone on ABCG2 expression (Imai et al. 2005, Yasuda et al. 2005). In particular, the effect of estradiol on the ABCG2 expression appears cell dependent and controversial (Imai et al. 2005). ABCG2 expression is upregulated in the mammary gland during lactation (Jonker et al. 2005). Overexpression of the ABCG2 gene is frequently observed in cancer cell lines selected with a number of chemotherapeutic drugs (Doyle et al. 1998, Maliepaard et al. 1999, Miyake et al. 1999, Robey et al. 2001, Volk et al. 2002). Gene amplification and chromosome translocation have been shown to play a role for the increased expression of ABCG2 (Knutsen et al. 2000). The use of alternative 5’ promoters at the ABCG2 gene due to differential expression of splice variants at the 5’-untranslated region (5’UTR) of ABCG2 mRNA in drug-selected cells may offer another novel mechanism of ABCG2 upregulation (Nakanishi et al. 2006), a finding similar to observations in MDR-1 where rearrangement of the 5’ region of MDR-1 resulted in capture of that gene by another promoter (Huff et al. 2005). ABCG2 has been shown to be under control of a number of epigenetic mechanisms. DNA methylation can repress ABCG2 expression in human renal carcinoma (To et al. 2006) and multiple myleoma cell lines (Turner et al. 2006). Recently, we reported that overexpression of ABCG2 in resistant cells was correlated with increased binding of a set of permissive histone modification marks, RNA polymerase II, and a chromatin remodeling factor Brg-1, but decreased association of a repressive histone mark, class I HDACs and Sp1 with the proximal ABCG2 promoter (To et al. 2008). Enhanced mRNA stability and protein translation are also involved in the overexpression of ABCG2 in drug-resistant cancer cells. ABCG2 mRNA is less stable in a number of sensitive parental cancer cell lines than in their drug-selected and ABCG2-overexpressed resistant counterparts (To et al. 2008). Interestingly, the 3’-untranslated region (3’UTR) of the ABCG2 mRNA was found to be longer in the parental cells than in the resistant cells. We identified a microRNA binding site (hsa-miR-519c), in the portion of 3’UTR missing from ABCG2 mRNA in the resistant cells. In resistant S1M180 cells, hsa-miR519c cannot bind to ABCG2 mRNA because of the shorter 3’UTR and thus mRNA
1 ABC Transporters in Drug Resistance
9
degradation and/or repression on protein translation are relieved, contributing to overexpression of ABCG2 (To et al. 2008) .
Significance of MDR-ABC Transporters in Cancer Effective treatment of metastatic cancer requires the use of toxic chemotherapy. In most cases, multiple drugs are used, since resistance to single agents occurs almost universally. In vitro, the three MDR-ABC transporters efflux a broad range of chemotherapeutics used clinically for first- and second-line treatment of cancer. In that setting, inhibitors can sensitize drug-resistant cell lines to known substrates (see Table 1.2), yet despite the wealth of information collected in the laboratories, translation of this knowledge from the bench to the bedside has proved to be unexpectedly difficult. The clinical relevance of Pgp is proven by correlative studies evaluating the effect of Pgp expression on patient survival. It remains to be seen whether clinical trials designed to evaluate transporter inhibition will translate into improved patient survival.
1st generation
2nd generation
3rd generation
Other
Amiodarone Cyclosporin A Quinidine Quinine Verapamil Nifedipine Dexniguldipine PSC833 VX-710 (Biricodar) GF120918 (Elacridar) LY475776 LY335979 (Zosuquidar) XR-9576 (Tariquidar) V-104 R101933 (Laniquidar) Disulfiram CBT-1 Flavonoids FTC Progesteron MK571 Pluronic L61 Campothecin
ABCG2
ABCC1
ABCB1
Table 1.2 Inhibitors of MDR-ABC transporters (Adapted from, Szakacs et al. 2006)
10
G. Szak´acs et al.
Association of MDR-ABC Transporters with Treatment Failure Anticancer drugs fail to kill cancer cells for a variety of reasons. To discern the contribution of individual factors, systemic studies using large cohorts of patients must be performed. To prove the association of a biomarker with poor prognosis, the studies must be evaluated in a strictly standardized fashion. Unfortunately, the scientific community working on MDR-ABC transporters has failed to define and embrace universally accepted guidelines for clinical validation. To date, differences in assay protocols result in confusing data that are often impossible to compare across institutions. As a result, the role of ABC transporters in clinical anticancer resistance has been difficult to assess. Evidence linking Pgp expression with poor clinical outcome is conclusive for breast cancer, sarcoma, and certain types of leukemia, suggesting that Pgp contributes to treatment failure of these malignancies (Szakacs et al. 2006). Importantly, over one-third of leukemic samples are found positive for Pgp expression. Pgp expression in patients with acute myelogenous leukemia (AML) has consistently been associated with reduced chemotherapy response rates and poor survival, and it was found to be an independent prognostic variable for induction failure in adult AML (Pallis and Russell 2004, van der Holt et al. 2005). The prognostic significance of the other two MDR-ABC transporters in clinical MDR is still unknown. MRP1 is not a significant factor in drug resistance in AML (Leith et al. 1999), and its prognostic implication in chronic lymphocytic and promyelocytic leukemia, non-small cell lung cancer (NSCLC), and breast cancer remains controversial (Michieli et al. 2000, Linenberger 2005, Filipits et al. 2005). Even less is known clinically about ABCG2, as most of the studies have been performed on drug-selected cell lines. According to the analysis of blast cells from acute leukemia patients, higher ABCG2 expression is associated with poor response to chemotherapy (Benderra et al. 2004, Steinbach et al. 2002, Suvannasankha et al. 2004, Suvannasankha, Minderman et al. 2004, Uggla et al. 2005). Like adult stem cells, cancer stem cells express high levels of ABC transporters, including Pgp and ABCG2. According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drugresistant tumor relapse (Dean et al. 2005).
Overcoming MDR with Inhibitors The activity of MDR-ABC transporters can be readily inhibited by a plethora of compounds (see Table 1.2). Due to the promiscuity of the transporters, it has been relatively easy to find high affinity substrates that block transport. In vitro, sensitization of resistant cells is achievable through the prevention of the efflux of cytotoxic drugs (Dano 1973), suggesting that inhibitors would prove effective in a therapeutic setting (Tsuruo et al. 1981). Emerging data from knockout mice studies (loss of mdr1a and mdr1b does not result in an obvious phenotype) were also
1 ABC Transporters in Drug Resistance
11
interpreted to suggest that pharmacological modulation of human Pgp is a feasible strategy to treat multidrug-resistant cancer. Over the years, the pharmaceutical industry has invested considerably into clinical trials. The first phase I and II clinical trials tested the clinical potential of “first-generation” Pgp inhibitors, including verapamil, quinine, and cyclosporine A, which were already FDA approved for other medical purposes. In general, these compounds were ineffective or toxic at the doses required to attenuate Pgp function. Accordingly, most of the trials conducted with first-generation inhibitors failed to show improvement of the outcome, and toxic side effects were common (see Table 1.3) (Daenen et al. 2004). Thus, the ultimate goal of the trials was not met, and it became evident that inhibition of ABC transporters had far-reaching pharmacokinetic consequences influencing drug clearance and metabolism. Despite these failures, the few positive outcomes suggested that successful Pgp modulation is feasible (Wattel et al. 1999). The hope of conquering MDR through the inhibition of ABC transporter-mediated drug efflux encouraged further development of second-generation inhibitors. Much interest was focused on cyclosporine A (CsA), which proved to be beneficial in a randomized phase III clinical trial conducted with poor-risk acute myeloid leukemia patients treated with cytarabine and daunorubicin (List et al. 2001). Second-generation inhibitors were synthesized around first-generation pharmacophores. The primary aim was to increase the affinity to Pgp while reducing dose-limiting toxicities. PSC-833 (Valspodar), a second-generation cyclosporine D analog lacking immunosuppressive effects, has been tested most frequently in clinical trials (see Table 1.3). While PSC833 is a high-affinity Pgp inhibitor, devoid of immunosuppressive effects, its use was associated with unwanted pharmacokinetic interactions. As a result of the inhibition of “physiological Pgp” in pharmacological barriers, PSC-833 decreased the systemic clearance of anticancer drugs, thus increasing exposure to normal and malignant cells. Pgp inhibitors, with a drug-binding site similar to that of cytochrome 3A (CYP3A), also interfered with CYP3A-mediated intestinal or liver metabolism, further reducing drug clearance. Taken together, these factors increased the severity and/or incidence of adverse effects associated with the anticancer therapy. To accommodate expected elevations in systemic drug exposure, the chemotherapy regimens were modified empirically. As a result, some patients were undertreated, while others were overdosed. Related to these problems, a phase III trial using PSC833 in previously untreated AML patients over age 60 was closed early due to excessive mortality during induction in the experimental arm (Baer et al. 2002) (see Table 1.3). A subsequent dose-escalation trial of 410 AML patients under age 60 revealed an overall survival advantage in an unplanned subset of patients younger than 45 years old when given PSC833 with variable doses of daunorubicin, etoposide, and fixed doses of cytarabine (Kolitz et al. 2004). That apparent benefit has not been duplicated, nor is it likely to be, as development of PSC-833 has been discontinued. Similarly, active development of another second-generation inhibitor showing initial promise (VX-710, Biricodar) has been curtailed (Goldman 2003). Third-generation inhibitors are products of combinatorial chemistry programs designed specifically for the development of compounds showing high transporter
3rd generation
2nd generation
1st generation
Poor-risk acute leukemia De novo AML
NSCLC SCLC Myeloma Breast SCLC Relapsed and refractory AML Poor-risk AML, RAEB-t Myeloma AML AML Untreated AML
Untreated AML
Ovarian Refractory AML, high-risk MDS NSCLC AML AML, MDS
Quinine
Verapamil Verapamil Verapamil Verapamil Megestrol acetate Cyclosporine
PSC-833
PSC-833 PSC-833
PSC-833 PSC-833 LY335979
Cyclosporine PSC-833 PSC-833 PSC-833
Cyclosporine
Quinine
Breast High-risk MDS
Cancer type
Quinidine Quinine
Modulator
Carboplatin, paclitaxel IL-2 Daunarubicin, Ara-C
VAD Daunorubicin, Ara-C, etoposide Mitoxantrone, etoposide, Ara-C Daunorubicin, etoposide, cytarabine Daunorubicin, etoposide, cytarabine Carboplatin, paclitaxel Mitoxantrone, etoposide, cytarabine
Daunorubicin, cytarabine
Vindesine, Ifosfamide CAVE VAD Vindesine, 5FU CAV/EP ADE (cytarabine, daunorubicin, etoposide)
Idarubicine, cytarabine, mitoxantrone
Mitoxantrone, Ara-C
Epirubicin Mitoxantrone, cytarabine
Anticancer drugs
Sonneveld et al. (2001) van der Holt et al. (2005) Sonneveld et al. (2001) Baer et al. (2002) Kolitz et al. (2004) Joly (2002) Greenberg et al. (2004)
Novartis Cancer.gov Cancer.gov
No O.S. advantage age > 45, survival benefit < age 45 No benefit No benefit Term. early 2◦ toxicity Results pending Results pending
List et al. (2001)
Millward et al. (1993) Milroy (1993) Dalton et al. (1995) Belpomme et al. (2000) Wood et al. (1998) Liu Yin et al. (2001)
Solary et al. (2003)
Wishart et al. (1994) Wattel et al. (1998) and Wattel et al. (1999) Solary et al. (1996)
References
No benefit No benefit No benefit Term. early 2◦ toxicity
Improved O.S. in CsA group
Significant improvement of the CR rate in Pgp-positive patients. No O.S. advantage Improved O.S. No benefit No benefit Improved O.S & R.R. No benefit No benefit
No benefit
No benefit Improved O.S. in Pgp + patients
Outcome
Table 1.3 Characteristics and results of complete and ongoing phase III clinical trials with ABC transporter inhibitors (Adapted from, Szakacs et al. 2006)
12 G. Szak´acs et al.
1 ABC Transporters in Drug Resistance
13
affinity and low PK interaction. Clinical trials conducted with Pgp inhibitors indicated that the “ultimate inhibitor” was to be efficient, devoid of unrelated pharmacological effects such as pharmacokinetic interactions with the concomitantly administered drugs or CYP interaction. Indeed, inhibition of CYP3A, responsible for many adverse PK effects with previous generation inhibitors, has generally been avoided with the third-generation of inhibitors, including laniquidar (R101933), OC144-093 (ONT-093), zosuquidar (LY335979), elacridar (GF-120918), CBT-1, and tariquidar (XR9576) (Rumpold et al. 2005). Tariquidar (XR9576) has the added benefit of extended Pgp inhibition, as a single intravenous dose inhibited efflux of rhodamine from CD56+ cells (biomarker lymphoid cells that express Pgp) for at least 48 hours (Stewart et al. 2000). In 2002, phase III clinical trials began using tariquidar as an adjunctive treatment in combination with first-line chemotherapy for patients with non-small-cell lung cancer (NSCLC). Despite the promising characteristics mentioned above, the studies were stopped early because of toxicities associated with the cytotoxic drugs. This study also illustrates a defect in experimental design, since there is no strong evidence to suggest that NSCLC expresses Pgp to a significant extent. Also, the combination chemotherapy was administered at a dose higher than the maximum tolerated dose in combination trials (Fox and Bates 2007). Following the review of the aborted trials, the National Cancer Institute has commenced further exploratory phase I/II and phase III studies with tariquidar. Zosuquidar (LY335979) has recently been evaluated in patients with AML. Preliminary analysis indicates that zosuquidar may be safely given without chemotherapy dose reductions; trial endpoints have not yet been analyzed (Szakacs et al. 2006).
Emerging Role of MDR-ABC Transporters in Resistance Against Targeted Agents The era of novel drug targets was supposed to leave chemotherapy behind, and with it, multidrug resistance. It was thought that the targeted agents, and especially those with vascular targets, would be so specific that resistance would not develop. While the introduction of targeted agents has had a marked impact on outcomes in patients, the disappointing fact is that most of these therapies improve progression-free survival but induce no cures. As a highly effective therapy for chronic myelogenous leukemia (CML), imatinib confers a complete hematologic response in 95% of patients and a complete cytogenetic response in 74% of patients – but, by 5 years, 20% of patients will have experienced disease progression (Moen et al. 2007). Several mechanisms mediating imatinib resistance have been identified (such as the amplification of the bcr-abl gene, the overexpression of the Bcr-Abl protein, and compensatory activation of the Src kinases); the most frequent mechanism seems to be the appearance of point mutations in the kinase domain of Abl. However, mutations are found in only 45% of patients with refractory CML, and only 26% in early chronic phase (Apperley 2007). Furthermore, when these mutations have been studied in vitro for their ability to confer resistance to imatinib, many were found
14
G. Szak´acs et al.
to confer only limited resistance (Apperley 2007). For example, while the most commonly reported mutation, T315I, confers a 23-fold resistance (as compared to the wild type), the third most commonly reported mutation confers only 2-fold resistance in biological assays. Furthermore, increasing the imatinib dose results in major cytogenetic response and complete hematologic response in 27% and 55% of patients, respectively (Kantarjian et al. 2007). These observations, together with data showing that though levels of imatinib are correlated with depth of response, are consistent with the notion that exposure to imatinib is important (Picard et al. 2007). These results, together with laboratory studies showing unequivocally that imatinib is a substrate for transport by both Pgp and ABCG2 (Rumpold et al. 2005, Brendel et al. 2007), suggest a hypothesis wherein the drug transporters, Pgp and ABCG2, could be important in drug resistance in CML. Oral absorption occurs because imatinib inhibits the transporters at the high local concentrations present in the GI tract. At the lower concentrations surrounding the tumor, however, a drug transporter could reduce intracellular concentrations just enough to allow a weak mutation to confer drug resistance. Unfortunately, systematic studies evaluating MDR1 expression in CML have not been performed.
Conclusion The exclusive focus on mutations in imatinib resistance reflects a recent bias that drug transporters are not important in clinical oncology. Rather, the story should show that drug resistance is complex, and that a single mechanism is unlikely to be exclusive, even in targeted therapy. A large number of studies have identified Pgp as a negative prognostic factor, particularly in acute myelogenous leukemia; such studies have not been done in CML. For any cancer, studies with ABCG2 have only just been initiated. The question is not whether ABC transporters can confer drug resistance, but rather in what disease and whether that drug resistance can be blocked in the clinic. The strategy of Pgp inhibition failed primarily because of the inadequate trial designs and the lack of proper target validation. An analysis of the literature clearly demonstrated serious flaws in the phase III clinical trial designs (Szakacs et al. 2006). Numerous studies were carried out with inferior agents, and few studies were actually been performed with the more potent, nontoxic agents that we now have available. Results from improved phase III trials using third-generation inhibitors will be pivotal in determining whether inhibition of Pgp, or other ABC transporters, can result in improved patient survival. The improved clinical trials should be based on a standardized system used to determine whether a tumor expresses the ABC transporter of interest. Using a proper, quantitative laboratory diagnostic method, an adequate transporter expression and/or function should be measured as a criterion for trial enrollment (the beneficial effect of transporter inhibition will likely be confined to patients “positive” for the transporter target). An improvement of therapy outcome is expected only if the chemotherapeutic regimens involve transported substrates. Additionally, chemotherapy–inhibitor
1 ABC Transporters in Drug Resistance
15
combinations should be used at concentrations previously proven safe and effective in phase I/II trials, taking into account potential PK interactions with either the parental drug compound or its metabolites. Drug pharmacokinetics and early signs of hepatic, neurological, or bone marrow toxicity should be monitored closely. To ensure abrogation of the MDR phenotype, surrogate assays should be performed to assess the effect of the inhibitor in each patient. This may either be done ex vivo, by using flow cytometry to measure Pgp function in CD56+ cells taken from patients treated with inhibitors, or in vivo using 99mTc-sestamibi (Agrawal et al. 2003) or other imaging modalities to directly image accumulation of Pgp substrates within tumors. With an ever-expanding list of drugs in the anticancer armamentarium, there is more reason than ever to develop methods of detecting Pgp-mediated or transportermediated drug resistance. Sensitive imaging modalities are needed to teach us the scope of the problem. In 2008, roughly 40% of the patients diagnosed with cancer in the United States are destined to die of their disease. Virtually, all of these deaths represent a failure of systemic therapy. We no longer think of resistance as solely due to Pgp or any other drug transporter as we may have in the 1980s; nor should its presence be ignored. We know that every other physiologic cell survival mechanism can be conscripted to cause drug resistance in cancer – such as DNA repair or antiapoptotic mechanisms – and there is no reason to think that drug transporters would not as well be exploited by cancer cells. Acknowledgments Support from OTKA (PF60435), NIH (R01TW007250), and EU-FP6 (046560, 041547) is gratefully acknowledged. Gergely Szak´acs is the recipient of a J´anos Bolyai Scholarship and a Special Fellow Award from the Leukemia and Lymphoma Society.
References Agrawal, M., J. Abraham, et al. (2003). “Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.“ Clin Cancer Res 9(2): 650–6. Allikmets, R., L. M. Schriml, et al. (1998). “A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.” Cancer Res 58(23): 5337–9. Apperley, J. F. (2007). “Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.” Lancet Oncol 8(11): 1018–29. Baer, M. R., S. L. George, et al. (2002). “Phase 3 study of the multidrug resistance modulator PSC833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.” Blood 100(4): 1224–32. Bailey-Dell, K. J., B. Hassel, et al. (2001). “Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene.” Biochim Biophys Acta 1520(3): 234–41. Baker, E. K., R. W. Johnstone, et al. (2005). “Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.” Oncogene 24(54): 8061–75. Bakos, E., R. Evers, et al. (2000). “Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1).” J Cell Sci 113 Pt 24: 4451–61. Bakos, E. and L. Homolya (2007). “Portrait of multifaceted transporter, the multidrug resistanceassociated protein 1 (MRP1/ABCC1).” Pflugers Arch 453(5): 621–41.
16
G. Szak´acs et al.
Belpomme, D., S. Gauthier, et al. (2000). “Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma.” Ann Oncol 11(11): 1471–6. Benderra, Z., A. M. Faussat, et al. (2004). “Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.” Clin Cancer Res 10(23): 7896–902. Borst, P. and R. O. Elferink (2002). “Mammalian ABC transporters in health and disease.” Annu Rev Biochem 71: 537–92. Borst, P., N. Zelcer, et al. (2006). “On the putative co-transport of drugs by multidrug resistance proteins.” FEBS Lett 580(4): 1085–93. Brendel, C., C. Scharenberg, et al. (2007). “Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.” Leukemia 21(6): 1267–75. Cerveny, L., L. Svecova, et al. (2007). “Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.” Drug Metab Dispos 35(7): 1032–41. Cole, S. P., G. Bhardwaj, et al. (1992). “Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line.” Science 258(5088): 1650–4. Comerford, K. M., T. J. Wallace, et al. (2002). “Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.” Cancer Res 62(12): 3387–94. Cordon-Cardo, C., J. P. O’Brien, et al. (1990). “Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.” J Histochem Cytochem 38(9): 1277–87. Cripe, L. D., V. M. Gelfanov, et al. (2002). “Role for c-jun N-terminal kinase in treatmentrefractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.” Leukemia 16(5): 799–812. Daenen, S., B. Van Der Holt, et al. (2004). “Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the Dutch-Belgian HaematoOncology Working Group for adults.” Leuk Res 28(10): 1057–67. Dalton, W. S., J. J. Crowley, et al. (1995). “A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.” Cancer 75(3): 815–20. Dano, K. (1973). “Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.” Biochim Biophys Acta 323(3): 466–83. Dawson, R. J. and K. P. Locher (2006). “Structure of a bacterial multidrug ABC transporter.” Nature 443(7108): 180–5. Dean, M., T. Fojo, et al. (2005). “Tumour stem cells and drug resistance.” Nat Rev Cancer 5(4): 275–84. Dean, M., A. Rzhetsky, et al. (2001). “The human ATP-binding cassette (ABC) transporter superfamily.” Genome Res 11(7): 1156–66. DeGorter, M. K., G. Conseil, et al. (2008). “Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1).” Biochem Biophys Res Commun 365(1): 29–34. Doyle, L. A., W. Yang, et al. (1998). “A multidrug resistance transporter from human MCF-7 breast cancer cells.” Proc Natl Acad Sci U S A 95(26): 15665–70. Ebert, B., A. Seidel, et al. (2005). “Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists.” Carcinogenesis 26(10): 1754–63. El-Osta, A., P. Kantharidis, et al. (2002). “Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.” Mol Cell Biol 22(6): 1844–57. Filipits, M., G. Pohl, et al. (2005). “Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.” J Clin Oncol 23(6): 1161–8. Fox, E. and S. E. Bates (2007). “Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.” Expert Rev Anticancer Ther 7(4): 447–59.
1 ABC Transporters in Drug Resistance
17
Goldman, B. (2003). “Multidrug resistance: can new drugs help chemotherapy score against cancer?” J Natl Cancer Inst 95(4): 255–7. Gomez-Martinez, A., P. Garcia-Morales, et al. (2007). “Post-transcriptional regulation of Pglycoprotein expression in cancer cell lines.” Mol Cancer Res 5(6): 641–53. Greenberg, P. L., S. J. Lee, et al. (2004). “Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).” J Clin Oncol 22(6): 1078–86. Harikrishnan, K. N., M. Z. Chow, et al. (2005). “Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing.” Nat Genet 37(3): 254–64. Hazai, E. and Z. Bikadi (2008). “Homology modeling of breast cancer resistance protein (ABCG2).” J Struct Biol 162(1): 63–74. Henriksen, U., U. Gether, et al. (2005). “Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.” J Cell Sci 118(Pt 7): 1417–26. Hollenstein, K., R. J. Dawson, et al. (2007). “Structure and mechanism of ABC transporter proteins.” Curr Opin Struct Biol 17(4): 412–8. Hu, Z., S. Jin, et al. (2000). “Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1.” J Biol Chem 275(4): 2979–85. Huff, L. M., J. S. Lee, et al. (2006). “Characterization of gene rearrangements leading to activation of MDR-1.” J Biol Chem 281(48): 36501–9. Huff, L. M., Z. Wang, et al. (2005). “Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples.” Cancer Res 65(24): 11694–703. Hvorup, R. N., B. A. Goetz, et al. (2007). “Asymmetry in the structure of the ABC transporterbinding protein complex BtuCD-BtuF.” Science 317(5843): 1387–90. Imai, Y., E. Ishikawa, et al. (2005). “Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.” Cancer Res 65(2): 596–604. Jin, S. and K. W. Scotto (1998). “Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y.” Mol Cell Biol 18(7): 4377–84. Joly F, J. C., Mangioni C, Nicoletto M, Manikhas GM, Walker J, Mietlowski W, Jones G, Wysowskyj M, Dugan M. (2002). “A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum (Abstract).” Proc Am Soc Clin Oncol 21. Jonker, J. W., G. Merino, et al. (2005). “The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.” Nat Med 11(2): 127–9. Juliano, R. L. and V. Ling (1976). “A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.” Biochim Biophys Acta 455(1): 152–62. Kage, K., S. Tsukahara, et al. (2002). “Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.” Int J Cancer 97(5): 626–30. Kantarjian, H., R. Pasquini, et al. (2007). “Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.” Blood 109(12): 5143–50. Knutsen, T., V. K. Rao, et al. (2000). “Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines.” Genes Chromosomes Cancer 27(1): 110–6. Kolitz, J. E., S. L. George, et al. (2004). “Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.” J Clin Oncol 22(21): 4290–301. Krishnamurthy, P., D. D. Ross, et al. (2004). “The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.” J Biol Chem 279(23): 24218–25.
18
G. Szak´acs et al.
Kurz, E. U., S. P. Cole, et al. (2001). “Identification of DNA-protein interactions in the 5 flanking and 5 untranslated regions of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-1 binding site.” Biochem Biophys Res Commun 285(4): 981–90. Leith, C. P., K. J. Kopecky, et al. (1999). “Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.” Blood 94(3): 1086–99. Linenberger, M. L. (2005). “CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.” Leukemia 19(2): 176–82. List, A. F., K. J. Kopecky, et al. (2001). “Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.” Blood 98(12): 3212–20. Liu Yin, J. A., K. Wheatley, et al. (2001). “Comparison of “sequential’ versus “standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.” Br J Haematol 113(3): 713–26. Locher, K. P., A. T. Lee, et al. (2002). “The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism.” Science 296(5570): 1091–8. Loe, D. W., R. G. Deeley, et al. (1998). “Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione.” Cancer Res 58(22): 5130–6. Maliepaard, M., M. A. van Gastelen, et al. (1999). “Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.” Cancer Res 59(18): 4559–63. Michieli, M., D. Damiani, et al. (2000). “P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.” Br J Haematol 108(4): 703–9. Millward, M. J., B. M. Cantwell, et al. (1993). “Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.” Br J Cancer 67(5): 1031–5. Milroy, R. (1993). “A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.” Br J Cancer 68(4): 813–8. Miyake, K., L. Mickley, et al. (1999). “Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.” Cancer Res 59(1): 8–13. Moen, M. D., K. McKeage, et al. (2007). “Imatinib: a review of its use in chronic myeloid leukaemia.” Drugs 67(2): 299–320. Nakanishi, T., K. J. Bailey-Dell, et al. (2006). “Novel 5 untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.” Cancer Res 66(10): 5007–11. Nakayama, M., M. Wada, et al. (1998). “Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias.” Blood 92(11): 4296–307. O’Mara, M. L. and D. P. Tieleman (2007). “P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK.” FEBS Letters 581(22): 4217–22. Oldham, M. L., D. Khare, et al. (2007). “Crystal structure of a catalytic intermediate of the maltose transporter.” Nature 450(7169): 515–21. Ozvegy, C., T. Litman, et al. (2001). “Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.” Biochem Biophys Res Commun 285(1): 111–7. Pallis, M. and N. Russell (2004). “Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia.” Leukemia 18(12): 1927–30.
1 ABC Transporters in Drug Resistance
19
Paul, S., L. M. Breuninger, et al. (1996). “ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter.” Proc Natl Acad Sci U S A 93(14): 6929–34. Picard, S., K. Titier, et al. (2007). “Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.” Blood 109(8): 3496–9. Pinkett, H. W., A. T. Lee, et al. (2007). “An inward-facing conformation of a putative metal-chelatetype ABC transporter.” Science 315(5810): 373–7. Renes, J., E. G. de Vries, et al. (1999). “ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.” Br J Pharmacol 126(3): 681–8. Robey, R. W., W. Y. Medina-Perez, et al. (2001). “Overexpression of the ATP-binding cassette halftransporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.” Clin Cancer Res 7(1): 145–52. Rumpold, H., A. M. Wolf, et al. (2005). “RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.” Exp Hematol 33(7): 767–75. Sampath, J., D. Sun, et al. (2001). “Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.” J Biol Chem 276(42): 39359–67. Sarkadi, B., L. Homolya, et al. (2006). “Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.” Physiol Rev 86(4): 1179–236. Solary, E., B. Drenou, et al. (2003). “Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.” Blood 102(4): 1202–10. Solary, E., B. Witz, et al. (1996). “Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.” Blood 88(4): 1198–205. Song, X., M. Xie, et al. (2004). “The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes.” Drug Metab Dispos 32(1): 35–42. Sonneveld, P., S. Suciu, et al. (2001). “Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).” Br J Haematol 115(4): 895–902. Steinbach, D., W. Sell, et al. (2002). “BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia.” Leukemia 16(8): 1443–7. Stewart, A., J. Steiner, et al. (2000). “Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.” Clin Cancer Res 6(11): 4186–91. Suvannasankha, A., H. Minderman, et al. (2004). “Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.” Br J Haematol 127(4): 392–8. Suvannasankha, A., H. Minderman, et al. (2004). “Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.” Leukemia 18(7): 1252–7. Synold, T. W., I. Dussault, et al. (2001). “The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.” Nat Med 7(5): 584–90. Szakacs, G., J. K. Paterson, et al. (2006). “Targeting multidrug resistance in cancer.” Nat Rev Drug Discov 5(3): 219–34. Szatmari, I., G. Vamosi, et al. (2006). “Peroxisome proliferator-activated receptor gammaregulated ABCG2 expression confers cytoprotection to human dendritic cells.” J Biol Chem 281(33): 23812–23.
20
G. Szak´acs et al.
Tada, Y., M. Wada, et al. (2000). “MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.” Clin Cancer Res 6(12): 4618–27. To, K. K., O. Polgar, et al. (2008). “Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.” Mol Cancer Res 6(1): 151–64. To, K. K., Z. Zhan, et al. (2006). “Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.” Mol Cell Biol 26(22): 8572–85. To, K. K., Z. Zhan, et al. (2008). “Regulation of ABCG2 expression at the 3 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative MicroRNA in the S1 colon cancer cell line.” Mol Cell Biol 28(17): 5147–61. Tsuruo, T., H. Iida, et al. (1981). “Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.” Cancer Res 41(5): 1967–72. Turner, J. G., J. L. Gump, et al. (2006). “ABCG2 expression, function, and promoter methylation in human multiple myeloma.” Blood 108(12): 3881–9. Uggla, B., E. Stahl, et al. (2005). “BCRP mRNA expression v. clinical outcome in 40 adult AML patients.” Leuk Res 29(2): 141–6. van der Holt, B., B. Lowenberg, et al. (2005). “The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.” Blood 106(8): 2646–54. Volk, E. L., K. M. Farley, et al. (2002). “Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.” Cancer Res 62(17): 5035–40. Wang, Q. and W. T. Beck (1998). “Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.” Cancer Res 58(24): 5762–9. Ward, A., C. L. Reyes, et al. (2007). “Flexibility in the ABC transporter MsbA: Alternating access with a twist.” Proceedings of the National Academy of Sciences of the United States of America 104(48): 19005–10. Wattel, E., E. Solary, et al. (1998). “Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.” Br J Haematol 102(4): 1015–24. Wattel, E., E. Solary, et al. (1999). “Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS.” Adv Exp Med Biol 457: 35–46. Wishart, G. C., D. Bissett, et al. (1994). “Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.” J Clin Oncol 12(9): 1771–7. Wood, L., M. Palmer, et al. (1998). “Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.” Br J Cancer 77(4): 627–31. Yang, Y., Q. Chen, et al. (2002). “Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1.” J Biol Chem 277(46): 44268–77. Yasuda, S., S. Itagaki, et al. (2005). “Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation.” Biosci Biotechnol Biochem 69(10): 1871–6. Zhu, H., H. Wu, et al. (2008). “Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.” Biochem Pharmacol. Zhu, Q. and M. S. Center (1994). “Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin.” Cancer Res 54(16): 4488–92. Zhu, Q. and M. S. Center (1996). “Evidence that SP1 modulates transcriptional activity of the multidrug resistance-associated protein gene.” DNA Cell Biol 15(2): 105–11.
Chapter 2
Metastasis and Drug Resistance Dominic Fan, Sun-Jin Kim, Robert L. Langley, and Isaiah J. Fidler
Abstract Multidrug resistance (MDR) phenotype emerging from chemotherapy is a major problem in managing patients with metastatic cancers. The discovery that a cardiovascular drug, verapamil, can bind to P-glycoprotein and reverse MDR initiated serious research efforts in MDR-reversal by various compounds and modes of pharmacological modifiers. Those include major calcium channel blockers such as bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine and nimodipine, verapamil and analogs; calmodulin antagonists; antibiotics and analogs; indole alkaloids; cyclosporins and analogs; hormones and antihormones; pharmaceutical emulsifying surfactants; liposomal encapsulation; etc. The majority of the studies targeted one of the MDR mechanisms, P-glycoprotein. These studies have been successful under in vitro and limited in vivo animal conditions; the correlations for clinical trails are still lacking. Therefore, an effective MDR-reversing chemotherapy is not available. It is the purpose of this chapter to review the past and current experimental reversal of MDR and, in particular, the importance in targeting drug resistance in relevant cancer metastasis models. Keywords Metastasis · MDR · Apoptosis · Animal models
Introduction Despite improvements in diagnosis, surgical techniques, patient care, and adjuvant therapies, most deaths from cancer are due to metastases that are resistant to conventional therapies (Fidler 1990). The major obstacle to effective treatment is tumor cell biologic heterogeneity. Moreover, the metastases can be located in different organs, and the specific organ environment can influence the biologic behavior of metastatic D. Fan (B) Department of Cancer Biology, Cancer Metastasis Research Center, Unit 854, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA e-mail:
[email protected]
K. Mehta, Z.H. Siddik (eds.), Drug Resistance in Cancer Cells, C Springer Science+Business Media, LLC 2009 DOI 10.1007/978-0-387-89445-4 2,
21
22
D. Fan et al.
cells, including their response to systemic therapy. Only a better understanding of the molecular mechanisms that regulate the process of metastasis and the interactions between the metastatic cells with the organ microenvironment can provide a foundation for the design of more effective therapy.
The Pathogenesis of Metastasis The process of metastasis is highly selective and consists of a series of sequential, interrelated steps. To produce clinically relevant lesions, metastatic cells must complete all steps of this process. After the initial transformation and growth of cells, vascularization must occur if a tumor mass is to exceed 1 mm in diameter. The synthesis and secretion of several proangiogenic factors by tumor and host cells and the absence of antiangiogenic factors play a key role in establishing a capillary network from the surrounding host tissues. Next, local invasion of the host stroma occurs as a consequence of the enhanced expression of a series of enzymes (e.g., collagenase). Once tumor cells penetrate lymphatic or vascular channels, they may grow at the invasion site or detach and be transported within the circulatory system. The tumor emboli must survive immune and nonimmune defenses and the turbulence of the circulation, then arrest in the capillary bed of receptive organs, extravasate into the organ parenchyma, proliferate, and establish a micrometastasis. Growth of these microscopic lesions requires development of a vascular supply and evasion of host defense cells. When the metastases grow, they can shed tumor cells into the circulation to produce metastasis of metastases (Fidler 1990). The outcome of the metastatic process depends on multiple and complex interactions of metastatic cells with host homeostatic mechanisms (Fidler 1997). More than a century ago, Stephen Paget researched the mechanisms that regulate organ-specific metastasis, i.e., pattern of metastasis by different cancers, and questioned whether the organ distribution of metastases produced by different human neoplasms was due to chance and analyzed more than 700 autopsy records of women with breast cancer. His research documented a nonrandom pattern of visceral (and bone) metastasis. This finding suggested to Paget that the process was not due to chance but, rather, that certain tumor cells (the “seed”) had a specific affinity for the milieu of certain organs (the “soil”). Metastases resulted only when the seed and soil were compatible (Paget 1889). A current definition of the “seed and soil” hypothesis consists of three principles. First, neoplasms are biologically heterogeneous and contain subpopulations of cells with different angiogenic, invasive, and metastatic properties (Fidler 2003; Langley and Fidler 2007). Second, the process of metastasis is selective for cells that succeed in invasion, embolization, survival in the circulation, arrest in a distant capillary bed, and extravasation into and multiplication within the organ parenchyma. Although some of the steps in this process contain stochastic elements, as a whole, metastasis favors the survival and growth of a few subpopulations of cells that preexist within the parent neoplasm (Fidler and Kripke 1977; Talmadge et al. 1982).
2 Metastasis and Drug Resistance
23
Thus, metastases can have a clonal origin, and different metastases can originate from the proliferation of different single cells (Fidler and Talmadge 1986; Hu et al. 1987; Talmadge et al. 1982). Third, and perhaps the most important principle for the design of new cancer therapies, is that the outcome of metastasis depends on multiple interactions (“cross-talk”) of metastatic cells with homeostatic mechanisms, which the tumor cells can usurp (Fidler 1995). Therapy of metastasis, therefore, can be targeted not only against tumor cells but also against the homeostatic factors that promote tumor cell growth, survival, angiogenesis, invasion, and metastasis.
Multidrug Resistance One of the most depressing and predictable facts of cancer management is the development of the multidrug resistance (MDR) phenotype in patients treated chronically with certain natural chemotherapeutic drugs. This clinical phenomenon accounts for the unsatisfactory low incidence of response rate for the majority of solid tumors to chemotherapy – one of the few conventional treatments for metastatic diseases in past few decades. Since the heterogeneous nature of tumor and cancer metastasis was conceptualized (Paget 1889; Fidler 1973; Fidler and Kripke 1977; Fidler 1978; Poste and Fidler 1979; Fidler and Poste 1985; Fidler 2001), it is clear that MDR is a resultant clinical outcome manifested by successful cancer cells endowed with multiple mechanisms for survival. Like other vital traits of metastatic cancer cells, MDR should be conceived as a phenotype marked by a collection of independent or collateral modifications, overexpressions, and/or amplifications of endogenous molecules that interplay with distinct normal cellular pathways (Fig. 2.1) that include
MDR P-glycoprotein PKC Expression ABC Transporters Tubulin Mutation Episomes Amplification Topoisomerase II Mutation Altered Cellular Calcium Levels Enhanced Sodium Pump Activity Altered Reduction-Oxidation Pathways Formation of Double Minute Chromosomes Overexpression of Cytoplasmic 22 kDa Sorcin Fig. 2.1 MDR-associated mechanisms
24
D. Fan et al.
P-glycoprotein (Juliano and Ling 1976; Kartner et al. 1983), protein kinase-C (PKC) overexpression (Fan et al. 1992a, b; Aftab et al. 1994), ABC transporters (Adachi et al. 2007), tubulin mutation (Inaba et al. 1987), episomes amplification (Ruiz et al. 1989), formation of double minute chromosomes (Von Hoff et al. 1990), altered cellular calcium levels (Nair et al. 1986), topoisomerase II mutation and altered reduction–oxidation (Deffie et al. 1988), and the overexpression of cytoplasmic 22kDa sorcin (Hamada et al. 1988). Those cancer cells employing single and especially unique oncogenic mechanism, presumably exist, would likely be eliminated by the host defense mechanisms during the progression of cancer or by conventional cancer therapy and would be without further clinical manifestation. Therefore, initial treatment with chemotherapeutic drugs and subsequent reversal of MDR should be combined as a standard protocol for effective chemotherapy at the onset of cancer management, rather than resolving to salvage therapies – when the patients return with compromised performance status and growth of refractory tumors. Unfortunately, an effective MDR-reversing chemotherapy is not available. Since the inception of an organized drug-screening program (DeVita et al. 1979), research efforts have been largely compound-oriented (sensitive drug-screens) (Frei 1982; Venditti 1981) rather than disease-oriented (tumor panels) (Alley et al. 1988), metastasis-oriented (orthotopic animal models) (Wilmanns et al. 1992; Singh et al. 1994; Killion et al. 1999; Langley and Fidler 2007) or MDR-oriented (relevant resistant drug-screens) (Mickisch et al. 1991a, b, Dong et al. 1994). In the following sections, we review the past and current experimental reversal of MDR and, in particular, the importance in targeting drug resistance in cancer metastasis.
Reversal of Experimental MDR The majority of the MDR-reversing studies were in vitro assays that cannot address the complexity of physiology and pathology in cancer patients, and in particular metastasis of the cancer. It is physiology and pathology that modulate the progression of cancer and metastasis and the pharmacokinetics (what the host and cells do to the drugs) and pharmacodynamics (what the drugs do to the host and cells) (Ford and Hait 1990). Decisively, the validity of an in vitro assay is governed by its ability to derive an acceptable level of sensitivity (the prediction of true positives) and specificity (the prediction of true negatives) (Fan et al. 1985).
Calcium Channel Blockers Verapamil and Other Clinically Approved Agents As the elements of time and costs stacking up against the development of new anticancer drugs, the initial observation of Tsuruo et al. (1981) of a reversal by verapamil (a coronary vasodilator) on an MDR phenotype in P388 leukemia cells (Tsuruo et al. 1981, 1982) inscribed the beginning of an explosive search for
2 Metastasis and Drug Resistance
25
MDR-reversing anticancer therapeutics. Several major calcium channel blockers approved for clinical use in the United States were candidates for such a search: bepridil (a pyrrolidylamine), diltiazem (a benzothiazepine), felodipine, isradipine, nicardipine, nifedipine and nimodipine (dihydropyridines), and verapamil (a benzeneacetonitrile). Although one of the major biological effects of verapamil is the blockage of the slow-channel-mediated calcium entry into cardiac cells (Kohlhardt et al. 1972) and drug-resistant cancer cells (Bucana et al. 1990), its MDR-reversing mechanism is not clearly understood and may be quite apart from its physiologic action, in which a trial depolarization plays an important role and is related to the fast-channel effect for sodium influx (Rougier et al. 1969). Verapamil-mediated enhancement of intracellular accumulation of MDR-linked anticancer drugs is universally observed and attributed to an effect on P-glycoprotein-mediated efflux in a variety of cancer cell lines (Tsuruo et al. 1982; Inaba et al. 1979; Harker et al. 1986). Extensive efforts were made to identifying and translating the unique MDRreversing properties of verapamil and other calcium channel blockers into clinical terms (Slater et al. 1982; Tsuruo et al. 1983a, b; Fojo et al. 1985; Fine et al. 1987; Ford et al. 1990; Fan et al. 1994a, b). Unfortunately, the adverse hematodynamic effects of verapamil have limited its clinical potential for routine use in adjunct chemotherapy (Ozols et al. 1987). In addition to verapamil, many clinically approved calcium channel blocker were shown to affect intracellular accumulation of MDR-linked anticancer drugs and to reverse MDR phenotype in vitro (Tsuruo et al. 1983a, b; Schuurhuis et al. 1987; Hollt et al. 1992; Fan et al. 1994a, b). However, with the exception of the bepridil studies, most preclinical studies employed concentrations of calcium channel blockers much higher (to achieve experimental MDR-reversing activity) than the peak plasma levels derived from patients whose performance status was less compromised than those of cancer patients entering clinical trials with advanced disease. Therefore, it was not surprising that difficulties were encountered in clinical trials using verapamil (Ozols et al. 1987) and with other calcium channel blockers for reversing drug resistance to standard chemotherapeutics in advanced cancer patients. At a micromolar dose range of verapamil, the cytotoxic effects to normal cells are remarkably severe (Lampidis et al. 1986). Furthermore, the high-dose requirement for reversal of MDR in vitro suggested additional effects (mechanisms of action) other than a simple physiologic blockage of the calcium channels (Huet and Robert 1988). Several groups have shown that verapamil can bind to P-glycoprotein and compete for binding sites for MDR-related agents to P-glycoprotein (Cornwell et al. 1987; Safa et al. 1987; Akiyama et al. 1988; Beck et al. 1988). It was shown that in the process of reversing an MDR phenotype, verapamil also stimulated marked ultrastructural changes (an MDR-associated twofold increase in the number of intramembrane particles) of drug-resistant P388 cells (Garcia-Segura et al. 1992). Moreover, under certain experimental conditions, treatments of the drug-resistant human colon LS 180 with verapamil, nifedipine, nicardipine, or diltiazem could increase mdr-1 mRNA expression and induce cell differentiation (Herzog et al. 1993). If one examines the bulk of in vitro literature and the clinical pharmacokinetic information, one finds in general a lack of consideration for controlled
26
D. Fan et al.
pharmacokinetic parameters (e.g., plasma elimination half-life of chemosensitizers and of standard anticancer drugs) to simulate relevant pharmacodynamic effects in vitro. As nonphysiologic as in vitro assays are, chemical–cell interactions do follow the law of concentration and time; this kind of pharmacologic consideration may help in reducing the frequency and costs in deriving false-positive experimental new drugs and MDR-reversing agents. Therefore, while it may be feasible to seek enhancement for the efficacy of standard anticancer drugs by verapamil and other calcium channel blockers, the selectivity, scheduling, and dose intensity of the chemosensitizers must be taken into consideration inasmuch as these parameters may influence MDR, tumor spread, and clinical outcome of therapy.
Verapamil Derivatives and Other Experimental Calcium Channel Blockers The disappointment of the initial clinical trials with verapamil (Ozols et al. 1987) stimulated an intense effort to develop chemosensitizers that were less cytotoxic to normal cells: one of the critical parameters in systemic cancer therapeutics (Lampidis et al. 1986; Fan et al. 1988). A number of structural analogs to verapamil (e.g., devapamil, emopamil, gallopamil, D528, D595, D792) have been implicated in the reversal of MDR in vitro (Pirker et al. 1990) with marginal toxicity in animal models (Nawrath and Raschack 1987; Pirker et al. 1989). The less calcium antagonistic and less cardiotoxic R-enantiomer of verapamil (versus that of clinically approved racemic verapamil) could reverse an MDR phenotype in vitro (Mickisch et al. 1990a, b). R-enantiomer of verapamil decreased the expression of P-glycoprotein, resistance to tamoxifen, and experimental pulmonary metastases of the R3230AC rat mammary adenocarcinoma in vivo (Kellen et al. 1991). Therefore, the potential for clinical enhancement of standard chemotherapeutic drugs mediated by verapamil and its derivatives remains on the horizon (Chatterjee et al. 1990; Mickisch et al. 1991a; Hollt et al. 1992; Kroemer et al. 1992; Teodori et al. 2005; Shen et al. 2008).
Calmodulin Antagonists Calmodulin is an intracellular calcium-binding protein that plays critical roles in a wide range of cellular activities (Ramakrishnan et al. 1989). Although the lack of down-regulation of calmodulin was found to produce higher levels of this protein in transformed cells (Jaffr´ezou and Laurent 1993), such difference was not found between the drug-sensitive and MDR P388 leukemia cells (Nair et al. 1986). However, its calcium-sequestrating regulatory roles prompted investigation on the MDRreversing effects of the potent calmodulin antagonist trifluoperazine (Tsuruo et al. 1982, 1983b; Klohs et al. 1986), and many antipsychotic phenothiazines marketed in the United States for clinical use and investigational compounds were found to reverse experimental MDR (Ganapathi et al. 1984; Ford et al. 1989; Ford et al. 1990; Fan et al. 1994b; Zhu et al. 2005).
2 Metastasis and Drug Resistance
27
Antibiotics and Analogs New drug development is time consuming and costly, hindering the availability of effective anticancer drug for the treatment of metastatic cancer. Similar to the circumvention of clinical side effects of anticancer drugs (Tsuruo et al. 1983a, b), one approach to overcome drug resistance of cancer cells would be the development of derivatives amongst clinically proven chemotherapeutic compounds. Several antibiotics such as the third-generation broad-spectrum cephalosporins (cefoperazone and ceftriaxone) (Gosland et al. 1989), protein synthesis inhibitor antibacterial erythromycin (Hofsli and Nissen-Meyer 1989), veterinary antimicrobial monensin (Ling et al. 1995), a variety of vinca alkaloid derivatives (Ruiz et al. 1989; Nasioulas et al. 1990) were found to reverse experimental MDR phenotypes. Of particular interest is the MDR-reversing effect of an anticancer benzylisoquinoline plant alkaloid thaliblastine that binds to P-glycoprotein and reverses doxorubicin resistance of the P388 MDR cells (Chen et al. 1993). Its low toxicity (Todorov 1988) and structural similarity to other compounds that have a photoaffinity for P-glycoprotein (Beck and Qian 1992) make it a potential chemosensitizer with a promising prospect (Pajeva et al. 2004).
Indole Alkaloids Mdr-like genes exist across the entire phylogenetic spectrum. The reversal of MDR phenotypes in mammalian cells by calcium channel antagonists has functional analogies with the effects of agents circumventing chloroquine resistance in parasite protozoa (Bitonti et al. 1988), in which the drug-resistant phenotype was conferred by a protein coded by a gene closely related to mammalian mdr1 (Wilson et al. 1989). The indole-containing antimalarial quinine and structurally related compounds such as its anti-arrhythmic stereoisomer sodium channel blocker quinidine have been found to produce an MDR-reversing activity (Tsuruo et al. 1984; Lehnert et al. 1991; Sato et al. 1991). Many of those compounds are neurohumoral antagonists that include reserpine (antihypertensive and antipsychotic) and yohimbine (α-adrenergic blocker chemically similar to reserpine) (Fan et al. 1994a). Although it is clear that the functionality of the human mdr1 gene product is distinct from the malarial counterpart (Ginsburg and Krugliak 1992), the reversal of drug resistance in both systems by similar compounds implies the possibility of similar responses for action (Vezmar and Georges 2000).
Cyclosporins and Analogs Cyclosporin A, the complex hydrophobic fungal cyclic undecapeptide, is commonly used as an immunosuppressant for organ transplantation. At concentrations achievable clinically, it is considered one of the most effective MDR-reversing agents.
28
D. Fan et al.
The original reports of Slater et al. (1986a, b) initiated extensive studies on MDRreversal, mediated by cyclosporins and related compounds (Twentyman et al. 1987; Chao et al. 1990; Dorr and Liddil 1991; Spoelstra et al. 1991; Loor et al. 1992; Arceci et al. 1992). Although cyclosporins have high affinity for P-glycoprotein (Goldberg et al. 1988; Foxwell et al. 1989), the reversal effects of cyclosporins did not correlate consistently with either drug accumulation (Slater et al. 1986a, b; Chambers et al. 1989; Hait et al. 1989) or direct interaction with P-glycoprotein (Hait et al. 1989). Nevertheless, cyclosporins and related compounds continue to produce reversal of experimental MDR phenotypes (Shen et al. 2008). Its derivative SDZ PSC-833 (Boesch et al. 1991; Ludwig et al. 2006; Shen et al. 2008) and the semi-synthetic cyclic peptolide derivative SDZ 280–446 (Loor et al. 1992; Lehne et al. 2000) showed MDR-reversing effects superior even to those of cyclosporin A, which was about one order of magnitude more active than other known chemosensitizers such as verapamil.
Hormones and Antihormones The induction, in pregnant murine uterus, of high levels of mdr1 mRNA, mediated by estrogen and progesterone (Arceci et al. 1988), and the cross-resistance of MDR breast carcinoma cells to antiestrogens with concomitant loss of estrogen receptors (Vickers et al. 1988) and progesterone receptors (Kacinski et al. 1989) initiated extensive studies on the role of steroid hormones in MDR-reversal (Berman et al. 1991; Hu et al. 1991; Fleming et al. 1992; Stuart et al. 1992; Mutoh et al. 2006). Although the effects of antiestrogens tamoxifen, toremifene, and 4-hydroxy tamoxifen may be influenced by serum protein binding (Wurz et al. 1993; Chatterjee and Harris 1990), the reversal effects by the most active hormone progesterone have been shown to interact directly with P-glycoprotein (Yang et al. 1989; Naito et al. 1989; Safa et al. 1990). Subsequently, it was demonstrated that progesterone distinguishes two mdr gene products (Yang et al. 1990) and specifically regulates the activity of the mdr1b promoter via the A form of the progesterone receptor (Piekarz et al. 1993). However, results from clinical trials with vinblastine and high-dose megestrol acetate were unremarkable (Matin et al. 2002).
Pharmaceutical Emulsifying Surfactants Woodcock et al. (1990) found that Cremophor EL, a relatively inert formula of polyethoxylated castor oil commonly used as pharmaceutical emulsifier (e.g., for preparations of water-insoluble compounds such as cyclosporins and taxol), could reverse experimental MDR at attainable clinical concentrations. This reversal effect has been since confirmed by using various MDR cells and pharmaceutical surfactants such as Solutol HS15 (Coon et al. 1991), Triton X-100, and Thesit (Friche et al. 1990; Spoelstra et al. 1991; Woodcock et al. 1992). There was also evidence
2 Metastasis and Drug Resistance
29
that nontoxic amounts of Cremophor EL and Tween 80 could effectively compete for P-glycoprotein binding with photoaffinity azidopine (Friche et al. 1990). The reformulation of conventional anticancer agents to include sufficient but nontoxic concentrations of these surfactants may enhance their clinical efficacy and overcome MDR.
Liposomal Encapsulation A major limitation to the use of anticancer drugs is their nonspecific clinical toxicities that impair the therapeutic efficacy of these agents. Liposomes are biodegradable, nonimmunogenic, and relatively nontoxic, and they can be safely used to modify pharmacokinetic properties such as distribution, circulatory transit time, and drug metabolism, to target drugs and biologicals to most of the major organs in animals and humans (Lopez-Berestein et al. 1984; Fogler et al. 1985), to avert systemic clinical toxicities (Forssen and Tokes 1981), and to improve therapeutic efficacy of antimicrobials (Lopez-Berestein et al. 1985), anticancer drugs (Huang et al. 1992; Ahmad et al. 1993), immunomodulators (Fidler 1988), and growth factors (Schackert et al. 1989; Fan et al. 1989). Other studies have shown that liposomes composed of various phospholipids can enhance the cytotoxicities of MDR-linked drugs such as doxorubicin, vinblastine, vincristine, and annamycin (Fan et al. 1990; Seid et al. 1991; Rahman et al. 1992; Thierry et al. 1993). Although the mode of action for MDR-reversal by liposomes is not clearly understood, the experimental reversal of drug resistance by liposomes containing specific phospholipids has been attributed to perturbation of the plasma membranes (Fan et al. 1990), to increasing drug incorporation and intracellular redistribution (Thierry et al. 1993), or to direct interaction with P-glycoprotein (Thierry et al. 1993). The practical utility of liposome encapsulation in cancer treatment is obvious, but its mechanism remains to be defined (Zalipsky et al. 2007).
Other Molecules The studies using calcium channel blockers and calmodulin antagonists to overcome MDR phenotypes continued. Dexniguldipine (B-859-35), the (–) isomer of antihypertensive niguldipine, was found better than verapamil in reversing MDR (Hofmann et al. 1991; Reymann et al. 1993; Dietel et al. 1996; He and Liu 2002). Various less toxic derivatives of verapamil (e.g., Ro11-2933) (Abderrabi et al. 1996), dihydropyridine (e.g., S16324, S16317) (Saponara et al. 2007), benzothiazepines (MDL 201,307) (Newman et al. 1996), and isoquinolinesulfonamides (e.g., W-77, CKA-1083) (Maeda et al. 1993), have been found potential agents for overcoming MDR. In the past years, many innovative molecules have also been investigated for their ability to circumvent MDR. Those findings included the studies of employing MRK16 anti-P-glycoprotein antibody to reverse bone marrow drug resistance
30
D. Fan et al.
of MDR transgenic mice (Mickisch et al. 1992a, b). Another anti-P-glycoprotein antibody, UIC2, was also effective in reversing experimental MDR (Mechetner and Roninson 1992). Other important compounds capable of reversing MDR include those of the adenyl cyclase inhibitor forskolin (Wadler and Wiernik 1988; Morris et al. 1991; Yin et al. 2000), potassium-sparing diuretic amilorides (Epand et al. 1991; Miraglia et al. 2005), α- or β-adrenoceptor antagonists amiodarone (Lehnert et al. 1996) and SKB 105854 (Fan et al. 1994b), antidepressant trazodone (Fan et al. 1994a), antipsychotic benzquinamide (Mazzanti et al. 1992), triazine S 9788 (Dhainaut et al. 1992; Moins et al. 2000), and the hydrophobic platelet anticoagulant dipyridamole (Verstuyft et al. 2003) and its derivative BIBW22BS (Schr¨oder et al. 1996). The antihistaminic terfenadine (Seldane) restored the sensitivity of MDR cells to doxorubicin (Hait et al. 1993). FB642 is a systemic benzimidazole fungicide with antitumor activity against a broad spectrum of tumors and drug-resistant and MDR cell lines (Hammond et al. 2001). Furthermore, it was found that introduction of an MDR1-targeted small interfering RNA duplex into drug-resistant cancer cells markedly inhibited the expression of MDR1 mRNA and P-gp and restored sensitivity to multidrug-resistant cancer cells (Wu et al. 2003).
Clinical Reversal of MDR Extensive clinical trials have been conducted in the past decade. As the first of such reversing agents entering clinical trials, calcium channel blocker verapamil was met with mixed outcomes that were discouraging in some studies (no response) (Rougier et al. 1969; Benson et al. 1985; Saltz et al. 1994) but were exceptionally promising in others (>50–70% response rate) (Cairo et al. 1989; Holmes et al. 1989; Figueredo et al. 1990; Miller et al. 1991; Salmon et al. 1991). Lymphoma was consistently more responsive to the chemosensitizing effects of verapamil (Holmes et al. 1989; Miller et al. 1991; Chabner et al. 1994). Although the number of patients was small, the combination trial of chloroquine with conventional chemotherapy and radiotherapy was clinically effective in improving midterm survival for glioblastoma multiforme (Sotelo et al. 2006). Unfortunately, the number of clinical studies of phenothiazines such as the calmodulin-inhibitor trifluoperazine (Miller et al. 1988; Murren et al. 1996) and antiemetic prochlorperazine (Sridhar et al. 1993; Raschko et al. 2000) was small, and the outcome was marginal. Likewise, trials of doxorubicin derivative 4 -iodo-4 -deoxydoxorubicin (Sessa et al. 1992), antiestrogen tamoxifen (Stuart et al. 1992; Trump et al. 1992; Millward et al. 1992), and calcium channel blocker nifedipine (Philip et al. 1992) were not highly remarkable. However, isolated trials of the benzothiazepine calcium channel blocker diltiazem and antimalarial quinine showed enhancement of leukemia responses to cytarabine, mitoxantrone, and vincristine (Bessho et al. 1985; Solary et al. 1992). Although cyclosporin A may not be effective in enhancing the efficacy of epidoxorubicin in colon cancer patients (Verweij et al. 1992), a Southwest Oncology Group study showed responses in poor-risk acute myeloid leukemia patients
2 Metastasis and Drug Resistance
31
receiving sequential treatments with cytarabine and daunomycin with concurrent infusion of cyclosporin A (List et al. 1992). Although clinical correlations are wanting (Holzmayer et al. 1992; Hait and Yang 2005), the use of biochemical modulation of clinical MDR remains a viable approach to improve treatments of cancer with conventional chemotherapy (Fojo and Bates 2003).
Overview of Experimental MDR-Reversal Many compounds, whose primary mechanism of action is blocking calcium channels, have been found to have MDR-reversing activities. It is not clear why chemicals that affect the flux of calcium in cells can elevate the accumulation of MDR-associated natural chemotherapeutic drugs. Many MDR-reversing agents are cationic amphiphiles (contains both hydrophobic and polar regions) that are highly lysosomotropic (Jaffr´ezou et al. 1991; Akiyama et al. 1984; Ramakrishnan et al. 1989) and could modulate intracellular turnover and trafficking of specific phospholipids that may affect the MDR phenotype (Jaffr´ezou et al. 1992; Jaffr´ezou and Laurent 1993). These implications may be unorthodox because of the seeming departure from the functionality of P-glycoprotein. It must be noted that proteins are rigid in nature and their functionality (mechanisms of action) and efficiency (kinetics) are often conformationally regulated by phospholipid matrix. This was shown by restoration of calcium accumulation across lipid bilayers by reconstitutive sarcoplasmic reticulum phospholipid-mediated, calcium- and magnesium-activated ATPase activity (Racker 1972) and by alterations in lipid fluidity that modulates P-glycoprotein-mediated drug transport in rat liver canalicular membrane vesicles (Sinicrope et al. 1992). Amplification of mdr1 and overexpression of its messenger underline that typical MDR phenotypes are probably by way of induction via plasma membrane with specific chemotherapeutic drugs. Unlike proteins, phospholipid compositions are remarkably different in transformed and tumor cells (Bergelson et al. 1970; Hatten et al. 1977), and the lipolytic activity of neoplasms is accentuated (Elwood and Morris 1968; Franson Patriaria and Elsbach 1974). The negative headgroup of the commonly internal phosphatidylserine (externalized in undifferentiated and neoplastic cells) has high affinity for calcium via coordination-chelation bonds (Paphadjopoulous 1968) that could initiate a localized drop in pH and a lateral phase separation of phosphatidylserine in the plasma membrane (Ohnishi and Ito 1973; Tr¨auble and Eibl 1974). Acidic pH can produce a reversible nonbilayer inverted micelle type in membranes containing phosphatidylserine (Hope and Cullis 1980). In addition to the regulatory effects of calcium and pH, phosphatidylserine was found deacylated by a unique membrane-associated phospholipase-A in SV40-transformed 3T3 fibroblasts and in human gastric carcinoma cells (Fan and Voelz 1977, 1980, 1984) to generate short-lived but fusogenic lysophosphatidylserine (Stein Y and Stein O 1966; Ahkong et al. 1973). Therefore, the unique properties of plasma membrane lipids such as phosphatidylserine allow them to participate in biological phenomena by
32
D. Fan et al.
means of a transient rearrangement of the membrane structure similar to that seen in MDR P388 leukemic cells (Garcia-Segura et al. 1992), and it regulates the efficiency (conformational changes and kinetic enhancements) of the efflux pump. It has been demonstrated that MDR phenotype of the human KB-V1 cell line (Ambudkar et al. 1992) and expression of the human mdr1 in Sf9 insect cells can generate a high-capacity drug-stimulated membrane ATPase (Sarkadi et al. 1992), and alterations in lipid fluidity can modulate P-glycoprotein-mediated drug transport in rat liver canalicular membrane vesicles (Sinicrope et al. 1992) and partially in the purified MDR CHRC5 Chinese hamster ovary cell plasma membrane P-glycoprotein (Doige et al. 1993). Therefore, the ATP-dependent calcium channel P-glycoprotein in cardiac and tumor cells could be retarded by blocking agents via a “nonspecific” perturbation (evidenced by the manifold variety of effectors) of the plasma membrane phospholipids to conformationally hinder ATPase activity (energy supply) and consequentially the functions of calcium channel and P-glycoprotein.
Metastasis and Drug Resistance The various modes of MDR-reversal put into effect that cancer is biologically heterogeneous and metastatic cells are the champions of survival. The process of tumor metastasis is highly selective and consists of a series of sequential and unified steps (Fidler 1990). Despite improvements in diagnosis, surgical techniques, patient care, and adjuvant therapies, most deaths from cancer are due to metastases that are resistant to conventional therapies. The major obstacle to effective treatment is the biologic heterogeneity of tumor cells. Moreover, metastases can be located in lymph nodes and different organs, and the specific organ microenvironment influences the biologic behavior of metastatic cells, including their response to systemic therapy (Fidler 2002). One of the factors is the development of drug resistance phenotype in metastatic cancer cells (Dutour et al. 2007; La Porta 2007). While cancer metastases are of clonal origin (Talmadge et al. 1982), variant clones with diverse phenotypes can form and rapidly result in the generation of significant cellular diversity within individual metastases (Fidler and Hart 1982). The outcome of the metastatic process depends on multiple and complex interactions of the metastatic cells with the host homeostatic mechanisms (Liotta et al. 1991; Fidler 1997). We determined whether the expression level of metastasis-related genes is regulated by specific organ microenvironments. Highly metastatic clones of human prostate cancer were implanted into the prostate (orthotopic site) and subcutis (ectopic site). Tumors were harvested and processed for in situ hybridization (ISH) analysis. Spontaneous metastases in the lymph nodes were also evaluated. Tumors growing in the prostate exhibited higher levels of epidermal growth factor-receptor (EGF-R), basic fibroblast growth factor (bFGF), interleukin (IL)-8, type IV collagenase, and the multidrug resistance (mdr-1) gene than those growing in the subcutis (Greene et al. 1997).
2 Metastasis and Drug Resistance
33
The orthotopic implantation of human cancer cells was mandatory for analysis of metastasis-related genes. Specifically, highly metastatic cells expressed higher mRNA levels of type IV collagenase (which affects invasion), bFGF and IL-8 (which affect angiogenesis), and mdr-1 compared with cells of low metastatic potential. No difference in EGF-R expression (which affects growth) was found between the cells, but the expression of E-cadherin (which affects cell cohesion) was decreased in the metastatic cells. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF), which affects tumor angiogenesis, has also been found to be overexpressed in prostate cancer in comparison with normal epithelium or benign prostatic hyperplasia. We found that VEGF/VPF levels correlated with microvessel density and metastatic potential of human prostate cancer cells growing in the prostate of nude mice (Balbay et al. 1999). Furthermore, there is an intratumoral heterogeneity of expression of tyrosine kinase growth receptors found in human colon cancer surgical specimens and in orthotopic tumors (Kuwai et al. 2008). Collectively, these data suggest that the expression level of metastasisregulating genes by metastatic cells can be induced by factors in the organ microenvironment and can influence the drug resistant phenotype of metastases. Since the expression of various cytokines, growth factors, and their receptors on metastatic tumor cells and their microenvironment (e.g., endothelial cells) can interact to provide survival advantage and mediate MDR phenotype, combining chemotherapy and targeting the receptors of specific tyrosine protein kinases may be effective in treating metastatic diseases. Our group has been successful in such combination therapies against several metastatic cancers in orthotopic animal models. These included inhibiting the EGFR signaling by PKI166 in human renal cell carcinoma growing orthotopically in nude mice (Kedar et al. 2002); targeting the expression of platelet-derived growth factor receptor (PDGF-R) by STI571 (Kim et al. 2006); targeting EGF-R by PKI166 and VEGF-R by AEE788 with irinotecan in orthotopic colon carcinoma (Kitadai et al. 2006; Sasaki et al. 2007); simultaneously inhibiting EGF-R/VEGF-R by AEE788 and PDGF-R by STI571 with gemcitabine against human pancreatic carcinoma (Yokoi et al. 2005); targeting tumor cells and tumor-associated endothelial cells in human prostate cancer cells growing in the bone of nude mice by inhibiting EGF-R using PKI166 (Kim et al. 2003); inhibiting EGF-R by PKI166 and PDGF-R by STI571 with taxol (Kim et al. 2004); or STI571 with zoledronate and paclitaxel (Kim et al. 2005).
Tumor Angiogenesis The survival and growth of cells is dependent on an adequate supply of oxygen and nutrients and on the removal of toxic molecules. Oxygen can diffuse from capillaries for only 150–200 μm. When distances of cells from a blood supply exceed this, cell death follows (Gimbrone et al. 1974; Folkman and Klagsbrun 1987; Kerbel and Folkman 2002; Fidler and Ellis 2004). Thus, the expansion of tumor masses beyond 1 mm in diameter depends on neovascularization, i.e., angiogenesis
34
D. Fan et al.
(Folkman 1986). The formation of new vasculature consists of multiple, interdependent steps. It begins with local degradation of the basement membrane surrounding capillaries, followed by invasion of the surrounding stroma and migration of endothelial cells in the direction of the angiogenic stimulus (Fidler et al. 2005). Proliferation of endothelial cells occurs at the leading edge of the migrating column, and the endothelial cells begin to organize into three-dimensional structures to form new capillary tubes (Auerbach and Auerbach 1994). Differences in cellular composition, vascular permeability, blood vessel stability, and growth regulation distinguish vessels in neoplasms from those in normal tissue (Fidler and Ellis 1994). The onset of angiogenesis involves a change in the local equilibrium between proangiogenic and antiangiogenic molecules (Fidler 2001; Kerbel and Folkman 2002). Some of the common proangiogenic factors include bFGF, which induces proliferation in a variety of cells and has also been shown to stimulate endothelial cells to migrate, to increase production of proteases, and to undergo morphogenesis (Folkman and Klagsbrun 1987). Likewise, VEGF/VPF has been shown to induce the proliferation of endothelial cells, to increase vascular permeability, and to induce production of urokinase plasminogen activator by endothelial cells (Dvorak 1986; Dvorak et al. 1995). Additional proangiogenic factors include IL-8, a cytokine produced by a variety of tissues and blood cells (Singh et al. 1994; Yoneda et al. 1998), platelet-derived endothelial cell growth factor, which has been shown to stimulate endothelial cell DNA synthesis and to induce production of FGF (Kim et al. 2005, 2006), hepatocyte growth factor (HGF), or scatter factor, that increases endothelial cell migration, invasion, and the production of proteases (Bussolino et al. 1992), and platelet-derived growth factor (PDGF) (Risau et al. 1992). Moreover, the structure and architecture of tumor vasculature can dramatically differ from those found in normal organs (Ebhard et al. 2000; Nor and Pulverini 1999; Nels et al. 1992). Indeed, blood vessels in tumors are different than those found in wound healing, and inflamed tissues. The blood flow through tumors can be tortuous and is characterized by regions of necrosis, rapid cell division, and presence of infiltrate cells. Receptors for VEGF (KDR in humans, Flt-1 in mice) are expressed specifically by tumor endothelium as well as the angiopoietin tyrosine kinase receptor, Tie-2 (reviewed in Liu et al. 2000). In addition, receptors for PDGF and EGF are found on tumor endothelial cells (Uehara et al. 2003; Suhardja and Hoffman 2003). The endothelium is fragile, and upregulation of survival factors (such as Bcl-2 and survivin) by molecules found in abundance within the tumor microenvironment such as VEGF and bFGF helps to prevent apoptosis of new endothelium (Wang et al. 2002; Karsan et al. 1997; Gerber et al. 1998). There is increased leakiness to macromolecules (perhaps due to the presence of VEGF) (Jain 1987; Dvorak 1990), and vessels often lose distinct features of arteriole, capillary, and venule formation. Modern techniques, such as phage-display targeting, have defined “vascular addresses” that may be distinct for different organs as well as tumors in those organs and perhaps offer attractive targets for antivasculature therapy (Pasqualini et al. 2002). Angiogenic heterogeneity exists within a single tumor (zonal or intralesional) between different metastases even in a single organ, and different neoplasms of the
2 Metastasis and Drug Resistance
35
same histologic type are also documented (Kumar et al. 1998; Yu et al. 2001). For example, the expression of proangiogenic molecules (and, therefore, blood vessel density) in murine or human tumors growing at orthotopic sites in athymic mice is zonal, i.e., demonstrates intralesional heterogeneity. Small tumors (3–4 mm in diameters) expressed more bFGF and IL-8 than large tumors (>10 mm in diameters), whereas more VEGF is expressed in large tumors. Immunostaining showed a heterogeneous distribution of these angiogenic factors within the tumor; expression of bFGF and Il-8 was highest on the periphery of a large tumor, where cell division was maximal. VEGF expression was higher in the center of the tumor (Kumar et al. 1998). Similarly, heterogeneous dependence on angiogenesis was reported for cell subpopulations isolated from human melanoma xenografts having differential expression of hypoxia-inducing factor-1 (Yu et al. 2001). Heterogeneity of blood vessel distribution in surgical specimens of human cancers is well documented (Weidner et al. 1992). Benign neoplasms are sparely vascularized and tend to grow slowly in contrast to highly vascularized and rapidly growing malignant tumors (Weidner et al. 1992). The distribution of vessels in a tumor, however, is not uniform, and Weidner et al. cautioned that to predict the aggressive nature of human cancers, one must determine the mean vessel density (MVD) in the “areas of most intense neovascularization”, i.e., tumors exhibit intralesional and zonal heterogeneity for MVD (Weidner et al. 1992; Jain 1987, 2008). Similarly, the expression of proangiogenic molecules in surgical specimens of human colon carcinoma was determined by in situ hybridization technique. Matrix metalloproteinase-9 and bFGF were overexpressed at the periphery of the tumor where cells were rapidly dividing, whereas VEGF expression was higher in the center of the lesions (Kitadai et al. 1995). The extent of angiogenic heterogeneity in malignant neoplasms is also regulated by the organ microenvironment. For example, human renal carcinoma cells implanted into the kidney of athymic mice produced a high incidence of lung metastasis, whereas those implanted subcutaneously did not (Singh et al. 1994). Histopathologic examination of the tissues revealed that the tumors grown in the subcutis of nude mice had few blood vessels, as compared to tumors in the kidney. The subcutaneous tumors also had a significantly lower level of mRNA transcripts for bFGF than tumor in the kidney, and the expression of the naturally occurring angiogenic inhibitor, IFN-β (which downregulates bFGF) was high in epithelial cells and fibroblasts surrounding the subcutaneous tumors. This was not detected in or around tumors grown in the kidney (Singh et al. 1995). The production of IL-8 by melanoma cells is regulated by complex interactions with skin keratinocytes (Herlyn 1990). IL-8 expression can be increased by co-culture of melanoma cells with skin keratinocytes, and this expression is inhibited by coincubation of melanoma cells with hepatocytes from the liver (Gutman et al. 1995). The organ microenvironment also influences the expression of VEGF. Human gastric cancer cells implanted into the stomach were highly vascularized and expressed high levels of VEGF, as compared to implantation into an ectopic (subcutaneous) site, such as the skin. In addition, metastasis only occurred from the tumor implanted in the stomach (Takahashi et al. 1996).
36
D. Fan et al.
The molecular cross-talk that occurs with tumor cells and endothelium within the tumor microenvironment results in sufficient recruitment of a vascular supply that has physiological properties that allow migration and eventual escape of subpopulations of tumor cells able to complete a cascade of events necessary for metastasis.
Antivascular Therapy of MDR Prostate Carcinoma Cancer of the prostate is the most common cancer affecting men in North America and is the second leading cause of cancer-related deaths. Mortality from prostate cancer usually results from the metastasis of hormone-refractory cancer cells. Reports examining the pattern of metastasis in advanced prostate cancer indicate that dissemination to bone and lymph nodes occurs in over 80% of the cases (Garnick and Fair 1996). The pathophysiology of prostate cancer bone metastases is complex and involves the interaction of tumor cells with osteoclasts, osteoblasts, endothelial cells and an assortment of regulatory proteins (e.g., steroid hormones, cytokines, and growth factors). To study the factors that are critical for growth of prostate cancer cells in the bone, we established a murine model of hormone-refractory prostate cancer bone metastasis. To generate prostate cancer growth in the bone, we performed a percutaneous intraosseal injection on nude mice by inserting a 27-gauge needle into the tibia immediately proximal to the tuberositas tibia (Uehara et al. 2003). After penetrating the cortical bone, we deposited 20 μl of tumor cell suspension (2 × 105 androgen-independent PC3-MM2 cells) in the bone cortex with the use of a calibrated, push button-controlled dispensing device. Five weeks later, we resected the tumor-bearing leg and performed an extensive immunohistochemical survey of the bone lesions in an effort to identify potential factors that may be involved in the regulation of prostate tumor cell growth. A preliminary immunohistochemical evaluation revealed robust tumor cell expression of bFGF, VEGF, IL-8, PDGF BB, and its receptor PDGFR-Rβ. Expression of these proteins was most pronounced in tumors that were growing adjacent to the bone. In contrast, in those tumors that had lyzed the bone and extended their growth to include the surrounding muscle, we detected only minimal levels of the angiogenic proteins, suggesting that factors within the bone environment were influencing the phenotype of the tumor cells. A more comprehensive examination of distribution pattern of PDGFRβ revealed that PDGFR-β was present on both prostate tumor cells and on tumor-associated endothelium and that, moreover, this receptor tyrosine kinase was activated. Phosphorylated PDGFR-β was not found in either the contralateral nontumor leg or in tumor cells growing away from the bone, i.e., in the muscle. These findings indicate that the PDGF BB produced by tumor cells was acting in an autocrine manner to stimulate tumor cells and in a paracrine fashion to convey information to tumorassociated endothelial cells. The expression pattern of activated PDGFR-β in the bone metastases suggested that it might be a target for therapy in that inhibition of
2 Metastasis and Drug Resistance
37
this signaling cascade could potentially affect both the malignant cell population and the tumor blood supply. To test this hypothesis, we treated mice with experimental bone metastasis using the tyrosine kinase inhibitor of PDGFR-β, STI571 (imatinib mesylate, Gleevec). In mice treated with STI571 or the combination of STI571 plus paclitaxel, we found induction of significant apoptosis of endothelial cells and tumor cells that resulted in inhibition of tumor growth, a significant decrease of lymphatic metastases, and a significant decrease of bone lysis (Uehara et al. 2003). These experiments demonstrated that tumor-associated endothelial cells express phosphorylated PDGFR when adjacent tumor cells express PDGF, and that inhibition of this activation with a PDGFR tyrosine kinase inhibitor, particularly in combination with chemotherapy, can produce significant therapy. To determine the molecular mechanism for the antiangiogenic effects observed on the tumor-associated endothelial cells in vivo, we established cultures of murine bone microvascular endothelial cells and examined their response to stimulation with PDGF BB ligand and to blockade of PDGFR signaling with STI571 (Langley et al. 2004). Cultured bone endothelial cells expressed PDGFR-β, and PDGF BB-induced phosphorylation on these cells could be inhibited by STI571 in a dosedependent manner. Stimulation of the bone endothelial cells with PDGF BB resulted in activation of Akt and ERK1/2, and this signaling cascade could be completely abrogated by STI571. In addition, we found that bone endothelial cells respond to PDGF BB by increasing their cell division and upregulating the anti-apoptotic protein Bcl-2. We then examined the response of bone endothelial cells to treatment with STI571 and taxol. Treatment of bone endothelial cells with only a single agent produced little effect. However, the combined treatment of STI571 and taxol resulted in a significant increase in the number of cells expressing activated caspase3 and a concomitant decline in Bcl-2. Consistent with these results, we found that when bone endothelial cells were confronted with both STI571 and low levels of taxol, there was a threefold increase in their cytotoxicity. Collectively, these data suggest that a primary target for the STI571 and paclitaxel therapy may be the tumor-associated blood vessels. To test this hypothesis, we established a multidrug resistant prostate cell line by chronically exposing PC3MM2 cells to increasing concentrations of taxol (Kim et al. 2006). The resulting cell line, PC3-MM2-MDR, is 70 times more resistant to paclitaxel in vitro, and the growth of the cells is not affected by treatment with paclitaxel or the combination of paclitaxel and STI571. When the PC3-MM2-MDR cells were implanted into the bone microenvironment, they displayed the same angiogenic profile as the parental cell line. Endothelial cells in normal tissues rarely divide, whereas 2–3% of the endothelial cells in prostate cancer divide daily (Augustin et al. 2002; Eberhard et al. 2000). These dividing endothelial cells should be sensitive to anticycling drugs such as paclitaxel. Nevertheless, in the present experiment, paclitaxel did not decrease the MVD appreciably, likely because of the fact that stimulation of endothelial cells with PDGF leads to resistance to paclitaxel, and that blockade of PDGF-R phosphorylation with imatinib reverses the resistance to paclitaxel (Langley et al. 2003). As stated above, the first wave of apoptosis in bone tumors from mice treated with imatinib and paclitaxel for only 2 weeks occurred in tumor-associated endothelial cells,
38
D. Fan et al.
followed by apoptosis of tumor cells and ultimately tumor necrosis. By the fourth week of treatment with imatinib and paclitaxel or imatinib alone, concurrent apoptosis of tumor cells and tumor-associated endothelial cells was observed. Without paclitaxel, imatinib may produce therapeutic effects by the blockade of PDGF-R, which serves as a survival factor (Langley et al. 2003). Thus, the imatinib-induced blockade of PDGF-R combined with paclitaxel appears to target the tumor-associated endothelial cells. Whether this approach can be useful for other types of tumors is unknown. The heterogeneity of angiogenesis in human tumors and the findings that endothelial cells of different organs are phenotypically distinct (Langley and Fidler 2007) indicate that further investigations to understand the interaction of different types of tumor cells and endothelial cells in different organs are necessary for the development of optimal regimens of targeted antivascular therapies. For this reason, we performed another series of experiments using the multidrug resistant PC-3MM2-MDR cells growing in the prostate of nude mice and treated the mice with paclitaxel and the tyrosine kinase inhibitor, AEE788, that targets phosphorylation of EGF-R/VEGF-R (Busby et al. 2006). The significant inhibition of local tumor growth and lymph node metastases again demonstrated that tumor-associated endothelial cells, rather than the tumor cells, were the primary target of the chemotherapy. Those studies provide a better understanding of the molecular mechanisms that regulate the process of metastasis and of the complex interactions between the metastatic cells and the organ microenvironment (Kim et al. in press).
References Abderrabi, M., Marchal, S., and Merlin, J. L. 1996. Comparative in vitro evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulators. Anticancer Drugs 7:430–436. Adachi, T., Nakagawa, H., Chung, I., Hagiya, Y., Hoshijima, K., Noguchi, N., Kuo, M. T., and Ishikawa, T. 2007. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J. Exp. Ther. Oncol. 6:335–348. Aftab DT, Yang JM, Hait WN. 1994. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol. Res. 6:59–70. Ahkong, Q. F., Cramp, F. C., Fisher, D., Howell, J. I., Tampion, W., Verrinder, M., and Lucy, J. A. 1973. Chemically-induced and thermally-induced cell fusion:lipid-lipid interactions. Nature (New Biol.) 242:215–217. Ahmad, I., Longenecker, M., Samuel, J., and Allen, T. M. 1993. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53:1484–1488. Akiyama, S., Cornwell, M. M., Kuwano, M., Pastan, I., and Gottesman, M. M. 1988. Most drugs that reverse multidrug resistance inhibits photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol. Pharmacol. 33:144–147. Akiyama, S., Gottesman, M. M., Hanover, J. A., FitzGerald, D. J. P., Willingham, M. C., and Pastan, I. 1984. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J. Cell Physiol. 120:271.
2 Metastasis and Drug Resistance
39
Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589–601. Ambudkar, S. V., Lelong, I. H., Zhang, J., Cardarelli, C. O., Gottesman, M. M., and Pastan, I. 1992. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. USA 89:8472–8476. Arceci, R. J., Croop, J. M., Horwitz, S. B., and Housman, D. 1988. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc. Natl. Acad. Sci. USA 85:4350–4354. Arceci, R. J., Stieglitz, K., and Bierer, B. E. 1992. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80:1528–1536. Auerbach, W., and Auerbach, R. 1994. Angiogenesis inhibition: a review. Pharmacol. Ther. 63:265–311. Augustin, H. G., Kmeta, J., Alves, F., Baumbach, J., Eberhard, A., Kahlert, S., and Dandekar, G. 2002. Quantitating angiogenesis and assessing the causal relationship between angiogenesis and tumorigenesis: problems and progress. Ann. Hematol. 81(suppl. 2):68–72. Balbay, D., Pettaway, C. A., Kuniyasu, H., Inoue, K., Ramirez, E., Li, E., and Fidler, I. J. 1999. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses a vascular endothelial growth factor. Clin. Cancer Res. 5:783–789. Beck, W. T., Cirtain, M. C., Glover, C. J., Felsted, R. L., and Safa, A. R. 1988. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem. Biophys. Res. Commun. 153:959–966. Beck, W. T., and Qian, X. D. 1992. Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol. 43:89–93. Benson, A. B., Trump, D. L., Koeller, J. M., Egorin, M. I., Olman, E. A., Witte, R. S., Davis, T. E., and Tormey, D. C. 1985. Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat. Rep. 69:795–799. Bergelson, L. D., Dyatlovitskaya, E. V., Torkhovskaya, T. I., Sorokina, I. B., and Gorkova, N. P. 1970. Phospholipid composition of membranes in the tumor cell, Biochim. Biophys. Acta, 210:287. Berman, E., Adams, M., Duigou-Osterndorf, R., Godfrey, L., Clarkson, B., and Andreeff, M. 1991. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 78: 1385–1387. Bessho, F., Kinumaki, H., Kobayashi, M., Habu, H., Nakamura, K., Yokota, S., Tsuruo, T., and Kobayashi, N. 1985. Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med. Pediatr. Oncol. 13:199–202. Bitonti, A. J., Sjoerdsma, A., McCann, P. P., Kyle, D. E., Oduola, A. M. J., Rossan, R. N., Milhous, W. K., and Davidson, D. E. Jr. 1988. Reversal of chloroquine resistance in malaria parasite plasmodium falciparum by desipramine. Science 242:1301–1303. Boesch, D., Muller, K., Pourtier-Manzanedo, A., and Loor, F. 1991. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res. 196:26–32. Bucana, C. D., Giavazzi, R., Nayar, R., O Brian, C. A., Seid, C., and Fan, D. 1990. Retention of vital dyes correlates inversely with the multidrug resistant phenotype of Adriamycin-selected murine fibrosarcoma variants. Exp. Cell Res. 190:69–75. Busby, J. E., Kim, S. J., Yazici, S., Nakamura, T., Kim, J. S., He, J., Maya, M., Wang, X., Do, K. A., Fan, D., and Fidler, I. J. 2006. Therapy of multidrug resistant prostate cancer by targeting the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumorassociated endothelial cells. Prostate 66:1788–1798. Bussolino, F., DiRenzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., and Comoglio, P. M. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119: 629–641.
40
D. Fan et al.
Cairo, M. S., Siegel, S., Anas, N., and Sender, L. 1989. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res. 49:1063–1066. Chabner, B. A., Bates, S. E., Fojo, A. T., Spolyar, M., and Wilson, W. H. 1994. Drug resistance in adult lymphomas. Semin. Hematol. 31:70–87. Chambers, S. K., Hait, W. N., Kacinski, B. M., Keyes, S. R., and Hand-Schumacher, R. E. 1989. Enhancement of anthracycline growth inhibition in parent and multidrugresistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res. 49: 6275–6279. Chao, N. J., Aihara, M., Blume, K. G., and Sikic, B. I. 1990. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. Exp. Hematol. 18:1193–1198. Chatterjee, M., and Harris, A. L. 1990. Reversal of acquired resistance to Adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen:role of drug interaction with alpha 1 acid glycoprotein. Br. J. Cancer 62:712–717. Chatterjee, M., Robson, C. N., and Harris, A. L. 1990. Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. Cancer Res. 50:2818–2822. Chen, G., Ramachandran, C., and Krishan, A. 1993. Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to P-glycoprotein. Cancer Res. 53:2544–2547. Coon, J. S., Knudson, W., Clodfelter, K., Lu, B., and Weinstein, R. S. 1991. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 51:897–902. Cornwell, M. M., Pastan, I., and Gottesman, M. M. 1987. Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262:2166–2170. Deffie, A. M., Alam, T., Seneviratne, C., Beenken, S. W., Batra, J. K., Shea, T. C., Henner, W. D., and Goldenberg, G. J. 1988. Multifactorial resistance to Adriamycin:relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res. 48:3595–3602. DeVita, V. T., Oliverio, V. T., Muggia, F. M., Wiernik, P. W., Ziegler, J., Goldin, A., Rubin, D., Henney, J., and Schepartz, S. 1979. The drug development and clinical trials programs of the Division of Cancer Treatment, National Cancer Institute. Cancer Clin. Trials 2:195–216. Dhainaut, A., Regnier, G., Atassi, G., Pierre, A., Leonce, S., Kraus-Berthier, L., and Prost, J. F. 1992., New triazine derivatives as potent modulators of multidrug resistance. J. Med. Chem. 35:2481–2496. Dietel, M., Boss, H., Reymann, A., Pest, S., and Seidel, A. 1996. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil. J. Exp. Ther. Oncol. 1:23–29. Doige, C. A., Yu, X., and Sharom, F. J., 1993. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim. Biophys. Acta 1146:65–72. Dong, Z., Radinsky, R., Fan, D., Tsan, R., Bucana, C. D., Wilmanns, C., and Fidler, I. J. 1994. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J. Natl. Cancer Inst. 86:913–920. Dorr, R. T., and Liddil, J. D. 1991. Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemother. Pharmacol. 27:290–294. Dutour, A., Leclers, D., Monteil, J., Paraf, F., Charissoux, J. L., Rousseau, R., and Rigaud, M. 2007. Non-invasive imaging correlates with histological and molecular characteristics of an osteosarcoma model: application for early detection and follow-up of MDR phenotype. Anticancer Res. 27:4171–4178. Dvorak, H. F., Brown, L. F., Detmar, M. and Dvorak, A. M. 1995. Vascular permeability factor/vascular endothelial growth factor, Microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029–1039.
2 Metastasis and Drug Resistance
41
Dvorak, H. F. 1990. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog. Clin. Biol. Res. 354A:317–330. Dvorak, H. F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 15(26):1650–1659. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. 2000. Heterogeneity of angiogenesis and blood vessel maturation in human tumors:implications for antiangiogenic tumor therapies. Cancer Res. 60:1388–1393. Elwood, J. C., and Morris, H. P. 1968. Lack of adaptation in lipogenesis by hepatoma 9121, J. Lipid Res. 9:337. Epand, R. F., Epand, R. M., Gupta, R. S., and Cragoe, E. J., Jr. 1991. Reversal of intrinsic multidrug resistance in Chinese hamster ovary cells by amiloride analogs. Br. J. Cancer 63:247–251. Fan, D., Baker, F. L., Khokhar, A. R., Ajani, J. A., Tomasovic, B., Newman, R. A., Brock, W. A., Tueni, E., and Spitzer, G. 1988. Antitumor activity against human tumor samples of cisdiamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. Cancer Res. 48:3135–3139. Fan, D., Bucana, C. D., O Brian, C. A., Zwelling, L. A., Seid, C., and Fidler, I. J. 1990. Enhancement of tumor cell sensitivity to Adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res. 50:3619–3626. Fan, D., Fidler, I.J., Ward, N.E., Seid, C., Earnest, L.E., Housey, G.M., and O Brian, C.A. 1992a. Stable expression of a cDNA encoding rat brain protein kinase C-ßI confers a multidrugresistant phenotype on rat fibroblasts. Anticancer Res. 12:661–668. Fan, D., Morgan, L. R., Schneider, C., Blank, H., and Fan, S. 1985. Cooperative evaluation of human tumor chemosensitivity in the soft-agar assay and its clinical correlations. J. Cancer Res. Clin. Oncol. 109:23–28. Fan, D., Poste, G., O Brian, C. A., Seid, C., Ward, N. E., Earnest, L. E., and Fidler, I. J. 1992b. Chemosensitization of murine fibrosarcoma cells to drugs affected by the multidrug resistance phenotype by the antidepressant trazodone: an experimental model for the reversal of intrinsic drug resistance. Int. J. Oncol. 1:735–742. Fan, D., Poste, G., Ruffolo, R. R., Jr., Dong, Z., Seid, C., Earnest, L. E, Campbell, T. E., Clyne, R. K., Beltran, P. J., and Fidler, I. J. 1994a. Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine. Int. J. Oncol. 4:789–798. Fan, D., Poste, G., Seid, C., Earnest, L. E., Bull, T., Clyne, R. K., and Fidler, I. J. 1994b. Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. Invest. New Drug 12:185–195. Fan, D., Price, J., Schackert, H., Seid, C., Wilmanns, C., Chakrabarty, S., and Fidler, I. J. 1989. Antiproliferative activity of liposome-encapsulated transforming growth factor-beta against MDA-MB-435 human breast carcinoma cells. Cancer Commun. 1:337–343. Fan, D., and Voelz, H. 1980. A plasma membrane-associated phospholipase in SV40-transformed 3T3 cells. Exp. Cell Res. 126:47–55. Fan, D., and Voelz, H. 1984. Phospholipase activity in human tumors: localization by cytochemical staining. J. Cancer Res. Clin. Oncol. 107:242–244. Fan, D., and Voelz, H. 1977. Phospholipid degradation by SV40-transformed murine fibroblasts. Exp. Cell Res. 106:79–87. Fidler, I. J. 2001. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment (Editorial). J. Natl. Cancer Inst. 93:1040–1041. Fidler, I. J. 1990. Critical factors in the biology of human cancer metastasis:twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 50:6130–6138. Fidler, I. J. 1995. Modulation of the organ microenvironment for treatment of cancer metastasis (Editorial). J. Natl. Cancer Inst. 84:1588–1592. Fidler, I. J. 1997. Molecular biology of cancer: invasion and metastasis. In Cancer: Principles and Practice of Oncology, eds. V. T. DeVita, S. Hellman, and S. A. Rosenberg,pp 135–152. Philadelphia: Lippincott-Raven.
42
D. Fan et al.
Fidler, I. J. 2001. Seed and soil revisited. Cancer Metastasis: Biol. Clin. Aspects 10:257–269. Fidler, I. J. 1973. Selection of successive tumor lines for metastasis. Nature (New Biol.) 242: 148–149. Fidler, I. J. 1988. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv. Drug Deliv. Rev. 3:405–418. Fidler, I. J. 2002. The organ microenvironment and cancer metastasis. Differentiation 70: 498–505. Fidler, I. J. 2003. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited (Timeline). Nat. Rev. Cancer 3:3453–458. Fidler, I. J. 1978. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38:2651–2660. Fidler, I. J. and Ellis, L. M. 2004. Neoplastic angiogenesis: All blood vessels are not created equal. N. Engl. J. Med. (Perspective), 351:215–216. Fidler, I. J., and Ellis, L. M. 1994. The implications of angiogenesis to the biology and therapy of cancer metastasis (Minireview). Cell, 79:185–188. Fidler, I. J., and Hart, I. R. 1982. Biological diversity in metastatic neoplasms: origins and implications. Science 217:998–1003. Fidler, I. J., and Kripke, M. L. 1977. Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893–895. Fidler, I. J., Langley, R. R., Kerbel, R. S., and Ellis, L. M. 2005. Biology of cancer: angiogenesis. In: Cancer: Principles and Practice of Oncology, 7th edt., eds. V. T, DeVita, Jr., S. Hellman, and S. A. Rosenberg,pp. 129–137. Philadelphia, PA: Lippincott & Wilkins. Fidler, I. J., and Poste, G. 1985. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin. Oncol. 12:207–221. Fidler, I. J., and Talmadge, J. 1986. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res. 46:5167–5171. Figueredo, A., Arnold, A., Goodyear, M., Findlay, B., Neville, A., Normandeau, R., and Jones, A. 1990. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer 65:1895–1902. Fine, R. L., Koizumi, S., Curt, G. A., and Chabner, B. A. 1987. Effects of calcium channel blockers on human CFU-GM with cytotoxic drugs. J. Clin. Oncol. 5:489–495. Fleming, G. F., Amato, J. M., Agresti, M., and Safa, A. R. 1992. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother. Pharmacol. 29: 445–449. Fogler, W. E., Wade, R., Brundish, D. E., and Fidler, I. J. 1985. Distribution and fate of free and liposome-encapsulated [3 H]nor-muramyl dipeptide and [3 H]muramyl tripeptide phosphatidylethanolamine in mice. J. Immunol. 135:1372–1377. Fojo, A. T., Akiyama, S., Gottesman, M. M., and Pastan, I. 1985. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 45:3002–3007. Fojo, A. T., and Bates, S. 2003. Strategies for reversing drug resistance. Oncogene 22: 7512–7523. Folkman, J. 1986. How is blood vessel growth regulated in normal and neoplastic tissue? – Twentysixth GHA Clowes Memorial Award Lecture. Cancer Res. 46:467–473. Folkman, J. and Klagsbrun, M. 1987. Angiogenic factors. Science 235:444–447. Ford, J. M., Bruggeman, E. P., Pastan, I., Gottesman, M. M., and Hait, W. N. 1990. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 50:1748–1756. Ford, J. M., and Hait, W. N. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmcol. Rev. 42:155–199. Ford, J. M., Prozialeck, W. C., and Hait, W. N. 1989. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:105–115.
2 Metastasis and Drug Resistance
43
Forssen, E. A., and Tokes, Z. A. 1981. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA 78:1873–1877. Foxwell, B. M. J., Mackie. A., Ling, V., and Ryffel, B. 1989. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporin binding protein. Mol. Pharmacol. 36: 543–546. Franson, R., Patriaria, P., and Elsbach, P. 1974. Phospholipid metabolism by phagocytic cells. Phospholipase A2 associated with rabbit polymorphonuclear leukocyte granules. J. Lipid Res. 15:380–388. Frei, E. 1982. The national cancer chemotherapy program. Science 217:600–606. Friche, E., Jensen, P. B., Sehested, M., Demant, E. J., and Nissen, N. N. 1990. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun. 2:297–303. Ganapathi, R., Grabowski, D., Turinic, R., and Valenzuela, R. 1984. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (Adriamycin) in resistant P388 mouse leukemia cells. Eur. J. Cancer Clin. Oncol. 20:799–806. Garcia-Segura, L. M., Soto, F., Planells-Cases, R., Gonzalez-Ros, J. M., and Ferragut, J. A. 1992. Verapamil reverses the ultrastructural alterations in the plasma membrane induced by drug resistance. FEBS Lett. 314:404–408. Garnick, M. B., and Fair, W. R. 1996. Prostate cancer:emerging concepts (Part II). Ann. Intern. Med. 125:205–212. Gerber, H. P., Dixit, V., and Ferrara, N. 1998. Vascular endothelial growth factor induces expression of the anti-apoptotic proteins Bcl-2 and A1 in vascular endothelial cells. Am. J. Pathol. 158:1757–1765. Gimbrone, M., Cotran, R. and Folkman, J. 1974. Tumor growth and neovascularization:an experimental model using rabbit cornea. J. Natl. Cancer Inst. 52:413–427. Ginsburg, H., and Krugliak, M. 1992. Quinoline-containing anti-malarials–mode of action, drug resistance and its reversal. An update with unresolved puzzles. Biochem. Pharmacol. 43: 63–70. Goldberg, H., Ling, V., Wong, P. Y., and Skorecki, K. 1988. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 152:552–558. Gosland, M. P., Lum, B. L., and Sikic, B. I. 1989. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res. 49:6901–6905. Greene, G., Kitadai, Y., Pettaway, C. A., von Eschenbach, A. C., and Fidler, I. J. 1997. Correlation of metastasis-related gene expression with metastatic potential in prostate carcinoma cells implanted in nude mice using an in situ mRNA hybridization technique. Am. J. Pathol. 150:1571–1582. Gutman, M., Singh, R. K., Xie, K., Bucana, C. D., and Fidler, I. J. 1995. Regulation of IL-8 expression in human melanoma cells by the organ environment. Cancer Res. 55:2470–2475. Hait, W. N., Gesmonde, J. F., Murren, J. R., Yang, J. M., Chen, H. X., and Reiss, M. 1993. Terfenadine (Seldane):a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. Pharmacol. 26;45:401–406. Hait, W. N., Stein, J. M., Koletsky, A. J., Harding. M. W., and Handschumacher, R. E. 1989. Activity of cyclosporin A and a non-immunosuppressive cyclosporin on multidrug resistant leukemic cell lines. Cancer Commun. 1:35–43. Hait, W. N., and Yang, J. M. 2005. Clinical management of recurrent breast cancer:development of multidrug resistance (MDR) and strategies to circumvent it. Semin. Oncol. 32:S16–S21. Hamada, H., Okochi, E., Oh-hara, T., and Tsuruo, T. 1988. Purification of the Mr 22,000 calciumbinding protein (sorcin) associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res. 48:3173–3178. Hammond, L. A., Davidson, K., Lawrence, R., Camden, J. B., Von Hoff, D. D., Weitman, S., and Izbicka, E. 2001. Exploring the mechanisms of action of FB642 at the cellular level. J. Cancer Res. Clin. Oncol. 127:301–313.
44
D. Fan et al.
Harker, W. G., Bauer, D., Etiz, B. B., Newman, R. A., and Sikic, B. I. 1986. Verapamil-mediated sensitization of doxorubicin-selected pleiotrophic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res. 46:2369–2373. Hatten, M. E., Horwitz, A. F., and Burger, M. M. 1977. The influence of membrane lipids on the proliferation of transsformed and untransformed cell lines. Exp. Cell Res. 107:31. He, L., and Liu, G. Q. 2002. Effects of various principles from Chinese herbal medicine on rhodamine123 accumulation in brain capillary endothelial cells. Acta Pharmacol Sin. 23: 591–596. Herlyn, M. 1990. Human melanoma: development and progression. Cancer Metastasis Rev. 9: 101–112. Herzog, C. E., Tsokos, M., Bates, S. E., and Fojo, A. T. 1993. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J. Biol. Chem. 268:2946–2952. Hofmann, J., Ueberall, F., Egle, A., and Grunicke, H. 1991. B-859–35, a new drug with anti-tumor activity reverses multi-drug resistance. Int. J. Cancer 47:870–874. Hofsli, E., and Nissen-Meyer, J. 1989. Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: reversal of drug resistance by erythromycin. Int. J. Cancer 43:520–525. Hollt, V., Kouba, M., Dietel, M., and Vogt, G. 1992. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol. 43:2601–2608. Holmes, J., Jacobs, A., Carter, G., Janowska-Wieczorek, A., and Padua, R. A. 1989. Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia. Br. J. Haematol. 72:40–44. Holzmayer, T. A., Hilsenbeck, S., Von Hoff, D. D., and Roninson, I. B. 1992. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst. 84:1486–1491. Hope, M. J., and Cullis, P. R. 1980. Effects of divalent cations and pH on phosphatidylserine model membranes: a 31P NMR study. Biochem. Biophys. Res. Commun. 92:846–852. Hu, F., Wang, R. Y., Hsu, T. C. 1987. Clonal origin of metastasis in B16 murine melanoma: a cytogenetic study. J. Natl. Cancer Inst. 78:155–164. Hu, X. F., Nadalin, G., De Luise, M., Martin, T. J., Wakeling, A., Huggins, R. and Zalcberg, J. R. 1991. Circumvention of doxorubicin resistance in multi-drug resistant human leukemia and lung cancer cells by the pure antioestrogen ICI 164384. Eur. J. Cancer 27:773–777. Huang, S. K., Mayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D. 1992. Pharmacokinetics and therapeutics of sterically stablized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:6774–6781. Huet, S. and Robert, J. 1988. The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels. Int. J. Cancer 41:283–286. Inaba, M., Kobayashi, H., Sakurai, Y., and Johnson, R. R. 1979. Active efflux of daunorubicin and Adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 39:2200–2203. Inaba, M., Watanabe, T., and Sugiyama, Y. 1987. Kinetic analysis of active efflux of vincristine from multidrug-resistant P388 leukemia cells. Jpn. J. Cancer Res. 78:397–404. Jaffr´ezou, J. P., and Laurent, G. 1993. The intriguing link between modulation of both multidrug resistance and ligand-toxin conjugate cytotoxicity. FEBS Lett. 323:191–197. Jaffr´ezou, J. P., Levade, T., Chatelain, P., and Laurent, G. 1992. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer {{2-isopropyl-1-{4-[3-N-methyl-N-(3,4-dimethoxy-b-phenethyl)amino]propyl oxy}benzenesulfonyl}}indolizine, Cancer Res. 52:6440. Jaffr´ezou, J. P., Herbert, J. M., Levade, T., Gau, M. N., Chatelain, P., and Laurent, G. 1991. Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein, J. Biol. Chem. 266:19858. Jain, R. K. 2008. Taming blood vessels to treat cancer. Sci. Am. 298:56–63.
2 Metastasis and Drug Resistance
45
Jain, R. K. 1987. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 151:1775–1784. Juliano, R. L., and Ling, V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152–162. Kacinski, B. M., Yee, L. D., Carter, D., Li, D., and Kuo, M. T. 1989. Human breast carcinoma cell levels of MDR-1 (P-glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumor progesterone receptor content. Cancer Commun. 1:1–6. Karsan, A., Yee, E., Poirier, G. G., Zhou, P., Craig, R., and Harlan, J. M. 1997. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am. J. Pathol. 151:1775–1784. Kartner, N., Riordan, J. R., and Ling, V. 1983. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285–1288. Kedar, D., Baker, C.H., Killion, J. J., Dinney, C. P., and Fidler, I. J. 2002. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 8:3592–3600. Kellen, J. A., Wong, A., Georges, E., and Ling, V. 1991. R-verapamil decreases anti-estrogen resistance in a breast cancer model. Anticancer Res. 11:809–812. Kerbel, R. and Folkman, J. 2002. Clinical translation of angiogenesis inhibtors. Nat. Rev. 2: 727–739. Killion, J. J., Radinsky, R., and Fidler, I. J. 1999. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 17:279–284. Kim, S. J., Baker, C. H., Kitadai, Y., Nakamura, T., Kuwai, T., Sasaki, T., Langley, R. R., and Fidler, I. J. The pathogenesis of cancer metastasis: relevance to therapy. In Principles of Cancer Biotherapy, 5 edn., eds. R. K. Oldham, and R. O. Dillman. London: Kluwer Academic Publishers, in press. Kim, S. J., Uehara, H., Karashima, T., Shepherd, D. L., Killion, J. J., and Fidler, I. J. 2003. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res. 9:1200–1210. Kim, S. J., Uehara, H., Yazici, S., Busby, J. E., Nakamura, T., He, J., Maya, M., Logothetis, C., Mathew, P., Wang, X., Do, K-A., Fan, D., and Fidler, I. J. 2006. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J. Natl. Cancer Inst. 98:783–793. Kim, S. J., Uehara, H., Yazici, S., He, J., Langley, R. R., Mathew, P., Fan, D., and Fidler, I. J. 2005. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and Paclitaxel against experimental bone metastasis of human prostate Cancer. Cancer Res. 65:3707–3715. Kim, S. J., Uehara, H., Yazici, S., Langley, R. R., He, J., Tsan, R., Fan, D., Killion, J. J., and Fidler, I. J. 2004. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res. 64: 4201–4208. Kitadai, Y., Bucana, C. D., Ellis, L. M., Anzai, H., Tahara, E., and Fidler, I. J. 1995. In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am. J. Pathol. 147:1238–1247. Kitadai, Y., Sasaki, T., Kuwai, T., Nakamura, T., Bucana, C. D, and Fidler, I. J. 2006. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am. J. Pathol. 169:2054–2065. Klohs, W. D., Steinkampf, R. W., Havlick, M. J., and Jackson, R. C. 1986. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists. Cancer Res. 46:4352–4356. Kohlhardt, M., Bauer, B., Krause, H., and Fleckenstein, A. 1972. Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibres by the use of specific inhibitors. Pflugers Arch. 335:309–332.
46
D. Fan et al.
Kroemer, H. K., Echizen, H., Heidemann, H., and Eichelbaum, M. 1992. Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260:1052–1057. Kumar, R., Kuniyasu, H., Bucana, C. D., Wilson, M. R., and Fidler, I. J. 1998. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol. Res. 10: 301–311. Kuwai, T., Nakamura, T., Kim, S. J., Sasaki, T., Kitadai, Y., Langley, R. R., Fan, D., Hamilton, S. R., and Fidler, I. J. 2008. Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. Am. J. Pathol. 172:358–366. Lampidis, T. J., Krishan, A., Planas, L., and Tapiero, H. 1986. Reversal of intrinsic resistance to Adriamycin in normal cells by verapamil. Cancer Drug Del. 3:251–259. Langley, R. R., Fan, D., Tsan, R. Z., Rebhun, R., He, J., Kim, S. J., and Fidler, I. J. 2004. Activation of the platelet-derived growth factor receptor enhances survival of murine bone endothelial cells. Cancer Res. (Adv. in Brief), 64:3727–3730. Langley, R. R., Ramirez, K. M., Tsan, R. Z., Van Arsdall, M., Nilsson, M. B., and Fidler, I. J. 2003. Tissue-specific microvascular endothelial cell lines from H-2kb-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 63:2971–2976. Langley, R. R., and Fidler, I. J. 2007. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28:297–321. La Porta, C. A. 2007. Drug resistance in melanoma: new perspectives. Curr. Med. Chem. 14: 387–391. Lehne, G., Mørkrid, L., den Boer, M., Rugstad, H. E. 2000. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int. J. Clin. Pharmacol. Ther. 38:187–195. Lehnert, M., Dalton, W. S., Roe, D., Emerson, S., and Salmon, S. E. 1991. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77:348–354. Lehnert, M., de Giuli, R., Kunke, K., Emerson, S., Dalton, W. S., and Salmon, S. E. 1996. Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur. J. Cancer 32A:862–867. Ling, Y. H., Zou, Y. Priebe, W., and Perez-Soler, R. 1995. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. Int. J. Cancer 61:402–408. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336. List, A. F., Spier, C., Greer, J., Azar, C., Hutter, J., Wolff, S., Salmon, S., Futscher, B., and Dalton, W., 1992. Biochemical modulation of anthracycline resistance in acute leukemia with cyclosporin-A (CSA). Proc. Am. Soc. Clin. Oncol., 11:A865. Liu, W., Ahmad, S. A., Reinmuth, N., Shaheen, R. M., Jung, Y. D., Fan, F., and Ellis, L. M. 2000. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5: 323–328. Loor, F., Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., and Emmer, G. 1992. SDZ 280–446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. Br. J. Cancer 65:11–18. Lopez-Berestein, G., Kasi, L., Rosenblum, M. G., and Hersh, E. M. 1984. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res. 44:375–378. Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., Reuben, J., Juliano, R. L., and Brody, G. P. 1985. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer, a preliminary study. J. Infect. Diseases 151:704–710. Ludwig, J. A., Szak´acs, G., Martin, S. E., Chu, B. F., Cardarelli, C., Sauna, Z. E., Caplen, N. J., Fales, H. M., Ambudkar, S.V., Weinstein, J. N., and Gottesman, M. M. 2006. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 66:4808–4815.
2 Metastasis and Drug Resistance
47
Maeda, O., Terasawa, M., Ishikawa, T., Oguchi, H., Mizuno, K., Kawai, M., Kikkawa, F., Tomoda, Y., and Hidaka, H. 1993. A newly synthesized bifunctional inhibitor W-77, enhances Adriamycin activity against human ovarian carcinoma cells. Cancer Res. 53:2051–2056. Matin, K., Egorin, M. J., Ballesteros, M. F., Smith, D. C., Lembersky, B., Day, R. S., Johnson, C. S., and Trump, D. L. 2002. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. Cancer Chemother. Pharmacol. 50:179–185. Mazzanti, R., Croop, J. M., Gatmaitan, Z., Budding, M., Steiglitz, K., Arceci, R., and Arias, I. M. 1992. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol. Res. 4:359–365. Mechetner, E. B., and Roninson, I. B. 1992. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. USA 89:5824–5828. Mickisch, G. H., Kossig, J., Keilhauer, G., Schlick, E., Tschada, R. K., and Alken, P. M. 1990. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res. 50:3670–3674. Mickisch, G. H., Merlino, G. T., Aiken, P. M., Gottesman, M. M., and Pastan, I. 1991a. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. J. Urol. 146:447–453. Mickisch, G. H., Merlino, G. T., Galski, H., Gottesman, M. M., and Pastan, I. 1991b. Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. U.S.A. 88:547–551. Mickisch, G. H., Pai, L. H., Gottesman, M. M., and Pastan, I. 1992. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res. 52:4427– 4432. Miller, R. L., Bukowski, R. M., Budd, G. T., Purvis, J., Weick, J. K., Shepard, K., Midha, K. K., and Ganapathi, R. 1988. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J. Clin. Oncol. 6:880–888. Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J., and Salmon, S. E. 1991. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9:17–24. Millward, M. J., Cantwell, B. M. J., Lien, E. A., Carmichael, J., and Harris, A. L. 1992. Intermitten high-dose tamoxifen as a potential modifier of multidrug resistance. Eur. J. Cancer 28A: 805–810. Miraglia, E., Viarisio, D., Riganti, C., Costamagna, C, Ghigo, D., and Bosia, A. 2005. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int. J. Cancer 115:924–929. Moins, N., Cayre, A., Chevillard, S., Maublant, J., Verrelle, P., and Finat-Duclos, F. 2000. Effects of MDR reversing agent combinations on the 3H-daunomycin accumulation in drug-sensitive and drug-resistant human cancer cells. Anticancer Res. 20:2617–2623. Morris, D. I., Speicher, L. A., Ruoho, A. E., Tew, K. D., and Seamon, K. B. 1991. Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry, 30:8371–8379. Murren, J. R., Durivage, H. J., Buzaid, A. C., Reiss, M., Flynn, S. D., Carter, D., Hait, W. N. 1996. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Cancer Chemother. Pharmacol. 38:65–70. Mutoh, K., Tsukahara, S., Mitsuhashi, J., Katayama, K., and Sugimoto, Y. 2006. Estrogenmediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. 97:1198–1204. Nair, S. Samy, T. S., and Krishan, A. 1986. Calcium, calmodulin, and protein content of Adriamycin-resistant and -sensitive murine leukemia cells. Cancer Res. 46:229–232. Naito, M., Yusa, K., and Tsuruo, T. 1989. Steroid hormones inhibit binding of Vinca alkaloid to multidrug resistance related P-glycoprotein. Biochem. Biophys. Res. Commun. 158: 1066–1071. Nasioulas, G., Granzow, C., Stohr, M., and Ponstingl, H. 1990. Sensitization of multidrug-resistant mouse ascites HD33 and Chinese hamster ovary CHRC5S3 cells by a photoreactive vinblastine derivative, NAPAVIN. Cancer Res. 50:403–408.
48
D. Fan et al.
Nawrath, H., and Raschack, M. 1987. Effects of (-)-Desmethoxy-verapamil on heart and vascular smooth muscle. J. Pharmacol. Exp. Ther. 242:1090–1097. Nels, V., Denzer, K., and Drenchahn D. 1992. Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res. 270:469–474. Newman, R. A., Fan, D., Munson, H. R., Martin, L. A., and Ahmed. N. K. 1996. MDL 201,307: a novel benzothiazepine modulator of multiple drug resistance. J. Exp. Ther. Oncol. 1: 109–118. Nor, J. E., and Polverini, P. J. 1999. Role of endothelial cell survival and death signals in angiogenesis. Angiogenesis 3:101–116. Ohnishi, S., and Ito, T. 1973. Clustering of lecithin molecules in phosphatidylserine membranes induced by calcium ion binding to phosphatidylserine. Biochem. Biophys. Res. Commun. 51:132–138. Ozols, R. F., Cunnion, R. E., Klecker, R. W., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., and Young, R. C. 1987. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:641–647. Paget, S. 1889. The distribution of secondary growths in cancer of the breast. Lancet 1:571–573. Pajeva, I., Todorov, D. K., and Seydel, J. 2004. Membrane effects of the antitumor drugs doxorubicin and thaliblastine: comparison to multidrug resistance modulators verapamil and transflupentixol. Eur. J. Pharm. Sci. 21:243–250. Paphadjopoulous, D. 1968. Surface properties of acidic phospholipids:interaction of monolayers and hydrated liquid crystals with uni- and bivalent metal ions. Biochim. Biophys. Acta 163:240–254. Pasqualini, R., Arap, W., and McDonald, D. M. 2002. Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med. 8:563–571. Philip, P. A., Joel, S., Monkman, S. C., Dolega-Ossowski, E., Tonkin, K., Carmichael, J., Idle, J. R., and Harris, A. L. 1992. A phase I study on the reversal of multidrug resistance (MDR) in vivo:nifedipine plus etoposide. Br. J. Cancer 65:267–270. Piekarz, R. L., Cohen, D., and Horwitz, S. B. 1993. Progesterone regulates the murine multidrug resistance mdr1b gene. J. Biol. Chem. 268:7613–7616. Pirker, R., FitzGerald, D. J. P., Raschack, M., Zimmermann, F., Willingham, M. C., and Pastan, I. 1989. Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res. 49:4791–4795. Pirker, R., Keilhauer, G., Raschack, M., Lechner, C., and Ludwig, H. 1990. Reversal of multidrug resistance in human KB cell lines by structural analogs of verapamil. Int. J. Cancer 45: 916–919. Poste, G., and Fidler, I. J. 1979. The pathogenesis of cancer metastasis. Nature (Lond.) 283: 139–146. Racker, E. 1972. Reconstitution of a calcium pump with phospholipids and a purified Ca++adenosine triphosphatase from sarcoplasmic reticulum, J. Biol. Chem. 247:8189. Rahman, A., Husain, S. R., Siddiqui, J., Verma, M., Agresti, M., Center, M., Safa, A. R., and Glazer, R. I. 1992. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl. Cancer Inst. 84:1909–1915. Ramakrishnan, S., Bjorn, M. J., and Houston, L. L. 1989. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Res. 49:613–617. Raschko, J. W., Synold, T. W., Chow, W., Coluzzi, P., Hamasaki, V., Leong, L. A., Margolin, K. A., Morgan, R. J., Shibata, S. I., Somlo, G., Tetef, M. L., Yen, Y., ter Veer, A., and Doroshow, J. H. 2000. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. Cancer Chemother Pharmacol. 46: 403–410. Reymann, A., Looft, G., Woermann, C., Dietel, M., and Erttmann, R. 1993. Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine HCl. Cancer Chemother. Pharmacol. 32:25–30.
2 Metastasis and Drug Resistance
49
Risau, W., Drexler, H., Mironov, V., Smits, A., Siegbahn, A., Funa, K. and Heldin, C. H. 1992. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7:261–266. Rougier, O., Vossort, G., Garnier, D., Gargouil, Y. M., and Coraboeuf, E. 1969. Existence and role of a slow inward current during the frog atrial action potential. Pflugers Arch. 308:91–110. Ruiz, J. C., Choi, K. H., Von Hoff, D. D., Robinson, I. B., and Wahl, G. M. 1989. Autonomously replicating episomes contain mdr1 genes in a multidrug-resistant human cell line. Mol. Cell Biol. 9:109–115. Safa, A. R., Glover, C. J., Sewell, J. L., Meyers, M. B., Biedler, J. L., and Felsted, R. L. 1987. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J. Biol. Chem. 262:7884–7888. Safa, A. R., Agresti, M., Tamai, I., Mehta, N. D. and Vahabi, S. 1990. The alpha 1-adrenergic photoaffinity probe 125I:arylazidoprazosin binds to a specific peptide of P-glycoprotein in multidrug-resistant cells. Biochem. Biophys. Res. Commun. 166:259–266. Salmon, S. E., Dalton, W. S., Grogan, T. M., Plezia, P., Lehnert, M., Roe, D. J., and Miller, T. P. 1991. Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44–50. Saltz, L., Murphy, B., Kemeny, N., Bertino, J., Tong, W., Keefe, D., Tzy-Jun, Y., Tao, Y., Kelsen, D., O Brien, J. P. 1994. A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. Cancer 74:2757–2764. Saponara, S., Ferrara, A, Gorelli, B., Shah, A., Kawase, M., Motohashi, N., Molnar, J., Sgaragli, G., and Fusi, F. 2007. 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart. Eur. J. Pharmacol. 563:160–163. Sarkadi, B., Price, E. M., Boucher, R. C., Germann, U. A., and Scarborough, G. A. 1992. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drugstimulated membrane ATPase. J. Biol. Chem. 267:4854–4858. Sasaki, T., Kitadai, Y., Nakamura, T., Kim, J. S., Tsan, R. Z., Kuwai, T., Langley, R. R., Fan, D., Kim, S. J., and Fidler, I. J. 2007. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia 9:1066–1077. Sato, W., Fukazawa, N., Suzuki, T., Yusa, K., and Tsuruo, T. 1991. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res. 51:2420–2424. Schackert, G., Fan, D., Nayar, R., and Fidler, I. J. 1989. Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. Sel. Cancer Ther. 5:73–79. Schr¨oder, J., Esteban, M., M¨uller, M. R., Kasimir-Bauer, S., Bamberger, U., Heckel, A., Seeber, S., and Scheulen, M. E. 1996. Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo. J. Cancer Res. Clin. Oncol. 122:307–312. Schuurhuis, G. J., Broxterman, H. J., van der Hoeven, J. J. M., Pinedo, H. M., and Lankelma, J. 1987. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. Cancer Chemother. Pharmacol. 20: 285–290. Seid, C. A., Fidler, I. J., Clyne, R. K., Earnest, L. E., and Fan, D. 1991. Overcoming murine tumor cell resistance to vinblastine by presentation of the drug in multilamellar liposomes consisting of phosphatidylcholine and phosphatidylserine. Sel. Cancer Ther. 7:103–112. Sessa, C., Calabresi, F., Cavalli, F., Cerny, T., Liati, P., Skovsgaard, T., Sorio, R., and Kaye, S. B. 1992. Phase II studies of 4 -iodo-4 -deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Ann. Oncol. 2:727–731. Shen, F., Chu, S., Bence, A. K., Bailey, B., Xue, X., Erickson, P. A., Montrose, M. H., Beck, W. T., and Erickson, L. C. 2008. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther. 324: 95–102.
50
D. Fan et al.
Singh, R. K., Bucana, C. D., Gutman, M., Fan D., Wilson, M., and Fidler, I. J. 1994. Organ sitedependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am. J. Pathol. 145:365–374. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. 1995. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92:4562–4566. Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D., and Fidler, I. J. 1994. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54:3242–3247. Sinicrope, F. A., Dudeja, P. K., Bissonnette, B. M., Safa, A. R., and Brasitus, T. A., 1992. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J. Biol. Chem. 267:24995–25002. Slater, L. M., Murray, S. L., Wetzel, M. W., Wisdom, R. M., and DuVall, E. M. 1982. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J. Clin. Invest. 70:1131–1134. Slater, L. M., Sweet, P., Stupecky, M., and Gupta, S. 1986a. Cyclosporin A reverses vincristine daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77: 1405–1408. Slater, L. M., Sweet, P., Stupecky, M., Wetzel, M. W. and Gupta, S. 1986b. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br. J. Cancer 54:235–238. Solary, E., Caillot, D., Chauffert, B., Casasnovas, R. O., Dumas, M., Maynadie, M., and Guy, H. 1992. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J. Clin. Oncol., 10:1730–1736. Sotelo, J., Brice˜no, E., and L´opez-Gonz´alez, M. A. 2006. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 144:337–43. Spoelstra, E. C., Dekker, H., Schuurhuis, G. J., Broxterman, H. J., and Lankelma, J. 1991. Pglycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport. Biochem. Pharmacol. 41:349–359. Sridhar, K. S., Krishan, A., Samy, T. S. A., Sauerteig, A., Wellham, L. L., McPhee, G., Duncan, R. C., Anac, S. Y., Ardalan, B., and Benedetto, P. W. 1993. Prochlorperazine as a doxorubicinefflux blocker:phase I clinical and pharmacokinetics studies. Cancer Chemother. Pharmacol. 31:423–430. Stein, Y., and Stein, O. 1966. Metabolism of labeled lysolecithin, lysophosphatidylethanolamine and lecithin in the rat. Biochim. Biophys. Acta 116:95–107. Stuart, N. S., Philip, P., Harris, A. L., Tonkin, K., Houlbrook, S., Kirk, J., Lien, E. A., and Carmichael, J. 1992. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br. J. Cancer 66: 833–839. Suhardja, A., and Hoffman, H. 2003. Role of growth factors and their receptors in proliferation of Microvascular endothelial cells. Microsc. Res. Tech. 60:70–75. Takahashi, Y., Mai, M., Wilson, M. R., and Ellis, L. M. 1996. Site-dependent expression of vascular endothelial growth factor, angiogenesis, and proliferation in human gastric carcinoma. Int. J. Oncol. 8:701–705. Talmadge, J. E., Wolman, S. R., and Fidler, I. J. 1982. Evidence for the clonal origin of spontaneous metastases. Science 217:361–363. Teodori, E., Dei, S., Garnier-Suillerot, A., Gualtieri, F., Manetti, D., Martelli, C., Romanelli, M. N, Scapecchi, S., Sudwan, P., and Salerno, M. 2005. Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. J. Med. Chem. 48:7426–36.
2 Metastasis and Drug Resistance
51
Thierry, A. R., Rahman, A., and Dritschilo, A. 1993. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem. Biophys. Res. Commun. 190:952–960. Thierry, A. R., Vige, D., Coughlin, S. S., Belli, J. A., Dritschilo, A., and Rahman, A. 1993. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. 7:572–579. Todorov, D. K. 1988. Thaliblastine. Drug Future 13:234–238. Tr¨auble, H., and Eibl, H. 1974. Electrostatic effects on lipid phase transitions:membrane structure and ionic environment. Proc. Natl. Acad. Sci. USA 71:214–219. Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C., Winer, E. P., Panella, T. J., Jordan, V. C., and Fine, R. L., 1992. High-dose oral tamoxifen, a potential multidrugresistance-reversal agent:phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 84: 1811–1816. Tsuruo, T., Iida, H. Kitani, Y., Yokota, K., Tsukaggoshi, S., and Sukurai, Y. 1984. Effects of quinidine and related compounds on cytoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res. 44:4303–4307. Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S., and Sakurai, Y. 1983a. Potentiation of vincristine and Adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 43:2267–2272. Tsuruo, T., Iida, H., Nojiri, M., Tsukagoshi, S., and Sakurai, Y. 1983b. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 43:2905–2910. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967–1972. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. 1982. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42:4730–4733. Twentyman, P. R., Fox, N. E., and White, D. J. G. 1987. Cyclosporine A and its analogues as modifiers of Adriamycin and vincristine resistance in a multidrug resistant human cancer cell line. Br. J. Cancer 56:55–57. Uehara, H., Kim, S. J., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C., Mathew, P., and Fidler, I. J. 2003. Effects of blocking platelet-derived growth factorreceptor signaling in a mouse model of prostate cancer bone metastasis. J. Natl. Cancer Inst. 95: 458–470. Venditti, J. M. 1981. Preclinical drug development: rationale and methods. Semin. Oncol. 8: 349–361. Verstuyft, C., Strabach, S., El-Morabet, H., Kerb, R., Brinkmann, U., Dubert, L., Jaillon, P., FunckBrentano, C., Trugnan, G., and Becquemont, L. 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73:51–60. Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M. E., Planting, A. S., Seynaeve, C., Stoter, G., and Nooter, K. 1992. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br. J. Cancer 64:361–364. Vezmar, M., and Georges, E. 2000. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem. Pharmacol. 59:1245–1252. Vickers, P. J., Dickson, R. B., Shoemaker, R., and Cowan, K. H. 1988. A multidrug-resistant MCF7 human breast cancer cell line which exhibits cross-resistance to anti-estrogens and hormoneindependent tumor growth in vivo. Mol. Endocrinol. 2:886–892. Von Hoff, D. D., Forseth, B., Clare, C. N., Hansen, K. L., and VanDevanter, D. 1990. Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells. J. Clin. Invest. 85:1887–1895. Wadler, S., and Wiernik, P. H. 1988. Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Res. 48:539–543.
52
D. Fan et al.
Wang, J. H., Wu, Q. D., Bouchier-Hayes, D., and Redmond, H. P. 2002. Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma-induced antiangiogenic activity in human tumor-derived endothelial cells. Cancer 15:2745–2755. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. 1992. Tumor angiogenesis:a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84:1875–1887. Wilmanns, C., Fan, D., O Brian, C. A., Bucana, C. D., and Fidler, I. J. 1992. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int. J. Cancer 52:98–104. Wilson, C. M., Serrano, A. E., Wasley, A., Bogenschutz, M. P., Shankar, A. H. and Wirth, D. F. 1989. Amplification of a gene related to mammalian mdr genes in drug-resistant Plsmodium faciparum. Science 244:1184–1186. Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Chojnowski, G. M., Williams, B. and Bertoncello, I. 1990. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:4199–4203. Woodcock, D. M., Linsenmeyer, M. E., Chojnowski, G., Kriegler, A. B., Nink, V., Webster, L. K., and Sawyer, W. H. 1992. Reversal of multidrug resistance by surfactants. Br. J. Cancer 66:62–68. Wu, H., Hait, W. N., and Yang, J. M. 2003. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63:1515– 1519. Wurz, G. T., Emshoff, V. D., Degregorio, M. W., and Wiebe, V. J. 1993. Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother. Pharmacol. 31:412–414. Yang, C. P., Cohen, D., Greenberger, L. M., Hsu, S. I., and Horwitz, S. B. 1990. Differential transport properties of two mdr gene products are distinguished by progesterone. J. Biol. Chem. 265:10282–10288. Yang, C. P., DePinho, S. G., Greenberger, l. M., Arceci, R. J., and Horwitz, S. B. 1989. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J. Biol. Chem. 264:782–788. Yin, Y., Allen, P. D., Jia, L., MacEy, M. G., Kelsey, S. M., and Newland, A. C. 2000. Constitutive levels of cAMP-dependent protein kinase activity determine sensitivity of human multidrugresistant leukaemic cell lines to growth inhibition and apoptosis by forskolin and tumour necrosis factor alpha. Br. J. Haematol. 108:565–573. Yokoi, K,, Sasaki, T., Bucana, C. D., Fan, D., Baker, C. H., Kitadai, Y., Kuwai, T., Abbruzzese, J. L., and Fidler, I. J. 2005. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. 65:10371–10380. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. 1998. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90:447–454. Yu, J.L., Rak, J. W., Carmeliet, P., Nagy, A., Kerbel, R. S., and Coomber, B. L. 2001. Heterogeneous vascular dependence of tumor cell populations. Am. J. Pathol. 158:1225–1234. Zalipsky, S., Saad, M., Kiwan, R., Ber, E., Yu, N., and Minko, T. 2007. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor:insights of the mechanism of action. J. Drug Target 15:518–530. Zhu, H. J., Wang, J. S., Guo, Q. L., Jiang, Y., and Liu, G. Q. 2005. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6. Biol. Pharm. Bull. 10:1974–1978.
Chapter 3
The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer Tomohisa Yokoyama, Yasuko Kondo, Oliver B¨ogler, and Seiji Kondo
Abstract Drug resistance is a major obstacle that limits the effectiveness of cancer therapy. Many cancer cells acquire resistance mechanisms that allow them to survive apoptosis, contributing to the initiation and progression of cancers. Therefore, novel therapeutic strategies are needed to address the emerging problem of drug resistance. Recent studies have suggested that the induction of autophagy could be a useful therapeutic approach to overcome drug resistance of cancers to some therapeutic agents, particularly those which typically induce an apoptotic response. However, the functional relationship between apoptosis and autophagy is extremely complex, and the molecular machinery is still obscure. Therefore, understanding the regulation of apoptotic and autophagic signaling pathways could provide important information for the development of novel cancer therapies in drug resistance. Keywords Autophagy · Apoptosis · Drug resistance · Cancer
Introduction Programmed cell death (PCD) is any form of cell death, mediated by an intracellular program, and it has been recognized since the 1960s (Kerr et al. 1972); tremendous amount of information has been accumulated regarding the molecular events of apoptotic signaling pathways (Schweichel and Merker 1973). In 1990, Clarke described that PCD is most commonly associated with apoptosis (type I PCD), but it can also occur through other mechanisms, including autophagy (type II PCD) and non-lysosomal vesiculate cell death (type III PCD) (Clarke 1990). Type I PCD is characterized by cell shrinkage, chromatin condensation, nucleosomal DNA degradation, and fragmentation. Activation of caspases gives rise to these characteristic S. Kondo (B) Department of Neurosurgery, BSRB1004, The University of Texas M. D. Anderson Cancer Center, 1515, Holcombe Boulevard, Houston, TX 77030, USA e-mail:
[email protected]
K. Mehta, Z.H. Siddik (eds.), Drug Resistance in Cancer Cells, C Springer Science+Business Media, LLC 2009 DOI 10.1007/978-0-387-89445-4 3,
53
54
T. Yokoyama et al.
morphological features of apoptosis (Gozuacik and Kimchi 2004, Bursch et al. 2000a, Bursch 2001). Type II PCD is characterized by the degradation of the Golgi apparatus, polyribosomes and endoplasmic reticulum before nuclear destruction, and the formation of numerous autophagic vacuoles. Type III PCD is defined as non-lysosomal vesiculate degradation. When cell death involves autophagy, it is designated as type II PCD, or autophagic cell death in contrast to apoptosis, which is referred to as type I (Bursch et al. 2000b). Drug resistance is a major obstacle in cancer treatment, and the acquisition of resistance to apoptosis is considered to be an important component. Recent studies have suggested that autophagy could be a useful therapeutic approach for the drug resistance of cancer, to some therapeutic agents (Shao et al. 2004, Carew et al. 2007, Amaravadi et al. 2007). This chapter covers the accumulating data about the role of autophagy and discusses some potential strategies for overcoming drug resistance in cancer.
Role of Autophagy in the Drug Resistance of Cancer The problem of drug resistance is complex as numerous factors affect drug sensitivity, such as accelerated drug efflux, DNA repair, drug activation and inactivation, alterations in drug target, DNA methylation, processing of drug-induced damage, and evasion of apoptosis (Wilson et al. 2006). Here we will focus on resistance mechanisms related to the cell’s ability to avoid entering PCD in the face of a drug’s impact. We believe that understanding how anticancer therapies induce cancer cell death will pave the way for the design of new approaches capable of overcoming this type of drug resistance.
Role of Autophagy in Cancer Treatment As cancer cells are frequently resistant to apoptosis, many therapeutic strategies involve sensitizing tumor cells to apoptosis-inducing treatments. However, the induction of autophagy in apoptosis-defective or apoptosis-resistant cancer cells might also be an effective therapeutic approach (Shao et al. 2004, Carew et al. 2007, Amaravadi et al. 2007). Indeed, cultured malignant glioma cells are typically resistant to apoptosis induced by such antitumor therapies as chemotherapy, γ-radiation therapy, and some adjuvant therapies (B¨ogler and Weller 2002). However, temozolomide (TMZ), a DNA-alkylating agent, rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), and γ-irradiation induce autophagy, but not apoptosis, in malignant glioma cells (Table 3.1) (Kanzawa et al. 2004, Takeuchi et al. 2005, Yao et al. 2003, Ito et al. 2005). This resistance is largely due to the fact that most malignant glioma cells express the BCL2 gene, which renders many tumor cells resistant to cancer therapies (Kondo et al. 1995). Another investigation showed that histone deacetylase inhibitors sodium butyrate and suberoylanilide hydroxamic
3 Autophagy and Drug Resistance
55
Table 3.1 Therapies that induce autophagy in cancer cells Treatment
Proposed target
Cancer type
References
Temozolomide Rapamycin
DNA mTOR
γ-irradiation
DNA
Sodium butyrate and SAHA
HDAC
Kanzawa et al. (2004) Takeuchi et al. (2005) and Gills et al. (2007) Yao et al. (2003), Ito et al. (2005) and Paglin et al. (2001) Shao et al. 2004
Tamoxifen
Oestrogen recepter
Arsenic trioxide
Multiple targets (for example, mitochondria) Multiple targets (for example, estogen receptor and mitochondria) Unknown
Malignant glioma Malignant glioma, lung cancer Malignant glioma, breast cancer, prostate cancer Cervical cancer that overexpresses BCL-XL , leukemia Breast cancer, lymphoma Malignant glioma, leukemia Ovarian cancer, lung cancer
Opipari et al. (2004) and Ohshiro et al. (2007)
Colon cancer
Ellington et al. (2005)
Cervical cancer, leukemia Malignant glioma, brain tumor stem cell
Maiuri et al. (2007) and Kessel et al. (2006) Ito et al. (2006), Jiang et al. (2007) and Alonso et al. (2008)
Resveratrol
Soybean B-group triterpenoid saponins ABT737 HA14-1 Oncolytic adenovirus
Beclin 1 and Bcl-2/Bcl-XL hTERT
Bursch et al. (1996) and Amaravadi et al. (2007) Kanzawa et al. (2003) and Kanzawa et al. (2005)
HDAC, histone deacetylase; mTOR, mammalian target of rapamycin; SAHA, suberoylanilide hydroxamic acid; hTERT, human telomerase reverse transcriptase.
acid (SAHA) induced autophagy in parental HeLa cervical cancer cells that overexpress the anti-apoptotic protein BCL-XL ; however, they induce apoptosis in parental HeLa cells (Shao et al. 2004). Thus, if the activity of anti-apoptotic proteins (BCL2 and BCL-XL ) is excessive, as it is in some cancers, the consequent suppression of autophagy could allow damaged cells to complete a cancerous transformation (Marx 2006). Other anticancer treatments also induce autophagy or autophagic cell death. Tamoxifen, which targets the estrogen receptor, induces autophagic cell death in breast cancer cells and lymphoma, and this has been shown to occur through downregulation of protein kinase B/AKT (Bursch et al. 1996, Scarlatti et al. 2004). The natural product arsenic trioxide (As2 O3 ) induces autophagy in malignant glioma cells, and the natural product resveratrol – a phytochemical found in grapes and red wine – has anti-neoplastic activities and induces autophagy in ovarian and lung cancer cells (Kanzawa et al. 2003, 2005, Opipari et al. 2004, Ohshiro et al. 2007). Another natural product, the soybean B-group triterpenoid saponins, causes autophagy in
56
T. Yokoyama et al.
colon cancer cells (Ellington et al. 2005). Pharmacological BCL2homology-3 (BH3) mimetic such as ABT737 and HA14-1 induces autophagy in HeLa cervical cancer and leukemia cells (Maiuri et al. 2007, Kessel and Reiners 2007). Telomeraseselective oncolytic adenovirus also induces autophagy in malignant glioma and brain tumor stem cells (Ito et al. 2006, Jiang et al. 2007, Alonso et al. 2008).
Role of Autophagy in Tumorigenesis To appreciate how alterations in autophagic pathways impinge on cancer therapy, it is necessary for us to first outline the role of autophagy in tumorigenesis. Autophagy is a dynamic multistep process in which intracellular membrane structures sequester proteins and organelles to degrade and turn over these materials (Kondo et al. 2005). At the beginning of autophagy, portions of the cytoplasm, as well as intracellular organelles, are sequestered in double-membrane-bound structures that are known as autophagosome (Fig. 3.1). These autophagosomes then fuse with lysosomes to form autolysosomes, and the sequestered contents are degraded by lysosomal hydrolases and are recycled. Thus, autophagy has cellular homeostasis function and can eliminate superfluous, damaged, or aged cells or organelles (Shintani and Klionsky 2004). To date, 30 Autophagy-related (ATG) genes, which are involved in various subtypes of macroautophagy, have been identified in yeast model systems (Xie and Klionsky 2007). BECN1 (the mammalian orthologue of ATG6), the first identified mammalian autophagy gene product, is a haplo-insufficient tumor suppressor that was originally isolated as a BCL2-interacting gene protein (Liang et al. 1999, Liang et al. 1998). Introduction of BECN1 into MCF7 breast cancer cells induced autophagy and inhibited tumorigenicity. Levels of BECN1 were significantly decreased in 18 of 32 breast cancer samples, compared with normal epithelial cells from the breast (Liang et al. 2006). These findings indicate that decreased expression of BECN1 might contribute to the development or progression of breast cancer. The allelic deletion of chromosome 17q21, where BECN1 is located, is common not only in breast tumors but also in ovarian and prostate tumors, suggesting that the deletion of BECN1 is involved in multiple types of cancer. Recently, other suppressors such as a novel coiled-coil ultraviolet irradiation resistance-associated tumor suppressor gene (UVRAG) and Bif-1 were also identified (Liang et al. 2006, 2007, Takahashi et al. 2007). UVRAG interacts with BECN1, leading to activation of autophagy and therefore inhibition of tumorigenesis. Bif-1 interacts with BECN1 through UVRAG and activates the BECN1/class III phosphatidylinositol 3-kinase (PI3K) complex, which regulates autophagosome formation and forms a complex that localizes in the trans-Golgi-network (TGN) (Kondo et al. 2005, Linder and Shoshan 2005). Thus, UVRAG and Bif-1 may play a role in cell growth control and/or tumor suppression (Levine and Kroemer 2008, Mizushima et al. 2008). In addition, damage-regulated modulator of autophagy (DRAM) is a new regulator of autophagy involved in the induction of autophagy by p53 in response to genotoxic stress (Crighton et al. 2006). That is, DRAM alone causes minimal cell
3 Autophagy and Drug Resistance
57 Lysosome
LC3
LC3
Membrane isolation (Phagophore)
3-MA ATG6/BECN1 siRNA ATG5 siRNA ATG10 siRNA ATG12 siRNA
Autophagosome
Autolysosome
Degradation
Bafilomycin A1 Vinblastine Nocodazole CQ Monensin LAMP2 siRNA
Fig. 3.1 The cellular process of autophagy. Autophagy begins with the isolation of double membrane (phagophore) inside an intact cell. The membrane structures elongate and mature, and microtubule-associated protein 1 light chain 3 (LC3) is recruited to the membrane. The elongated double membranes form autophagosomes, which sequester cytoplasmic proteins and organelles such as mitochondria. The formation of the pre-autophagosomal structure can be inhibited by the class III phosphatidylinositol 3-phosphate kinase (PI3K) inhibitor 3-methyladenine (3-MA) and short interfering RNAs (siRNA) targeted against ATG6 (BECN1), ATG5, ATG10, and ATG12. Sequestration requires ATP and is regulated mainly by class III PI3K (Petiot et al. 2000). The autophagosomes mature with acidification by H+ -ATPase and fuse with lysosomes to become autolysosomes [80]. Microtubules are important mediators of this fusion process. This process is inhibited by the H+ -ATPase inhibitor bafilomycin A1 , by microtubule inhibitors such as vinblastine and nocodazole (Reunanen, Marttinen and Hirsim¨aki 1988, Punnonen and Reunanen 1990, Kihara et al. 2001, Saeki et al. 2000), or by lysosomotropic agents such as chloroquine (CQ), monensin, and siRNA targeted against lysosome-associated membrane protein 2 (LAMP2). Eventually, the sequestered contents are degraded by lysosomal hydrolases for recycling
death; however, activation of p53 induces autophagy in DRAM-dependent manner. Knockdown of DRAM inhibits the accumulation of autophagosomes induced by p53 and also reduces the induction of apoptosis.
Mechanism Regulating Autophagy and Apoptosis Signaling pathways are extremely complex, with a number of feed-forward and feed-back loops and crosstalk with many other signaling networks; furthermore, signaling pathways that regulate autophagy, proliferation, and apoptosis are frequently
58
T. Yokoyama et al.
altered in cancer cells. Here we will briefly touch upon some of the most important pathways that regulate PCD.
PI3K-AKT-mTOR Signaling Pathway The PI3K-AKT-mamalian target of mTOR pathway, which is activated in many types of cancer, is important in autophagy (Gozuacik and Kimchi 2004, Shintani and Klionsky 2007, Blume-Jensen and Hunter 2001, Vivanco and Sawyers 2002, Ogier-Denis and Codogno 2003). AKT is a serine–threonine kinase, located downstream of class I PI3K, that activates the kinase mTOR, leading to suppression of autophagy (Fig. 3.2) (Schmelzle and Hall 2000, Gingras et al. 2001). A role of this
Growth factor receptor Plasma membrane
PI3K Class III
LY294002 Wortmannin
BECN1
PI3K Class I
BCL2
AKT
ER stress p53
UCN-01
RAS
PTEN
BNIP3 3-MA RAF1
DRAM
p53 PD98059
DAPK
ERK1/2
DRP1
mTOR
MEK1/2
p70S6K
Rapamycin CCI-779 RAD-001
Autophagy
Fig. 3.2 The molecular regulation of autophagy. In the presence of growth factors, growth factor receptor signaling activates class I phosphatidylinositol 3-phosphate kinase (PI3K) at the plasma membrane to keep cells from undergoing autophagy (Kondo et al. 2005). PI3K activates the downstream target AKT, leading to activation of mammalian target of rapamycin (mTOR), which results in inhibition of autophagy. p70S60 kinase (p70S6K) might be a good candidate for the control of autophagy, downstream of mTOR. Overexpression of phosphatase and tensin homologue (PTEN) gene, by an inducible promoter, antagonizes class I PI3K and induces autophagy (Arico et al. 2001). RAS has dual effect on autophagy – when it activates class I PI3K (Furuta et al. 2004), autophagy is inhibited, but when it selectively activates the RAF-1-mitogen-activation protein kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade, autophagy is stimulated (Ogier-Denis et al. 2000). Activation of p53 inhibits mTOR activity and regulates its downstream targets, including autophagy (Feng et al. 2005, 2007). Further, activation of p53 positively regulates in DNA-damaged cells in a DRAM-dependent manner (Crighton et al. 2006). A complex of class III PI3K and BECN1 induces autophagy at the trans-Golgi network acts to induce autophagy (Kihara et al. 2001). This pathway is inhibited by 3-methyladenine (3-MA). Downregulation of BCL2, or upregulation of BCL2-adenovirus E1B 19-kD-interacting protein 3 (BNIP3) at the mitochondria, also induces autophagy, interacting that BCL2 protects against autophagy (Saeki et al. 2000). Autophagy is also induced by the cell death-associated protein kinase (DAPK), the deathassociated related protein kinase 1 (DRP1), and endoplasmic reticulum (ER) stress (Ogata et al. 2006, Inbal et al. 2002)
3 Autophagy and Drug Resistance
59
signaling pathway in the negative regulation of autophagy has been observed in nonmammalian cells (Levine and Klionsky 2004, Wang and Klionsky 2003). Downregulation of this pathway has been implicated in tumorigenesis and resistance to therapy in breast, prostate, pancreatic, ovarian, and stomach cancers (Nicholson and Anderson 2002). Class I and class IIII PI3K regulate autophagy differently – the class I PI3K-AKT-mTOR signal, which is activated in cancer cells through the growth factor receptor, inhibits autophagy. By contrast, class III PI3K promotes the sequestration of cytoplasmic material that occurs during autophagy (Petiot et al. 2000). Oncogenic forms of RAS are also implicated in the negative control of autophagy, through activation of class I PI3K (Furuta et al. 2004). The phosphatase and tensin homologue (PTEN) is tumor-suppressor gene that also regulates autophagy. PTEN dephosphorylates PIP3 and thereby antagonizes the function of class I PI3K, suppressing AKT activity and allowing autophagy to be initiated (Arico et al. 2001). Several studies have demonstrated a high frequency of PTEN mutations or deletions in a variety of human cancers, such as malignant gliomas and prostate, breast and endometrial cancers (Steck et al. 1997). When PTEN is deleted, mutated, or otherwise inactivated, activation of PI3K/AKT/mTOR pathway leads to tumorigenesis, and in addition to promoting proliferation suppresses autophagy (Cully et al. 2006). This antagonism of PCD may be how activation of the PI3K/AKT/mTOR pathways confers resistance to many type of cancer therapy, and so is poor prognostic factor for many types of cancers.
BECN1 BECN1 (ATG6), the first identified tumor suppressor protein that functions in the lysosomal degradation pathway of autophagy, was isolated as a BCL2-interacting protein (Liang et al. 1999, Liang et al. 1998). When mutant forms of BECN1 that cannot bind to BCL2 are expressed, this resulted in excess levels of autophagy in the absence of exposure to nutrient deprivation or autophagy specific stimuli (Pattingre et al. 2005). These excess levels of autophagy are associated with cell death that is caspase-independent and inhibited by small interfering RNA (siRNA) directed against a downstream autophagy execution gene, ATG5. Thus, BCL2 blocks autophagic cell death by binding to BECN1. In addition, BECN1 binds to a class III PI3K complex, which regulates autophagosome formation. Consistent with the role of the BECN1-classIII PI3K complex in autophagy induction, 3-methyaldenine (3-MA), an inhibitor of PI3K, inhibits autophagy (Shintani and Klionsky 2004).
BCL2 and Adenovirus E1B 19kDa Interaction Protein 3 (BNIP3) BNIP3 is a cell-death-inducing factor that is member of the BCL2homology 3 (BH3)-only subfamily of the BCL2 family protein. It is expressed on the mitochondrial membrane, thereby inhibiting the anti-apoptotic BCL2-family members (BCL2 and BCL-XL ) or activating the pro-apoptotic BCL2-family members (BAX and BAK). Overexpression of BNIP3 induced caspase-independent non-apoptotic
60
T. Yokoyama et al.
or necrosis-like cell death in MCF7 and HeLa cells (Vande et al. 2000). BNIP3 was upregulated in several malignant glioma cell lines that were undergoing autophagy as a result of treatment with As2 O3 and ceramide (Kanzawa et al. 2003, Daido et al. 2004). Murine embryonic fibroblasts (MEFs) and bone marrow-derived cells from mice deficient in the BCL2 family proteins BAX and BAK are resistant to apoptosis but undergo autophagy after exposure to chemotherapeutic agent etoposide or growth factor withdrawal (Shimizu et al. 2004, Lum et al. 2005). Another study also reported that BAX and BAK double knockout MEFs were more radiosensitive than the wild-type MEFs, and that irradiation of cells resulted in an increase in pro-autophagic proteins such as the ATG12-ATG5 complex, and BECN1, which resulted in up-regulation of autophagy (Kim et al. 2006). These observations indicate that the pro-apoptotic protein (BAX and BAK) not only control apoptosis, but also regulate the autophagic pathway. Thus, mitochondria-associated cell death protein BNIP3 plays a central role in both apoptotic and autophagic cell death.
p53 Tumor Suppressor Pathway The transcription factor p53, which is mutated in about half of all human cancers, coordinates DNA repair, cell cycle arrest, apoptosis, and senescence to preserve genomic stability and prevent tumor formation (Levine 1997, Vogelstein et al. 2000). Activation of p53 inhibits mTOR activity and regulates its downstream targets, including autophagy, via AMP-activated protein kinase (AMPK) and tumor suppressors tuberous sclerosis-1 (TSC1) and TSC2 (Feng et al. 2005, 2007). In addition, another study reported that p53 positively regulates autophagy in DNAdamaged cells in a DRAM-dependent manner . Thus, p53 can be an inducer of autophagy and induce cell death.
ER Stress The endoplasmic reticulum (ER) has a role in cellular homeostasis regulation, particularly in unfolded protein response (UPR), which plays a major role in cancer and many other diseases (Kim et al. 2006, Moenner et al. 2007). When UPR is activated, the expression of chaperones such as glucose-regulated protein 78 (GRP78)/immunoglobulin binding protein (BiP) is induced, resulting in up-regulation of the cellular folding capacity. Several anticancer agents generate survival responses through activation of the UPR. When the ER system is overloaded with misfolded proteins, cells will undergo cell death, typically by apoptosis. However, hypoxia and glucose starvation, which are common features of solid tumors, are involved in tumor progression and drug resistance (Tsuruo et al. 2003). For example, GRP-inducing conditions caused significant resistance to VP-16 and adriamycin through a decreased expression of DNA topoisomerase II in human ovarian, breast cancer cells (Yun et al. 1995). Thus, glucose-related stress response
3 Autophagy and Drug Resistance
61
activates the UPR, and subsequent downstream signaling events can undermine the therapeutic efficacy. Some papers recently connected ER stress to the induction of autophagy (Ogata et al. 2006, Yorimitsu et al. 2006). Under conditions of ER stress, the pre-autophagosomal structure is assembled, and transport of autophagosomes to the vacuole is stimulated in an ATG protein-dependent manner. However, our understanding of ER stress-induce autophagy is at a very early stage, and further studies are needed.
Other Pathways Other molecules have been shown to regulate autophagy in cancer cells, such as death-associated protein kinase (DAPK), death-associated related protein kinase 1 (DAP1) as well as the mitogen-activated kinases (Inbal et al. 2002, Ogier-Denis et al. 2000). The DAPK and DRP1 proteins are Ca2+ -calmodulin-regulated serinethreonine kinases that are identified as a positive mediator of apoptosis in response to various stimuli (Inbal et al. 1997). A recent investigation indicated that DAPK and DAP1 induce autophagy in MCF7 breast and HeLa cervical cancer cells (Inbal et al. 2002). The mitogen-activated protein kinases are a family of serine-threonine kinases that are involved in regulating a wide range of cellular responses to growth factor receptor signaling (Su et al. 1996). This includes promoting autophagy: the extracellular signal-regulated kinases 1 (ERK1) and ERK2, when stimulated by RAS-RAF1-mitogen-activated protein kinase (MEK) signaling pathway, have been shown to induce autophagy in HT-29 colon cancer cells (Ogier-Denis et al. 2000).
Targeting Autophagy in Drug Resistance of Cancer Although autophagy is designated type II PCD, the role of autophagy in cell death has been a controversial issue (Kondo et al. 2005, Levine and Yuan 2005, Maiuri et al. 2007). In fact, inhibitors of autophagy can produce different outcomes – cell survival or cell death – that highlight the need to elucidate the mechanisms of autophagy, and its inhibition, in detail. It is necessary for clinical oncologists and cancer researchers to determine which cancer cell types most commonly undergo autophagy in response to therapy, and whether increased autophagy is a sign of drug responsiveness or resistance.
Crosstalk Between Autophagy and Apoptosis Autophagy can be inhibited at several levels, and inhibiting autophagy might be an effective therapeutic approach for overcoming drug resistance in cancer (Table 3.2) (Shao et al. 2004, Carew et al. 2007, Amaravadi et al. 2007). The class III PI3K inhibitor 3-MA inhibits pre-autophagosome formation and prevents the death of
62
T. Yokoyama et al. Table 3.2 Inhibitors of autophagy
Compound
Modification of cellular component
Cancer type
References
Breast cancer, prostate cancer, colon cancer, malignant glioma, cervical cancer
Bursch et al. (2000a), Amaravadi et al (2007), Kanzawa et al. (2004), Bursch et al. (1996), Petiot et al. (2000), Boya et al. (2005) and Yamamoto et al. (1998) Boya et al. (2005)
Inhibition of autophagosome formation 3-MA
Class III P13K inhibitor. Inhibits the formation of preautophagosomal structure.
siRNA against Blocks translation of these proteins. ATG6/BECN1, ATG5,ATG10, ATG12
Cervical cancer
Inhibition of lysosomal proton pump Bafilomycin A1
H+ -ATPase inhibitor. Blocks the fusion of the autophagosome and lysosome.
Breast cancer, prostate cancer, colon cancer, malignant glioma, cervical cancer
CQ
A lysosomotropic agent. Block the fusion of the autophagosome and lysosome.
Leukemia, cervical cancer
Monensin
Protein exchange for potassium or sodium. Blocks the fusion of the autophagosome and lysosome. Blocks translation of the lysosome protein.
Leukemia, cervical cancer
siRNA against LAMP2
Cervical cancer
Kanzawa et al. (2003, 2004), Komata et al. (2004), Boya et al. (2005), Yamamoto et al. (1998) and Paglin et al. (2001) Carew et al. (2007), Amaravadi et al. (2007), Boya et al. (2005), Yamamoto et al. (1998) and Gonzalez-polo et al. (2005) Boya et al. (2005)
Gonzalez-polo et al. (2005)
3-MA, 3-methyladenine; CQ, chloroquine; P13K, phosphatidylinositol 3-phosphate kinase; siRNA, small interfering RNA.
breast cancer cells treated with tamoxifen (Bursch et al. 2000a, b, Carew et al. 2007, Kanzawa et al. 2004, Bursch et al. 1996, Petiot et al. 2000, Boya et al. 2005, Paglin et al. 2001). On the other hands, bafilomycin A1 , chloroquine (CQ), and monensin and siRNA targeted against lysosome-associated membrane protein2 (LAMP2) inhibit autophagy by preventing the fusion of autophagosomes and lysosomes (Boya et al. 2005, Paglin et al. 2001, Yamamoto et al. 1998, Gonz´alez-Polo et al. 2005). Several earlier studies have demonstrated that the use of autophagy inhibitors, such as 3-MA, CQ, bafilomycin A1 , and siRNA targeted against autophagy-associated genes, such as BECN1, and ATG5, and LAMP2 induced apoptosis in various cancer
3 Autophagy and Drug Resistance
63
cells. However, these agents have different effects. 3-MA inhibits γ-irradiationinduced autophagy in breast, prostate and colon cancer, as well as inhibiting TMZinduced autophagy in malignant glioma cells (Kanzawa et al. 2004, Paglin et al. 2001). When autophagy was inhibited by 3-MA, these cancer cells did not undergo apoptosis. In contrast,, when bafilomycin A1 was used to inhibit γ-irradiationinduced autophagy in breast, prostate and colon cancer cells, cells still underwent apoptosis, and the antitumor effect of γ-irradiation was increased (Paglin et al. 2001). These results indicate that autophagy could be defense mechanism of cancer cells against γ-irradiation-induced apoptosis. A similar effect of bafilomycin A1 was observed in As2 O3 - and hyperthermia-induced autophagy (Kanzawa et al. 2003, Komata et al. 2004). So, if autophagy protects cells from drug-induced apoptosis (‘protective autophagy’), the use of agents that disrupt the autophagic pathway might strengthen the antitumor efficacy of cytotoxic agents. More recent study reported that either CQ or 3-MA synergistically enhanced the antitumor effects of SAHA in chronic myelogenous leukemia (CML) cell lines and primary CML cells expressing wild-type and imatinib mesylate- (an inhibitor of the BCR-ABL tyrosine kinase) resistant mutant forms of BCR-ABL (Carew et al. 2007). Another study also reported that inhibition of autophagy with either CQ or short hairpin RNA (shRNA) targeted against ATG5 enhanced the antitumor effects in Myc-driven model of lymphoma, which is resistant to apoptosis due to a lack of nuclear p53 (Amaravadi et al. 2007). These findings support the use of agents that disrupt the autophagy pathway for drug resistance of cancer. Especially, CQ has been used safely in patients with malaria prophylaxis and with rheumatoid arthritis (O’Neill et al. 1998, Kremer 2001), therefore, the time is ripe for a large-scale randomized trial for drug resistance of cancer. In addition, when apoptosis was inhibited by defects in the function of the proapoptotic proteins BAX and BAK, autophagic cell death was triggered by DNAdamaging agents such as etoposide (a topoisomerase-2 inhibitor) in MEFs and bone marrow-derived immortalized cells (Shimizu et al. 2004, Lum et al. 2005). Therefore, another possible approach is to inhibit apoptotic pathways, using some apoptosis inhibitors. For example, when apoptosis was inhibited in mouse fibroblasts by a caspase-8 inhibitor, autophagic cell death, depend on ATG7 and BECN1 activity, was induced, and autophagy inhibitor decreased the amount of cell death (Yu et al. 2004). However, if cancer cells already acquired apoptosis-resistance, this approach would not be expected to have efficacy. Collectively, these findings raise the possibility of the existence of unknown feedback or crosstalk network between autophagy and apoptosis, and also suggest an attractive strategy for drug resistance of cancer; when tumor cells induce protective autophagy, inhibition of autophagy could sensitize tumor cells to the treatment by activating apoptosis (Fig. 3.3).
Combination Treatment for Drug Resistance The PI3K/AKT/mTOR pathway is an attractive therapeutic target in cancer, because it regulates tumorigenesis, tumor metastasis, and drug resistance as well as autophagy (Nicholson and Anderson 2002, West et al. 2002). Together with the RAS/
64
T. Yokoyama et al.
a. Cancer cells that undergo apoptosis after treatment Anticancer therapy (Apoptosis inducer)
Cell death Apoptosis
b. Cancer cells that undergo apoptosis after treatment Anticancer therapy (Apoptosis inducer)
Cell death by autophagic cell death Apoptosis inhibitor (for example, caspase-8 inhibitor)
c. Cancer cells that undergo autophagic cell death after treatment Anticancer therapy (Autophagy inducer)
Cell death Autophagy
d. Cancer cells that undergo protective autophagy after treatment Anticancer therapy (Autophagy inducer)
Cell death by apoptosis Autophagic inhibitor (for example, bafilomycin A1)
Fig. 3.3 Potential strategies for drug resistance of cancer. (a) Cancer cells that are capable of undergoing apoptosis in response to anticancer therapies might be treated with apoptosis inducers to promote apoptosis-induced cell death. (b) Cancer cells that undergo apoptosis might be treated with apoptosis inhibitors, such as caspase-8 inhibitor, to promote autophagy-induced cell death. (c) Cancer cells that are capable of undergoing autophagy in response to anticancer therapies might be treated with autophagy inducers, such as rapamycin, to promote autophagy-induced cell death. (d) Cancer cells that undergo autophagy, to protect themselves from the effects of anticancer therapies, might be treated with autophagy inhibitors, such as bafilomycin A1 or short interfering RNAs specific for the autophagy-related genes, to induce apoptosis. However, it should be noted that inhibition of apoptosis or autophagy does not always induce cell death by each other
RAF-1/MEK1/2/ERK pathway, which is regulated by amino acid levels, it is well known to regulate autophagy in response to starvation in mammalian cells (Codogno and Meijer 2005, Meijer and Codogno 2004). In our study, curcumin, which is natural compound, inhibited the former pathway and activated the latter pathway thereby inducing autophagy (Aoki et al. 2007). Another study also showed that triterpenoid B-group soyasaponins induce autophagy by inhibiting AKT signaling and enhancing ERK activity, in accordance with our findings (Ellington et al. 2006). Thus, AKT inhibition and ERK activation are probably the common mechanism of autophagy induced by anticancer agents. Interestingly, inhibition of ERK1/2 pathway using PD98059, a MEK1 inhibitor, inhibited autophagy and induced apoptosis, thus resulting in the enhanced cytotoxicity of curcumin. Consequently, these two autophagic pathways have opposite effects on curcumin’s cytotoxicity. That is, autophagy that is inhibited by the AKT pathway confers cell death, whereas the autophagy that is stimulated by the ERK1/2 pathway confers cell
3 Autophagy and Drug Resistance
65
survival. Therefore, modulating autophagy using pathway-specific inhibitors may be helpful in promoting tumor regression as well as another autophagy inhibitors. Several preclinical and early clinical studies indicate that the PI3K/AKT/mTOR pathway inhibitors might be effective in inhibiting the growth of a broad range of tumors (Chan 2004, Lopiccolo et al. 2007). Furthermore, these pathway inhibitors have been studied in combination with standard chemotherapies. For example, rapamycin, an inhibitor of mTOR, induces apoptosis in multiple myeloma, lymphoma, and rhabdomyosarcoma cells (Clemens et al. 1998, Hosoi et al. 1999, Pene et al. 2002) and combined with cisplatin, it sensitizes some tumor cells to apoptosis induction (Shi et al. 1995). PI3K kinase inhibitors such as LY294002 and wortmannin have also been shown to enhance apoptosis of several cell lines when used in combination with paclitaxel, cisplatin, gemcitabine, or 5-fluorouracil (Hu et al. 2002, Asselin et al. 2001, Ng et al. 2000, Wang et al. 2002). In addition, LY294002 and UCN-01, an AKT inhibitor, synergistically sensitize rapamycin-sensitive and rapamycin-resistant malignant glioma cells to rapamycin by promoting autophagy, but not apoptosis (Takeuchi et al. 2005). Thus, these pathway inhibitors might be an effective approach to drug resistance of cancer, when combined with proximal pathway inhibitors. However, mTOR, which is a more distal pathway component, can control whether a cell undergoes apoptosis or autophagy, which may depend on the cell type, as in some cells the inhibition of mTOR stimulates autophagy rather than apoptosis (Takeuchi et al. 2005, Clemens et al. 1998, Hosoi et al. 1999, Pene et al. 2002, Castedo et al. 2002). Thus, it is still unclear what determines why cells enter apoptosis or autophagy. Recently, several agents such as AKT inhibitors (perifosine, phosphatidylinositol ether lipid analogues; PIAs, and triciribine), rapamycin analogues (CCI-779 and RAD-001), and dual inhibitor of PI3Kα and mTOR (PI-103) have been designed for development as anticancer agents (Lopiccolo et al. 2007). Only a few clinical trials combining PI3K/AKT/mTOR pathway inhibitors with various type of chemotherapy have been reported, however, and showed no objective responses (Lopiccolo et al. 2007). A potential explanation of these negative results is that off-target effects are involved. If the PI3K/AKT/mTOR pathway is not activated in tumor cells, these inhibitors would not be expected to have efficacy; however, they might be a valid approach to treat drug resistance of cancer in patients selected on the basis of data on which pathways are mediating this resistance. Overall, the crosstalk between apoptosis and autophagy is complex, and the two processes share common inducers. Therefore, the cross-inhibitory interactions between apoptosis and autophagy may cause polarization between the two processes. In this strategy, conventional cancer therapies that can induce autophagy might be combined to augment the antitumor effect of autophagy inducers. This idea is supported by recent investigations indicating that mTOR inhibitors have increased efficacy when combined with γ-irradiation therapy, chemotherapy, and anti-angiogenesis therapy (Eshleman et al. 2002, Mondesire et al. 2004, Stephan et al. 2004). Recently our studies also indicated that autophagy-inducing agents (rapamycin and temozolomide) not only enhance oncolytic adenovirus-induced autophagy but also synergize with oncolytic adenovirus to induce cell death of
66
T. Yokoyama et al.
malignant glioma cells (Yokoyama et al. 2008). This may be a common feature of pathway inhibition, whereby rapamycin, temozolomide, and oncolytic adenovirus inhibits the PI3K/AKT/mTOR pathway, and the antitumor effect of oncolytic adenovirus would be augmented by combinatorial therapy with other autophagyinducing agents. Thus, combination of autophagy-inducing agents may give us novel therapeutic ideas for overcoming the drug resistance of cancer. To date, several methods has been developed to prove the presence of autophagy in normal and cancer cells, such as electron microscopy, acridine orange, and green-fluorescent protein (GFP)-tagged-rat microtubule-associated protein 1 light chain 3 (LC3) expression vector (Klionsky et al. 2008). However, these assays are not applicable to tissue samples. Recently, we developed an antibody against the isoform B of human LC3 (LC3B), which is useful tool for monitoring the induction of autophagy in various types of clinical specimens, including surgically resected cancer cells (Aoki et al. 2008). Future trials could prospectively assess induction of autophagy in clinical tissue samples.
Conclusion Autophagy has been associated with both cell survival and cell death, however, the role of autophagy in PCD is still poorly understood. A huge increase in the number of research publications on autophagy and cancer therapy suggests that it plays an important role in drug resistance of cancer to some therapeutic agents, which typically induce apoptosis. If autophagy only has a defensive role in cancer treatment, then inhibitors such as CQ or siRNAs specific for autophagy-regulatory genes might provide a clear therapeutic benefit. Additionally, understanding the relationship between autophagic and apoptotic pathways may provide novel therapeutic approaches to treating drug resistant cancers.
References Alonso MM, Jiang H, Yokoyama T et al. (2008) Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16: 487–493. Amaravadi RK, Yu D, Lum JJ et al. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326–336. Aoki H, Takada Y, Kondo S et al. (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72: 29–39. Aoki H, Kondo Y, Aldape K et al. (2008) Monitoring Autophagy in Glioblastoma with Antibody against Isoform B of Human Microtubule-Associated Protein 1 Light Chain 3. Autophagy 4: 467–475. Arico S, Petiot A, Bauvy C et al. (2001) The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 276: 35243–33246. Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61: 1862–1868.
3 Autophagy and Drug Resistance
67
Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355–365. B¨ogler O, Weller M (2002) Apoptosis in gliomas, and its role in their current and future treatment. Front Biosci 7: e339–353. Neurosurg 98: 378–384. Boya P, Gonz´alez-Polo RA, Casares N et al. (2005) Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25:1025–1040. Bursch W, Ellinger A, Kienzl H et al. (1996) Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17: 1595–1607. Bursch W, Hochegger K, Torok L et al. (2000a) Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 13: 1189–1198. Bursch W, Ellinger A, Gerner C et al. (2000b) Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann N Y Acad Sci 926: 1–12. Bursch W (2001) The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 8: 69–81. Castedo M, Ferri KF, Kroemer G (2002) Mammalian target of rapamycin (mTOR): pro- and antiapoptotic. Cell Death Differ 9: 99–100. Carew JS, Nawrocki ST, Kahue CN et al. (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110: 313–322. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91: 1420–1424. Clarke PG (1990) Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol (Berl) 181: 195–213. Clemens MJ, Bushell M, Morley SJ (1998) Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines. Oncogene 17: 2921–2931. Codogno P, Meijer AJ (2005) Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12: 1509–1518. Crighton D, Wilkinson S, O’Prey J et al. (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126: 121–134. Cully M, You H, Levine AJ et al. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184–192. Daido S, Kanzawa T, Yamamoto A et al. (2004) Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 64: 4286–4293. Ellington AA, Berhow M, Singletary KW (2005) Induction of macroautophagy in human colon cancer cells by soybean B-group triterpenoid saponins. Carcinogenesis 26:159–167. Ellington AA, Berhow MA, Singletary KW (2006) Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis 27: 298–306. Eshleman JS, Carlson BL, Mladek AC et al. (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62: 7291–7297. Feng Z, Zhang H, Levine AJ et al. (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102: 8204–8209. Feng Z, Hu W, de Stanchina E et al. (2007) The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67: 3043–3053. Furuta S, Hidaka E, Ogata A et al. (2004) Ras is involved in the negative control of autophagy through the class I PI3-kinase. Oncogene 23: 3898–3904. Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807–826. Gonz´alez-Polo RA, Boya P, Pauleau AL et al. (2005) The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci ;118: 3091–3102.
68
T. Yokoyama et al.
Gozuacik D, Kimchi A. (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891–2906. Hosoi H, Dilling MB, Shikata T et al. (1999) Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59: 886–894. Hu L, Hofmann J, Lu Y et al. (2002) Inhibition of phosphatidylinositol 3 -kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087–1092. Inbal B, Cohen O, Polak-Charcon S et al. (1997) DAP kinase links the control of apoptosis to metastasis. Nature 390: 180–184. Inbal B, Bialik S, Sabanay I et al. (2002) DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol 157: 455–468. Ito H, Daido S, Kanzawa T et al. (2005) Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 26: 1401–1410. Ito H, Aoki H, K¨uhnel F et al. (2006) Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 98: 625–636. Jiang H, Gomez-Manzano C, Aoki H et al. (2007) Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99: 1410–1414. Kanzawa T, Kondo Y, Ito H et al. (2003) Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63: 2103–2108. Kanzawa T, Germano IM, Komata T et al. (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11: 448–457. Kanzawa T, Zhang L, Xiao L et al. (2005) Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 24: 980–991. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer 26: 239–257. Kessel D, Reiners JJ Jr (2007) Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett 249: 294–299. Kihara A, Kabeya Y, Ohsumi Y et al. (2001) Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2001 2: 330–335. Kim KW, Mutter RW, Cao C et al. (2006) Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 281: 36883–36890. Kim R, Emi M, Tanabe K et al. (2006) Role of the unfolded protein response in cell death. Apoptosis 11: 5–13. Klionsky DJ, Abeliovich H, Agostinis P et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151–175. Komata T, Kanzawa T, Nashimoto T et al. (2004) Mild heat shock induces autophagic growth arrest, but not apoptosis in U251-MG and U87-MG human malignant glioma cells. J Neurooncol 68: 101–111. Kondo S, Barna BP, Morimura T et al. (1995) Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res 55: 6166–6671. Kondo Y, Kanzawa T, Sawaya R et al. (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726–734. Kremer JM (2001) Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 134: 695–706. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6: 463–477. Levine B, Yuan J (2005) Autophagy in cell death: an innocent convict? J Clin Invest 115: 2679–2688. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27–42.
3 Autophagy and Drug Resistance
69
Liang XH, Kleeman LK, Jiang HH et al. (1998) Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol 72: 8586–8596. Liang XH, Jackson S, Seaman M et al. (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672–676. Liang C, Feng P, Ku B et al. (2006) Autophagic and tumour suppressor activity of a novel Beclin1binding protein UVRAG. Nat Cell Biol 8: 688–699. Liang C, Feng P, Ku B et al. (2007) UVRAG: a new player in autophagy and tumor cell growth. Autophagy 3: 69–71. Linder S, Shoshan MC (2005) Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy. Drug Resist Updat 8: 199–204. Lopiccolo J, Blumenthal GM, Bernstein WB et al. (2007) Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat 11: 32–50. Lum JJ, Bauer DE, Kong M et al. (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120: 237–248. Maiuri MC, Zalckvar E, Kimchi A et al. (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741–752. Maiuri MC, Le Toumelin G, Criollo A et al. (2007) Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 26: 2527–2539. Marx J (2006) Autophagy: is it cancer’s friend or foe? Science 312: 1160–1161. Meijer AJ, Codogno P (2004) Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol 36: 2445–2462. Mizushima N, Levine B, Cuervo AM et al. (2008) Autophagy fights disease through cellular selfdigestion. Nature 451: 1069–1075. Moenner M, Pluquet O, Bouchecareilh M et al. (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 67: 10631–10634. Mondesire WH, Jian W, Zhang H et al. (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031–7042. Ng SSW, Tsao MS, Chow S et al. (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60: 5451–5455. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381–395. Ogata M, Hino S, Saito A et al. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26: 9220–9231. Ogier-Denis E, Pattingre S, El Benna J et al. (2000) Erk1/2-dependent phosphorylation of Galphainteracting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. J Biol Chem 275: 39090–39095. Ogier-Denis E, Codogno P (2003) Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta 1603: 113–128. Ohshiro K, Rayala SK, Kondo S et al. (2007) Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Cancer Res 67: 8164–8171. O’Neill PM, Bray PG, Hawley SR et al. (1998) 4-Aminoquinolines – past, present, and future: a chemical perspective. Pharmacol Ther 77: 29–58. Opipari AW Jr, Tan L, Boitano AE et al. (2004) Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 64: 696–703. Paglin S, Hollister T, Delohery T et al. (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61: 439–444. Pattingre S, Tassa A, Qu X et al. (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122: 927–939. Pene F, Claessens YE, Muller O et al. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21: 6587–6597.
70
T. Yokoyama et al.
Petiot A, Ogier-Denis E, Blommaart EF et al. (2000) Distinct classes of phosphatidylinositol 3 -kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 275: 992–998. Punnonen EL, Reunanen H (1990) Effects of vinblastine, leucine, and histidine, and 3-methyladenine on autophagy in Ehrlich ascites cells. Exp Mol Pathol 52: 87–97. Reunanen H, Marttinen M, Hirsim¨aki P (1988) Effects of griseofulvin and nocodazole on the accumulation of autophagic vacuoles in Ehrlich ascites tumor cells. Exp Mol Pathol 48: 97–102. Saeki K, Yuo A, Okuma E et al. (2000) Bcl-2 down-regulation causes autophagy in a caspaseindependent manner in human leukemic HL60 cells. Cell Death Differ 7: 1263–1269. Scarlatti F, Bauvy C, Ventruti A et al. (2004) Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem 279: 18384–18391. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253–262. Schweichel JU, Merker HJ (1973) The morphology of various types of cell death in prenatal tissues. Teratology 7: 253–266. Shao Y, Gao Z, Marks PA et al. (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101: 18030–18035. Shi Y, Frankel A, Radvanyi LG et al. (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55: 1982–1988. Shimizu S, Kanaseki T, Mizushima N et al. (2004) Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6: 1221–1228. Shintani T, Klionsky DJ (2004) Autophagy in health and disease: a double-edged sword. Science 306: 990–995. Steck PA, Pershouse MA, Jasser SA et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362. Stephan S, Datta K, Wang E et al. (2004) Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 10: 6993–7000. Su B, Karin M et al. (1996) Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402–411. Takahashi Y, Coppola D, Matsushita N et al. (2007) Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 9: 1142–1151. Takeuchi H, Kondo Y, Fujiwara K et al. (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65: 3336–3346. Tsuruo T, Naito M, Tomida A et al. (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94: 15–21. Vande Velde C, Cizeau J, Dubik D et al. (2000) BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20: 5454–5468. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310. Wang Q, Li N, Wang X et al. (2002) Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3 -kinase inhibition in the KM20 human colon cancer cell line. Clin Cancer Res 8: 1940–1947. Wang CW, Klionsky DJ (2003) The molecular mechanism of autophagy. Mol Med 9: 65–76. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234–248. Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17: 315–324. Xie Z, Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. Nat Cell Biol 9: 1102–1109.
3 Autophagy and Drug Resistance
71
Yamamoto A, Tagawa Y, Yoshimori T et al. (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23: 33–42. Yao KC, Komata T, Kondo Y et al. (2003) Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg 98: 378–384. Yokoyama T, Iwado E, Kondo Y et al. (2008) Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Therapy, in press. Yorimitsu T, Nair U, Yang Z et al. (2006) Endoplasmic reticulum stress triggers autophagy. J Biol Chem 281: 30299–30304. Yu L, Alva A, Su H et al. (2004) Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 304: 1500–1502. Yun J, Tomida A, Nagata K et al. (1995) Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 7: 583–590.
Chapter 4
Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors Stacey J. Baker and E. Premkumar Reddy
Abstract The recent surge in the development of targeted kinase inhibitors R as therapies for cancer was spurred from the success of imatinib (Gleevec, STI571) for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia. This drug, for the first time, showed that a small molecule could be designed to inhibit an oncogenic tyrosine kinase (BCR-ABL) that was responsible for inducing malignant transformation of a particular cell type. Targeted inhibitors against the epidermal growth factor receptor (EGFR), gefitinib and erlotinib, soon followed for the treatment of certain forms of lung cancer. While these drugs can effectively treat disease without many of the unwanted side effects associated with more traditional chemotherapeutic agents, it has become clear that some patients become resistant to these agents due to the development of mutations in the kinase domains of their target proteins. This review discusses the development of these inhibitors as well as the mechanisms associated with resistance to them. Secondgeneration kinase inhibitors aimed at overriding resistance to these therapies are also discussed. Keywords Kinase inhibitor · Targeted therapy · Resistance
Introduction It has been recognized for almost a century that cancer is a multistep process, which takes decades to develop. The facts that cancer cells grow at a much faster rate than normal cells and do not obey rules of ordered growth immediately suggested that cancer is an aberration associated with cell growth. This observation, combined with the fact that cancer is a multistep process, suggested the involvement of multiple E.P. Reddy (B) Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, PA 19140, USA e-mail:
[email protected]
K. Mehta, Z.H. Siddik (eds.), Drug Resistance in Cancer Cells, C Springer Science+Business Media, LLC 2009 DOI 10.1007/978-0-387-89445-4 4,
73
74
S.J. Baker and E.P. Reddy
genetic events that are associated with the growth deregulation seen in cancer cells. Research during the past few decades has shown that these genetic events include the activation of a group of genes termed “oncogenes” and inactivation of another group of genes termed “growth suppressor genes.” A fine balance between the activities of these two groups of gene products seems to dictate normal cell growth, and disruption of this balance appears to provide a cell with a growth advantage that ultimately results in a neoplastic state.
Discovery of Viral and Cellular Oncogenes Oncogenes were initially discovered through the study of transforming retroviruses that produced tumors in animals. An important breakthrough in cancer research came from the discovery that oncogenes of acute transforming viruses are in fact derived from normal cellular DNA and that this genetic information is transduced by acute transforming viruses via genetic recombination. In the past two decades, several of the acute transforming viruses isolated from different animal species have been characterized and have been found to encode growth factors, their receptors, and other signaling molecules that transduce proliferation and survival signals transmitted by growth factor receptors. Studies within the last few decades have also shown that tumor cells often gain a growth advantage through amplification or mutation of various oncogenes, the end result of which appears to be a profound enhancement in the amplitude of the growth and survival signals. Some examples of these changes include amplification of the epidermal growth factor (EGF; also known as ErbB1) and ErbB2 receptors in lung and breast tumors, mutation of the ras oncogene in a wide variety of human tumors and chromosomal translocations such as the Philadelphia chromosome, which results in the activation of the ABL tyrosine kinase. With an understanding of these molecular changes that accompany cell transformation, cancer drug discovery has undergone a dramatic change in the past few years. While most of the emphasis in the past has been placed on developing drugs that induce cell death based on mechanisms that do not discriminate between normal and tumor cells, recent strategies have emphasized targeting specific mechanisms that have gone awry in tumor cells. The elucidation of signaling pathways that are deregulated in tumor cells as well as the identification of mutations in both oncogenes and growth suppressor genes in these cells has suggested multiple targets and revealed approaches for the development of new classes of drugs including antibodies to receptors and small molecule inhibitors to mutant kinases. The most R (imatinib, STI57; Novartis), successful of these types of agents, by far, is Gleevec and it is because of the tremendous success that this drug has had in the clinic that additional kinase inhibitors have been and are being developed. To date, there are numerous kinase inhibitors undergoing clinical trials, and many more are in various pre-clinical stages of development. Nearly all of these compounds are ATP mimetics and are therefore, for the most part, inhibitory to more than one kinase.
4 Tyrosine Kinase Inhibitors and Resistance
75
Because the past 5 years have seen a large amount of research performed in the area of targeted kinase inhibitors, it is regrettably not possible to review all of the agents that are currently being developed. We have therefore limited this article to the discussion of a few rationally designed therapies that have been approved for use in the clinic by the US Food and Drug Administration. All of these agents exemplify the dramatic success of targeted therapies as well as highlight the limitations of targeted kinase inhibitors.
BCR-ABL Targeted Therapy The Philadelphia Chromosome The Philadelphia chromosome (Ph) was discovered in 1960 by Nowell and Hungerford, who analyzed samples derived from seven patients suffering from what was known at that time as chronic granulocytic leukemia. Each patient harbored a similar “minute chromosome,” and none showed any other chromosomal abnormality (Nowell and Hungerford 1960). We now know that this abnormal Ph chromosome results from a reciprocal translocation between chromosomes 9 at band q34 and 22 at band q11. More importantly, this translocation fuses the breakpoint cluster region (Bcr) gene with the Abl gene and creates the BCR-ABL oncogene (Heisterkamp et al. 1985), whose expression is responsible for greater than 90% of chronic myelogenous leukemias (CML) (reviewed in Shah and Sawyers 2003).
BCR-ABL Signaling in CML Oncogenic forms of ABL play a key role in the pathogenesis of CML as these proteins induce growth factor independence (Hariharan et al. 1988, Rovera et al. 1987) and resistance to apoptosis (Bedi et al. 1994, McGahon et al. 1994). These phenotypes are associated with enhanced expression of effector proteins such as Ras, PI-3 kinase, Bcl-2 and the signal transducer and activator of transcription (STAT) family of transcription factors (reviewed in Steelman et al. 2004). Constitutive STAT activation has been documented in lymphoma and leukemic cells, thereby implicating them in leukemogenesis. STATs 1, 3, 5a, and 5b are constitutively activated in BCR-ABL+ hematopoietic cell lines and CML cells, although the majority of BCRABL induced STAT activation is due to STAT-5. Activation of STAT-5 by BCRABL proceeds by a mechanism that is distinct to other effectors and plays a role in mediating the antiapoptotic and cell cycle effects that are imposed by BCR-ABL (Nieborowska-Skorska et al. 1999).
Imatinib Until recently, CML was treated with a variety of chemo- and biotherapeutic drugs (reviewed in Hehlmann 2003). Because the BCR-ABL protein is active in the
76
S.J. Baker and E.P. Reddy
majority of CML cases, and because our understanding of the mechanisms by which this protein functions has increased dramatically, it has been possible to synthesize small molecules that inhibit BCR-ABL kinase activity in leukemic cells without R (STI571, imatinib mesyadversely affecting the normal cell population. Gleevec late; Novartis) (Fig. 4.1) is a small molecule that binds to the kinase domain of BCR-ABL when the protein is in its closed, inactive conformation (Druker et al. 1996). In this conformation, the catalytic central domain is blocked by the regulatory activation (A) loop, and mutations within this loop have been shown to prevent the kinase from adopting an inactive conformation (reviewed in Apperley 2007). As with most kinase inhibitors that are ATP mimetics, imatinib inhibits several tyrosine kinases, including but not limited to platelet-derived growth factor receptor (PDGFR) a and b, c-Kit, Lck, FGFR-1, VEGFR-1, 2, 3, and c-raf (reviewed in Deininger et al. 2005). A recent study has also shown that the drug inhibits the NQO2 oxidoreductase (Rix et al. 2007), which is not a kinase. Imatinib, however, is most active against c-ABL and, more so, its oncogenic forms. BCR-ABL+ cells that are exposed to this drug do not proliferate and have been shown to undergo apoptosis, while normal, IL-3-dependent cells remain virtually unaffected (Druker et al. 1996, Deininger et al. 1997). In the clinic, the Phase I trials aimed at assessing the safety of imatinib were remarkably successful. In those CML patients who were previously treated with interferon (IFN)-α but failed to respond, almost all of the patients who were treated with 300 mg imatinib or greater achieved complete hematological responses. Furthermore, complete cytogenetic responses were observed in 13% of these patients. In Phase II studies evaluating the efficacy of imatinib as a single agent, the results mirrored those obtained in Phase I trials, whereby a significant number of patients in various stages of disease showed cytogenic responses. Phase III trials and those assessing the effectiveness of imatinib in combination with other cytotoxic agents and/or those aimed at improving the efficacy of imatinib monotherapy were equally successful, whereby imatinib proved to be the most effective treatment for various stages of leukemic disease. As a result, imatinib is now considered as a first-line therapy for the majority of CML cases due to its high efficacy level and relatively mild side effects (reviewed in Deininger et al. 2005).
Imatinib Resistance in CML In spite of the fact that the majority of patients receiving imatinib respond to treatment at both the hematological and cytogenetic levels, relapse occurs in a subset of patients with chronic disease, and this number jumps significantly to nearly 100% in those patients whose disease is in the advanced stages (reviewed in Shah and Sawyers 2003). Several studies have attempted to address the mechanism(s) by which CML cells acquire imatinib resistance.
4 Tyrosine Kinase Inhibitors and Resistance
77
Imatinib
H N
N
N
H N
N
N O
N
Nilotinib F
F
O
H N
N
F
N H
N
N
N
N
Dasatinib O
H N
N
S N H
N
N
Cl
N N
OH
Erlotinib
Gefitinib
F NH
Cl O
N N
O
O O
NH
O O
N N
O
Fig. 4.1 Chemical structure of imatinib, dasatinib, nilotinib, gefitinib, and erlotinib
N
78
S.J. Baker and E.P. Reddy
Nonmutation-Dependent Mechanisms The use of in vitro-generated resistant subclones has revealed that elevated levels of BCR-ABL are sometimes expressed as a result of genomic amplification of the BCR-ABL locus (le Coutre et al. 2000, Mahon et al. 2000, Weisberg and Griffin 2000). Amplification of the locus and/or multiple copies of the Philadelphia chromosome have also been reported in patients, although the percentage of such cases that represent primary imatinib resistance is small (Gorre et al. 2001, Hochhaus et al. 2002). Similar studies also revealed that imatinib resistance is also mediated by increased levels of the Pgp multidrug resistance protein (MDR1; ABCB1) (Mahon et. al. 2000). However, analysis of patient-derived samples does not support such a mechanism in a clinical setting, and even overexpression of MDR1 in in vitro model systems does not confer imatinib resistance (Ferrao et al. 2003). Other studies have examined signaling pathways and proteins that are activated downstream of BCR-ABL. The Src family kinase Lyn is overexpressed in an imatinib-resistant variant of the K562 cell line (Donato et al. 2003), and in advanced stages of CML, it is overexpressed and constitutively phosphorylated independently of imatinib treatment and/or BCR-ABL expression. In the chronic phase of the disease, however, imatinib can actually inhibit phosphorylation of the protein, suggesting that Lyn may play different roles depending on the stage of the disease (Donato et al. 2003, 2004, Wu et al. 2008). Another member of the Src family, Hck, associates with BCR-ABL (Warmuth et al. 1997), and a kinase-defective Hck mutant has been shown to abrogate cytokineindependent growth of BCR-ABL transformed cells (Lionberger et al. 2000). In some blast-crisis samples derived from patients treated with imatinib, levels of phosphorylated Hck expression are increased (Donato et al. 2003), suggesting that like Lyn, Hck may mediate sensitivity to imatinib in a BCR-ABL independent mechanism. In addition to Src family kinases, Janus kinase 2 (JAK2) has also been shown to play a role in imatinib (and second-generation ABL kinase inhibitor) resistance. Inhibition of JAK2 expression in cells ectopically expressing both wildtype and imatinib-resistant forms of BCR-ABL results in their apoptosis (Samanta et al. 2006). Subsequent studies have also revealed that STAT5 is activated in a BCR-ABL independent mechanism in response to GM-CSF in LAMA cell clones and that inhibition of JAK2 using a targeted JAK-2 inhibitor (AG490) antagonized this activation (Wang et al. 2007). Interestingly, GM-CSF mRNA and protein levels were increased in a percentage of imatinib-resistant patients, and these elevated levels were independent of BCR-ABL mutation status (Wang et al. 2007). Other BCR-ABL independent mechanisms that mediate imatinib resistance include (but are not limited to) the activation of the Akt/PI-3 kinase/mtor pathway (Burchert et al. 2005), activation of RUNX transcription factors (Miething et al. 2007), activation of MAP kinase activity (Chu et al. 2004), and inactivation/mutation of p53 (Wendel et al. 2006; reviewed in Burchert 2007).
4 Tyrosine Kinase Inhibitors and Resistance
79
Mutation of BCR-ABL In spite of these studies, the majority of reports indicate that the mechanism that accounts for the majority of imatinib-resistant leukemias, in vivo, is mutation of the BCR-ABL gene itself. Mutation within the kinase domain is most common. The first study that analyzed the frequency of these mutations was published in 2001 by Gorre et al. This study examined cells derived from 11 patients in the advanced stages of CML who were being treated with imatinib and had initially responded well to treatment but had relapsed. Although genomic amplification was detected in three of the samples, a specific mutation within the BCR-ABL kinase domain was present in six cases. Specifically, this mutation resulted in the substitution of a threonine residue with isoleucine at amino acid position 315 (T315I). This substitution, based on the crystal structure of the Abl kinase domain complexed with an imatinib derivative, is thought to decrease the binding affinity of imatinib to the BCR-ABL protein whereby the isoleucine substitution prevents hydrogen bond formation between BCR-ABL and imatinib (Schindler et al. 2000). This hypothesis is supported by the fact that cell lines that ectopically express this mutant protein are markedly insensitive to imatinib (Gorre et al. 2001). Since that initial report, more than 50 mutations in the kinase domain of the BCR-ABL gene have been identified in imatinib-resistant leukemic cells. The list of mutations has been extensively summarized and reviewed in 2007 by Apperley (2007). Although the exact mechanism(s) that drive the mutation process is at present unclear, it is widely believed that many (if not all) result from the “selection pressure” exerted by exposure to imatinib. However, recent studies indicate that they may also arise due to genetic instability induced by BCR-ABL (Jiang et al. 2007a, b) and inhibition of the mismatch (MMR) and nucleotide excision repair (NER) processes (Canitrot et al. 2003, Sliwinski et al. 2008, Stoklosa et al. 2008). The imatinib-resistant mutations that arise in BCR-ABL can be classified as those that potentially interfere with the ability of imatinib to interact directly with the BCR-ABL kinase domain and those that are predicted to destroy or hinder the ability of the BCR-ABL kinase domain to adopt a conformation that is required for imatinib binding (reviewed in Shah and Sawyers 2003, Sawyers 2004). The number of mutations that occur with the highest frequency tend to be clustered within the P-loop (ATP-binding site), the imatinib-binding site, the catalytic domain, and the activation loop. In patients, it is clear that certain mutations are present in particular phases of CML. However, it is at present unclear whether some or any of the mutations are causative of disease or whether they merely correlate with certain phases (reviewed in Apperley 2007).
Second-Generation BCR-ABL Inhibitors Aimed at Overcoming Imatinib Resistance Because of the frequency of mutations, efforts have been focused on the identification of novel inhibitors that are active against imatinib-resistant mutants of
80
S.J. Baker and E.P. Reddy
BCR-ABL. Several approaches have been reported to overcome this resistance in at least some CML cases. MEK1, RAF-1, PI-3 kinase, farnesyltransferase, CDK, proteasome, and other inhibitors have been shown to have growth inhibitory effects on certain imatinib-resistant leukemias (reviewed in Deininger et al. 2005). However, the most successful alternatives to imatinib to date are second-generation inhibitors of BCR-ABL that inhibit the protein at lower concentrations than imatinib. Some agents, such as dasatinib, are unrelated to imatinib and are also inhibitory to other tyrosine kinases, making them active against a variety of imatinib-resistant tumors. Nilotinib, on the other hand, was developed as a rationally designed alternative to imatinib that exploited imatinib’s affinity and selectivity for the Abl kinase domain.
Dasatinib Originally termed BMS-354825 (Lombardo et al. 2004, Shah et al. 2004), dasatinib R Bristol-Myers Squibb) (Fig. 4.1) is an orally bioavailable inhibitor of (Sprycel; BCR-ABL and was the first drug to be approved for the treatment of imatinibresistant Ph+ leukemias. Although structurally unrelated to imatinib, dasatinib also inhibits BCR-ABL (albeit at lower concentrations than imatinib), c-Kit, and PDGFR. It is also inhibitory to other kinases such as the Src family tyrosine kinases, the Tec kinases Btk and Tec, and the ephrin A (EphA) receptor tyrosine kinase (Lombardo et al. 2004, Nam et al. 2005, Schittenhelm et al. 2006, Hantschel et al. 2007). Dasatinib does not share structural conformation requirements for BCR-ABL with imatinib and therefore binds to both active and inactive conformations of the protein (Tokarski et al. 2006). As a result, the drug has been successful in inhibiting nearly all imatinib-resistant forms of the protein. In in vitro assays, dasatinib was inhibitory to all imatinib-resistant mutations tested, with the exception of T315I (Shah et al. 2004, O’Hare et al. 2005a). In the clinic, the drug is remarkably and equally effective in patients harboring imatinib-resistant mutations with the exception of T315I, where no effect was observed (reviewed in Ramirez and DiPersio 2008).
Dasatinib Resistance In the clinic, dasatinib has been successful in treating patients who were intolerant to imatinib or whose disease was resistant to imatinib. In clinical trials, the drug has shown the greatest efficacy in patients in the chronic phase of CML. Nonetheless, cases of dasatinib resistance have begun to emerge. Specifically, sequencing of BCR-ABL+ clones isolated from patients receiving dasatinib after failing or showing intolerance to imatinib revealed a predominance of mutations at the T315 and F317 residues. In addition to the T315I mutation, which was consistent with earlier in vitro assays, a second mutation at this residue, T315A, has also been detected in one patient (Soverini et al. 2007, Khorashad et al. 2008). Interestingly, this same
4 Tyrosine Kinase Inhibitors and Resistance
81
mutation was isolated during a mutagenesis screen aimed at isolating dasatinibresistant forms of BCR-ABL (Burgess et al. 2005). At the F317 residue, four different mutations have been identified (F317I/L/V/C), although the F317L mutation has been documented in the greatest percentage of cases. These results suggest that these two residues may be key in the ability of dasatinib to inhibit BCR-ABL (Soverini et al. 2006, 2007). It is interesting to note that the F317L was tested as part of the panel of imatinib-resistant mutants in in vitro cell-based assays as well as in animal tumor model systems (Shah et al. 2004, O’Hare et al. 2005a). While it has been noted that higher amounts of dasatinib were required to inhibit kinase activity and cellular proliferation, the levels were not such that they substantially exceeded those for other imatinib-resistant mutations that do not arise in dasatinib sensitive patients. Additional studies have identified mutations at several additional residues (Shah et al. 2007, Soverini et al. 2007, reviewed in Lee et al. 2008), and compound mutations have also been observed in patients undergoing sequential imatinib and dasatinib therapies. However, of these mutations, the V299L is of interest as it occurs at a residue that directly binds to dasatinib. This mutation, however, is sensitive to both imatinib and nilotinib (Shah et al. 2007), further underscoring the differences between these drugs.
Nilotinib R AMN107; Novartis) (Weisberg et al. 2005) (Fig. 4.1) is Nilotinib (Tasigna, structurally related to imatinib and has a greater affinity (approximately 20-fold) for wild-type BCR-ABL (reviewed in O’Hare et al. 2005b). Because of the structural similarities between the two drugs, in addition to inhibiting BCR-ABL, nilotinib is also inhibitory to c-Kit, PDGFR, and the TEL-PDGFRα and FIP1L1-PDGFRα fusion proteins (Stover et al. 2005, reviewed in Lee et al. 2008). Also similar to imatinib, nilotinib binds to BCR-ABL when it is in an inactive conformation; however, its design allows it to bind more tightly, thereby enhancing its inhibitory activity (Manley et al. 2005). As a result, most of the imatinib-resistant forms of BCR-ABL tested in in vitro cell-based assays are also 20-fold more sensitive to this drug, although studies using certain imatinib-sensitive cell lines have shown that the increased potency may be as high as 60-fold (Weisberg et al. 2005, Golemovic et al. 2005). Nilotinib does, however, when compared to wild-type BCR-ABL, show a reduced ability to inhibit P-loop mutations, and this is correlated with a response to the drug in the clinic (Kantarjian et al. 2006). The only exception is the T315I mutation, which is completely insensitive to nilotinib in vitro and in vivo as well as in the clinic (Weisberg et al. 2005; reviewed in Deininger 2008).
Overcoming T315I Resistance The T315 residue is commonly referred to as the “gatekeeper” due to the fact that the T315I mutation confers complete resistance to imatinib, dasatinib, and nilotinib.
82
S.J. Baker and E.P. Reddy
Developing inhibitors that have the ability to overcome such resistance is a challenging and ever-growing area of research. It has become clear that the use of ATP mimetics that have the ability to target the kinase domain drives the emergence of such mutations, and hence, compounds that inhibit the T315I conformation directly are invaluable. Use of x-ray crystallography in conjunction with structure-guided optimization has led to the isolation of SGX393, a compound that inhibits both T315I and T315A. It does not, however, inhibit certain other P-loop mutations. Fortunately, some of these mutations are inhibited by either nilotinib and/or dasatinib, suggesting that this agent, should it be used in a clinical setting, could be used in combination therapy (O’Hare et al. 2008). Other drugs with the ability to inhibit T315I directly that are undergoing clinical trials are inhibitors of the Aurora kinases and include MK-0457, XL228, PHA-739358, and KW-2449 (reviewed in Quint´as-Cardama et al. 2007, Quint´as-Cardama and Cortes 2008). In addition to T315I inhibitors, it may also be possible to target signaling pathways that are either downstream or parallel to BCR-ABL. There are numerous compounds at various stages of development that could possibly fill such a need, including (but not limited to) Src family kinase inhibitors, inhibitors of HSP90, inducers of apoptosis, activators of protein phosphatases and histone deacetylase (HDAC) inhibitors (reviewed in Quint´as-Cardama et al. 2007, Quint´as-Cardama and Cortes 2008).
EGFR-Targeted Therapy EGFR and Cancer The significance of the epidermal growth factor receptor (EGFR) in cancer was suggested years before it was shown that the protein was altered or aberrantly expressed in tumors. During the early 1980s, studies of the avian erythroblastosis virus led to the identification of viral, transforming versions of the EGFR (Anderson et al. 1980, Vennstrom and Bishop 1982, Yamamoto et al. 1983), and subsequent studies showed that introduction of the EGFR gene into NIH-3T3 cells results in ligand-dependent transformation (Di Fiore et al. 1987, Velu et al. 1987, Hudziak et al. 1987). In certain types of tumors, such as gliomas, the EGFR locus is amplified, resulting in high levels of the receptor. Other tumor types express mutant, constitutively active forms of the protein (reviewed in Pao et al. 2004a). Activation of the EGFR stimulates proliferation, metastasis, angiogenesis, and other phenotypes that are beneficial for tumor growth. EGFR is expressed in a variety of cell types and tumors, including (but not limited to) those of the bladder, lung, head and neck, breast, colon, and pancreas. In certain types of malignancies, such as head and neck cancers, the level of EGFR expression is of prognostic value where elevated levels are correlated with decreased survival, whereas in others, this link is not as well defined (reviewed in Pao et al. 2004a).
4 Tyrosine Kinase Inhibitors and Resistance
83
Gefitinib and Erlotinib: EGFR-Targeted Therapies R AstraZeneca) (Fig. 4.1) belongs to a class of comGefitinib (ZD1839, Iressa; pounds termed anilinoquinazolinones and is an inhibitor of EGFR enzymatic activity in the low nanomolar range (Ward et al. 1994). Subsequent studies also revealed that gefitinib effectively inhibited the proliferation of a variety of established tumor cell lines (Sirotnak 2003), although this did not necessarily correlate with EGFR expression. Gefitinib, as well as most targeted kinase inhibitors developed to date, acts by reversibly competing with adenosine triphosphate (ATP) for binding to the EGFR, thereby inhibiting its autophosphorylation and activity (Wakeling et al. 2002). Cells that have been exposed to this drug undergo cell cycle arrest and apoptosis (Magne et al. 2002, Di Gennaro et al. 2003) and express lower levels of pro-angiogenic proteins such as VEGF (Ciardiello et al. 2001, Hirata et al. 2002). EGF has been shown to regulate the expression of VEGF, IL-8 and other angiogenic factors. It is therefore not surprising that gefitinib has the ability to regulate tumor growth by controlling the neovasculature (reviewed in Ono and Kuwano 2006).
Response to Gefitinib Treatment In the United States, Gefitinib was initially approved for the treatment of nonsmall lung cancer (NSCLC) in patients who had failed or were not able to receive standard chemotherapeutic regimens. However, as it was later shown that the drug was only modestly effective as a single agent and in combination therapy, the US FDA restricted administration of the drug to only those patients who were currently enrolled in clinical trials or who had benefitted from its prior use. As a result, gefitinib was removed from the US drug market, although it continues to be used in several other countries (reviewed in Dutta and Maity 2007, Gridelli et al. 2007). In general, non-smokers, women, and Asians have an overall more favorable response to EGFR kinase inhibition (reviewed in Fukui and Mitsudomi 2008). However, overall response to gefitinib has been shown to vary considerably in these and other patient cohorts, thereby prompting research to identify biomarkers that could account for this variability and predict sensitivity. Sequence analysis of the EGFR in primary NSCLC tumors derived from patients in Japan and the United States (Lynch et al. 2004, Paez et al. 2004) identified mutations within the tyrosine kinase domain that correlated with sensitivity to gefitinib. For the most part, the abnormalities are in-frame deletions in amino acids 747–750 (del746–750) or a point mutation at position 858 (L858R) (Lynch et al. 2004, Paez et al. 2004, Pao et al. 2004b). These studies also showed that such mutations, which result in increased levels of ligandinduced receptor autophosphorylation, are more common in non-smokers, women, Japanese patients, and those with the adenocarcinoma form of the disease. Since these initial studies, other mutations in the forms of in-frame deletions and insertions, point mutations, and duplications within exons 19–22 of the EGFR gene that
84
S.J. Baker and E.P. Reddy
confer some level of response to gefitinib have been identified. However, the “classical” L858R (exon 21) and the del746–750 (exon 19) mutations still account for roughly 90% of the alterations in this region (reviewed in Irmer et al. 2007). Overall, NSCLC patients treated with gefitinib (or erlotinib) who harbor the del746–750 mutation have a longer median survival when compared to those with the L858R mutation (Riely et al. 2006, J¨anne and Johnson 2006). In addition, immunohistochemical staining of tumor specimens for proteins that are downstream of the EGFR revealed that patients with tumors that stained positive for phosphorylated Akt (pAkt) responded better to gefitinib treatment than those which stained negative; however, there was no such correlation for phosphorylated MAP kinase (Cappuzzo et al. 2004). Similar results were obtained using human NSCLC cell lines, although these studies also revealed an association between p-Akt and ERK1/2 phosphorylation in gefitinib-resistant cells (Ono et al. 2004, Han et al. 2005).
Erlotinib R OSI-774, Genentech) (Fig. 4.1) belongs to the class of quinaErlotinib (Tarceva, zolinones and is a selective but reversible inhibitor of EGFR enzymatic activity in the low nanomolar range (Pollack et al. 1999). It also inhibits the constitutively active EGFRvIII variant that contains an in-frame deletion in exons 2–7 of the EGFR gene (Lal et al. 2002). Erlotinib is currently approved for the treatment of advanced or metastatic resistant NSCLC patients and for use in combination therapy with gemcitabine in treating advanced, unresectable, or metastatic pancreatic cancer (reviewed in Bareschino et al. 2007, Gridelli et al. 2007). In in vitro assays, while the degree to which wild-type EGFR and the delL474-S752 mutant was inhibited by both gefitinib and erlotinib was similar, the L858R exhibited an approximate 10-fold increased sensitivity to both drugs. It is therefore not surprising that in the clinic, patients whose tumors harbor mutant forms of the EGFR respond to treatment with erlotinib, which is similar to what has been observed with gefitinib (Pao et al. 2004b, reviewed in Gridelli et al. 2007).
Gefitinib and Erlotinib Resistance Secondary EGFR Mutations In spite of the success that these drugs have had in treating NSCLCs with EGFRactivating mutations, resistance emerges in a percentage of patients who have initially responded to treatment. Biochemical analysis and structural modeling have resulted in the identification of a second point mutation at amino acid position T790 (T790M) in a patient who had initially responded to gefitinib treatment but who had relapsed (Kobayashi et al. 2005). At that time, resistance was also predicted to occur in patients treated with erlotinib (Kobayashi et al. 2005), and as expected, cases of erlotinib-resistant disease that harbor this mutation have emerged in the
4 Tyrosine Kinase Inhibitors and Resistance
85
clinic (Pao et al. 2005a). The same mutation has also been identified in a family with several cases of inherited NSCLC and is thought to act in cis with a second somatic T790M mutation (Bell et al. 2005). In cis cooperation has also been observed with both the L858R and del746–750 EGFR mutations as is evidenced by increased transformation potential and ligand-independent signaling (Godin-Heymann et al. 2007). Termed as EGFR’s “gatekeeper,” T790 is analogous to T315 of BCR-ABL as it is necessary to maintain proper conformation of the ATP-binding cleft and because of its ability to confer resistance to gefitinib and erlotinib. However, T790M does differ from T315I in that it does not have increased enzymatic activity in vitro (Pao et al. 2005a). At a basic mechanistic level, T790M increases the affinity of the EGFR kinase domain for ATP (Yun et al. 2008), and this single mutation accounts for approximately 50% of all resistance to both gefitinib and erlotinib (Kosaka et al. 2006, Balak et al. 2006). In addition to T790M, other mutations that arise in TKIresistant tumors inhibition have been isolated in rare instances (Balak et al. 2006). Non-EGFR Mutation-Dependent Mechanisms In addition to mutation of the EGFR, mutations in RAS family genes are present in approximately 15–30% of lung adenocarcinomas in patients with a history of cigarette smoking. Most of these mutations are located in exons 12 and 13 of the K-ras gene and are associated with resistance to gefitinib and erlotinib (Pao et al. 2005b). Activation of parallel signaling pathways or those that are downstream of the EGFR can also result in resistance to gefitinib and erlotinib. MET locus amplification was originally identified in a gefitinib-resistant cell line, and the resultant increased levels of MET protein signal through Akt via ErbB3. Subsequent analysis revealed that the same pathway was activated in the majority of gefitinib- and erlotinib-resistant tumors with MET amplification and that this amplification occurs in the presence or absence of the T790M mutation (Engelman et al. 2007, Bean et al. 2007). Other proteins/pathways whose activation is associated with EGFR kinase inhibition include, but are not limited, to PI-3 kinase/Akt (Engelman et al. 2006), the insulin-like growth factor receptor (IGF-1R) (Morgillo et al. 2006, Guix et al. 2008), s-Src (in conjunction with c-Met) (Mueller et al. 2008), and MAPK (Morgillo et al. 2006).
Overcoming T790M Resistance Overcoming resistance to the T790M mutation is of critical importance in the area of EGFR kinase inhibition. This mutation is a “generic” mutation, and biochemical assays and x-ray crystallization predict that it will confer resistance or at least reduce the inhibitory properties of most if not all ATP-competitive inhibitors (Yun et al. 2008). Both erlotinib and gefitinib are reversible inhibitors of the EGFR, and T790M reduces the affinity of the EGFR for both. Second-generation irreversible EGFR
86
S.J. Baker and E.P. Reddy
inhibitors, such as HKI-272 (Rabindran et al. 2004, Kwak et al. 2005), have shown efficacy in mouse models and are predicted to overcome this resistance through their ability to form covalent bonds with the EGFR protein (Li et al. 2007, Yun et al. 2008). While these results are encouraging, resistance to HKI-272 has recently been shown in in vitro cell culture systems (Godin-Heymann et al. 2008); it is predicted that other irreversible EGFR inhibitors will be required to overcome the effects of T790M.
Concluding Remarks When we look back at the advances made in cancer research in the past two decades, we cannot but be amazed at the monumental progress that has been achieved in our understanding of how normal cells grow and how events that disrupt this process result in a cancerous state. This fundamental understanding of the molecular biology of cancer has made it possible for us to develop new therapies that will make cancer a much less dreaded disease. While most of the emphasis in the past has been placed on developing drugs that induce cell death based on mechanisms that do not discriminate between normal and tumor cells, recent strategies have emphasized targeting specific mechanisms that have gone awry in tumor cells. A glimpse into the future of these new therapies is shown through the development of imatinib, a specific inhibitor of the BCR-ABL kinase, which has revolutionized the treatment of CML. The remarkable success of this drug can be attributed to several factors: the critical role of BCR-ABL in the pathogenesis of CML, exceptional target specificity of imatinib, and a very high therapeutic index shown by this compound. Imatinib’s success in the clinic has spawned the development of other successful targeted therapies for CML (dasatinib and nilotinib), as well as EGFRtargeted inhibitors (erlotinib and gefitinib) for the treatment of NSCLC. While it is clear that we are witnessing a change in the paradigm of cancer therapy, resistance to these inhibitors presents a challenge to researchers and physicians alike. The emergence of gatekeeper and other mutations in the ATP-binding domains of tyrosine kinases highlights the difficulty in generating inhibitors that can effectively overcome resistant forms of the disease and reminds us that treating TKI-resistant tumors will almost certainly involve inhibition of multiple signaling pathways. Acknowledgments
We are thankful to M.V. Ramana Reddy for preparing Fig. 4.1.
References Anderson SM, Hayward WS, Neel BG, Hanafusa H. 1980. Avian erythroblastosis virus produces two mRNAs. J. Virol. 36, 676–683. Apperley J.F. 2007. Part II: management of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol. 8: 1116–1128. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. 2006. Novel D761Y and common secondary T790M
4 Tyrosine Kinase Inhibitors and Resistance
87
mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12: 6494–6501. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. 2007. Erlotinib in cancer treatment. Annal. Oncol. 18: vi35-vi41. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA 104: 20932–20937. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. 1994. Inhibition of apoptosis by BCRABL in chronic myeloid leukemia. Blood. 83, 2038–2044. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA. 2005. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37: 1315–1316. Burchert A. 2007. Roots of imatinib resistance: a question of self-renewal? Drug Resust. Updat. 10: 152–161. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, M¨uller-Br¨usselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A. 2005. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774–1782. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. 2005. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. 102: 3395–3400. Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS, Lautier D, Skorski T. 2003. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 102: 2632–2637. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L. 2004. Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmall-cell lung cancer. J. Natl. Cancer Inst.96, 1133–1141. Chu S, Holtz M, Gupta M, Bhatia R. 2004. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167–3174. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. 2001. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7, 2958–2970. Deininger MW. 2008. Nilotinib. Clin. Cancer Res. 14: 4027–4031. Deininger M, Buchdunger E, Druker BJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653. Deininger MW, Goldman JM, Lydon N, Melo JV. 1997. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691–3698. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA. 1987. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51, 1063–1070. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella, .P, Caponigro F, Pepe S, Budillon A. 2003. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (’Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Cell. Physiol. 195, 139–150. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. 2003. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690–698.
88
S.J. Baker and E.P. Reddy
Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. 2004. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 64, 672–677. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566. Dutta PR, Maity A. 2007. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Let. 254: 165–177. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borr´as AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, J¨anne PA. 2006. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer. J. Clin. Invest. 116: 2695–2706. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, J¨anne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043. Ferrao PT, Frost MJ, Siah SP, Ashman LK. 2003. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 102: 449–503. Fukui T, Mitsudomi T. 2008. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen. Thorac. Cardiovasc. Surg. 56: 97–103. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, Settleman J, Haber DA. 2007. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 67: 7319–7326. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA. 2008. The T790M ”gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 7: 874–879. Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M. 2005. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11: 4941–4947. Gorre ME, Mohamed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293, 876–880. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. 2007. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12: 840–849. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. 2008. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118: 2609–2619. Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK. 2005. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int. J. Cancer 113, 109–115. Hantschel O, Rix U, Schmidt U, B¨urckst¨ummer T, Kneidinger M, Sch¨utze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. 2007. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. USA. 104: 13283–13288. Hariharan IK, Adams JM, Cory S. 1988. Bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res. 3, 387–399. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. 1985. Structural organization of the bcr gene and its role in the Ph’ translocation. Nature. 315, 758–61. Hehlmann R. 2003. Current CML therapy: progress and dilemma. Leukemia. 17, 1010–1012.
4 Tyrosine Kinase Inhibitors and Resistance
89
Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M. 2002. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62, 2554–2560. Hochhaus A, Kreil S, Corbin AS, La Ros´ee P, M¨uller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190–2196. Hudziak RM, Schlessinger J, Ullrich A 1987. Increased expression of the putative grwoth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 84, 7159–7163. Irmer D., Funk JO, Blaukat A. 2007. EGFR kinase domain mutations- functional impact and relevance for lung cancer therapy. Oncogene 26: 5693–5701. J¨anne PA, Johnson BE. 2006. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 12: 4416s-4420s. Jiang X, Saw KM, Eaves A, Eaves C. 2007a. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl. Cancer Inst. 99: 680–693. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C. 2007b. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926–935. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354: 2542–2551. Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, De Melo V, Babb A, de Lavallade H, Olavarria E, Marin D, Goldman JM, Apperley JF, Kaeda JS. 2008. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111: 2378–2381. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352, 786–792. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. 2006. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12: 5764–5769. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102: 7665–7670. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, Riggins GJ. 2002. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62: 3335–3339. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. 2000. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 95, 1758–1766. Lee F., Fandi A. and Voi M. 2008. Overcoming kinase resistance in chronic myeloid leukemia. Int. J. Biochem. Cell Biol. 40: 334–343. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, J¨anne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. 2007. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12: 81–93. Lionberger JM, Wilson MB, Smithgall TE. 2000. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem. 275: 18581–18585.
90
S.J. Baker and E.P. Reddy
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. 2004. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47: 6658–6661. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 3129–3139. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G. 2002. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (”Iressa”). Br. J. Cancer 86, 1518–1523. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. 2000. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 96, 1070–1079. Manley PW, Cowan-Jacob-SW, Fendrich G, Metan J. 2005. Molecular interactions between the highly selective pan-Bcr-Abl inhibitor, AMN107 and the kinase domain of Abl. Blood 106: 940a. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. 1994. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83, 1179–1187. Miething C, Grundler R, Mugler C, Brero S, Hoepfl J, Geigl J, Speicher MR, Ottmann O, Peschel C, Duyster J. 2007. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc. Natl. Acad. Sci. USA. 104: 4594–4599. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. 2006. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66: 10100–10111. Mueller KL, Hunter LA, Ethier SP, Boerner JL. 2008. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 68: 3314–3322. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R. 2005. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 65: 9185–9189. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. 1999. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229–1242. Nowell PC, Hungerford DA. 1960. A minute chromosome in human granulocytic leukemia. Science. 132, 1497. O’Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW. 2008. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc. Natl. Acad. Sci. USA. 105: 5507–5512. O’Hare T, Walters DK, Deininger MW, Druker BJ. 2005b. AMN107: tightening the grip of imatinib. Cancer Cell. 7, 117–119. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. 2005a. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 66: 4500–4505.
4 Tyrosine Kinase Inhibitors and Resistance
91
Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. 2004. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signalregulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3, 465–472. Ono M, Kuwano M. 2006. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeted drugs. Clin. Cancer Res. 12: 7242–7251. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500. Pao W, Miller VA, Kris MG. 2004a. ‘Targeting’ the epidermal growth factor receptor tyrosine R in non-small cell lung cancer (NSCLC). Sem. Cancer Biol. 14, kinase with gefitinib (Iressa) 33–40. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. 2005a. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med. 3: 225–235. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. 2005b. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2: 57–61. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. 2004b. EGF receptor gene mutations are common in lung cancers from ”never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 101, 13306–13311. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. 1999. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291: 739–748. Quint´as-Cardama A, Kantarjian H, Cortes J. 2007. Flying under the radar: the new wave of BCRABL inhibitors. Nat. Rev. Drug Discov. 6: 834–848. Quint´as-Cardama A, Cortes J. 2008. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin. Cancer Res. 14: 4392–4399. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A. 2004. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64: 3958–3965. Ramirez P. and DiPersio JF. 2008. Therapy options in imatinib failures. The Oncologist 13: 424–434. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. 2006. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12: 839–844. Rix U, Hantschel O, D¨urnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, K¨ocher T, Superti-Furga G. 2007. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055–4063. Rovera G, Valtieri M, Mavilio F, Reddy EP. 1987. Effect of Abelson murine leukemia virus on granulocytic differentiation and interleukin-3 dependence of a murine progenitor cell line. Oncogene 1, 29–35. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. 2006. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 13: 6468–6472.
92
S.J. Baker and E.P. Reddy
Sawyers CL. 2004. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998–3010. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289, 1938–1942. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. 2006. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66: 473–481. Shah NP, Sawyers CL. 2003. Mechanisms of resistance to STI571 in Philadelphia chromosomeassociated leukemias. Oncogene. 22, 7389–7395. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. 2007. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117: 2562–2569. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305, 399–401. Sliwinski T, Czechowska A, Szemraj J, Morawiec Z, Skorski T, Blasiak J. 2008. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat. Res. 654: 162–167. Sirotnak FM. 2003. Studies with ZD1839 in preclinical models. Semin. Oncol. 30, 12–20. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G. 2007. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Hematologica 92: 404–404. Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M. 2006. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J. Clin. Onol. 24: e51–52. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18, 189–218. Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T. 2008. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 68: 2576–2580. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG. 2005. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106: 3206–13. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. 2006. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinibresistant ABL mutants. Cancer Res. 66: 5790–5797. Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I, Lowy DR. 1987. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238, 1408–1410. Vennstrom B, Bishop JM. 1982. Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus. Cell 28, 135–143. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. 2002. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749–5754. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A. 2007. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF)
4 Tyrosine Kinase Inhibitors and Resistance
93
mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 109: 2147–2155. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. 1994. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48, 659–666. Warmuth M, Bergmann M, Priess A, H¨auslmann K, Emmerich B, Hallek M. 1997. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J. Biol. Chem. 272: 33260–33270. Weisberg E, Griffin JD. 2000. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 95, 3498–3505. Weisberg E, Manley PW, Breitenstein W, Br¨uggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129–141. Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. 2006. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc. Natl. Acad. Sci. USA. 103: 7444–7449. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. 2008. Association between imatinib-resistant BCR-ABL mutationnegative leukemia and persistent activation of LYN kinase. J. Natl. Cancer Inst. 100: 926–939. Yamamoto T, Hihara H, Nishida T, Kawai S, Toyoshima K. 1983. A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell 34, 225–232. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. 2008. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA. 105: 2070–2075.
Chapter 5
Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells Kapil Mehta and Jansina Y. Fok
Abstract The ability of tumor cells to develop resistance to chemotherapy and radiation therapy and to metastasize to distant organs represents a major roadblock in the successful treatment of cancer. In fact, more than 90% of cancer deaths can be attributed to the failure of drugs to kill tumor cells. One feature common among drug-resistant and metastatic tumor cells is an increased resistance to apoptosis— the ability of cancer cells not only to grow and survive successfully in the stressful environments of foreign tissues (metastasis) but also to display resistance to genotoxic therapies. Therefore, to improve cancer therapy, tumor-encoded genes, whose increased expression in cancer cells contributes to the development of resistance to drug-induced damage (apoptosis), need to be defined. One such gene is TGM2 (NM-004613), whose expression is upregulated in many drug-resistant and metastatic tumors and tumor cell lines. The product of the TGM2 gene, tissue type transglutaminase-2 (TG2), is structurally and functionally a complex protein that is implicated in such diverse processes as apoptosis, wound healing, cell migration, cell attachment, cell growth, angiogenesis, and matrix assembly. In this chapter, we will provide recent evidence linking aberrant expression of TG2 with the development of chemoresistance and a metastatic phenotype in cancer cells. In addition, we will discuss some specific antiapoptotic pathways that are regulated by TG2 and how inhibition or downregulation of this protein can enhance the sensitivity of cancer cells to conventional chemotherapy. Keywords Metastasis · Drug resistance · Focal adhesion kinase · Integrins · NF-κB · AKT · PTEN · Autophagy · Apoptosis
Supported in part by a grant from the Susan G. Komen for Cure. K. Mehta (B) Department of Experimental Therapeutics, Unit 362, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA e-mail:
[email protected]
K. Mehta, Z.H. Siddik (eds.), Drug Resistance in Cancer Cells, C Springer Science+Business Media, LLC 2009 DOI 10.1007/978-0-387-89445-4 5,
95
96
K. Mehta and J.Y. Fok
Introduction Six decades after the first anticancer drug was developed, chemotherapy still remains the major therapeutic tool for treating unresectable or disseminated tumors. Although chemotherapy has a significant impact on the overall survival of patients with certain malignancies, the majority of human cancers exhibit resistance to chemotherapy, either at presentation or acquired after the initial response to therapy. This suggests that resistance is either an intrinsic property of certain tumor cells or that it can evolve under the pressure of drug treatment. In general, tumor cells exhibit resistance not only to one particular drug or to a group of structurally and functionally similar drugs but also to unrelated drugs. This type of resistance is referred to as multidrug resistance (Gottesman et al. 2002). Various mechanisms have been implicated in the development of chemoresistance, including exclusion of a drug from cells by overexpression of P-glycoprotein (P-gp) or other members of the multidrug resistance-related proteins (MRP), altered expression of drug targets, detoxification of drugs due to increased glutathione S-transferase (GST), increased metabolism of the drug to inactive molecules, enhanced ability of tumor cells to repair the damage, and failure of the tumor cells to respond appropriately to the drug-induced damage (that is to undergo apoptosis). Although it is generally accepted that the majority of cancers arise from a single precursor cell, it is na¨ıve to think that a tumor is a collection of genetically identical cells. Genetic instability and the accumulation of mutations are important hallmarks of cancer cells. Thus, dividing cancer cells are able to acquire genetic and epigenetic changes that will favor their malignant phenotype as well as drug resistance (Richardson and Kaye 2005). In addition to acquired genetic and epigenetic changes, host factors such as microtumor environment, tumor vascularity, drug bioavailability, metabolism, elimination, and dose-dependent toxicity are some of the limitations that play a role in the final outcome of conventional chemotherapy. For example, the tumor vascularity may affect the transit time of drugs within tumors and the interaction of tumor cells with the surrounding interstitial cells (Green et al. 1999). Also, vascularity may dictate the extent to which high-molecular-weight monoclonal antibodies and immunotoxins are able to penetrate tumors (Pluen et al. 2001). The realization that most anticancer drugs kill tumor cells by activating apoptotic pathways raised an interesting notion that deregulation of apoptotic pathways may be a key determinant in the development of chemoresistance by tumor cells (Mashima and Tsuruo 2005). Indeed, numerous alterations that confer resistance to apoptosis have been associated with highly malignant phenotype. For example, advanced cancers often exhibit activation of prosurvival signal transduction pathways such as those mediated by Ras, PI3K/Akt, or NF-κB; inactivation of apoptotic pathways (e.g., due to mutation or silencing of p53, pRb, Bax, Bad, Apaf-1, or caspase-8 genes); or overexpression of prosurvival proteins such as Bcl2, IAP, and FLIP (Fesik 2005). Therefore, many recent approaches to improve cancer therapy have been based on combinations of cytotoxic agents with new molecularly targeted agents. The rationale for such combination cancer therapies
5 TG2 and Chemoresistance
97
is based on the assumption that agents affecting molecular signaling pathways involved in apoptosis or other cell death mechanisms (Chen et al. 2006), migration and invasion (Sierra 2005), angiogenesis (Broxterman and Georgopapadakou 2005, Morabito et al. 2006), tumor cell signal transduction (Bloom and Kloog 2005, Adjei 2006), and protein turnover (Richardson et al. 2003, Demarchi and Brancolini 2005, Nawrocki et al. 2005, Horton et al. 2006) will lead to synergistic tumor cell death. Experts in the field have summarized their views on various mechanisms that are known to confer drug resistance as well as approaches to overcome this problem elsewhere in this monograph. Though all of these approaches seem logical and promising, the understanding of cellular drug resistance behavior does not necessarily translate to understanding completely the resistance observed in tumors clinically, because tumors consist of a mixed population of cells that may not exhibit very high levels of drug resistance. Therefore, a considerable interest still exists to define novel resistance mechanisms as potential targets for novel compounds with greater effectiveness and for optimal drug combinations. This review will focus on recent information on the significance of increased TG2 expression in the development of drug resistance and the therapeutic potential of this protein to overcome chemoresistance in cancer cells.
TG2—The Protein with a Split Personality TG2 is a structurally and mechanistically complex protein with both intracellular and extracellular functions (Lorand and Graham 2003, Griffin et al. 2002, Mehta 2005). TG2 can catalyze protein cross-linking reactions during apoptosis, act as a G-protein in adrenoreceptor signaling, act as protein disulfide isomerase in maintaining the mitochondrial integrity, or be secreted outside the cell for stabilization of the extracellular matrix (ECM). TG2-mediated cross-linking of ECM plays a role in the deposition and stabilization of the ECM, which in turn promotes cell attachment and spreading (Verderio et al. 2005). TG2 can translocate to the cell membrane where it binds tightly to both the cell-surface integrins and fibronectin and consequently promotes cell attachment, migration, and invasion (Akimov et al. 2000, Akimov and Belkin 2001, Herman et al. 2006). Another enigmatic feature of TG2 is that it can function as both a proapoptotic (Rodolfo et al. 2004) and an antiapoptotic (Boehm et al. 2002, Milakovic et al. 2004, Yamaguchi and Wang 2006) (Fig. 5.1) protein. Under normal physiological conditions, TG2 is enzymatically inactive in the cytosolic compartment (where GTP’s concentration is approximately 100 μM [IC50 (GTP) = 9 μM]) (Lai et al. 1998), and the free calcium level is approximately 100 nM (Vmax [Ca2+ =2 mM]) (Datta et al. 2006). This cytosolic-inactive fraction of TG2 may fulfill another function by serving as a scaffold protein and associating with certain signaling proteins such as integrins, focal adhesion kinase (FAK), fibronectin, and PTEN (Fig. 5.2). Such protein interaction with TG2 can modulate the function and stability of the interacting protein. For example, the association of TG2 with FAK and IκBα proteins
98
K. Mehta and J.Y. Fok
Normal cell Stress chemical infection Radiation hypoxia
Nrf2(?)
ROS–
TG2 DNA Damage
Low Ca2+ High GTP
Ca2+
Tumor cell
ΔTG2
Repair Macrophages Lymphocytes Endothelial cells
Apoptosis
chemoresistance and metastasis
Integrins NF-κB FAK PTEN
Fig. 5.1 TG2 serves as a prosurvival and proapoptotic signaling protein in normal and cancerous cells. TG2 is an early response gene that is upregulated in response to inflammatory or other stresses. It is likely that transcription factors, such as Nrf-2 or NF-κB, that get activated in response to inflammatory and reactive oxygen species (ROS- ) are responsible for the upregulation of the TGM2 gene. Under normal circumstances, the low cytosolic calcium (nM) and high GTP concentrations do not permit the activation of TG2 to its protein cross-linking configuration. However, this catalytically inactive TG2 can perform other functions; the signaling pathways can be activated by associating with integrins and other such signaling molecules. The TG2-mediated activation of these pathways can confer resistance to apoptosis. When ROS- -inflicted cell damage has been repaired, the cells return to ground level, including shutting down of TGM2. Nevertheless, if the stress or cellular damage is too severe, the calcium probably can escape inside the cell due to leaky membranes, leading to the activation of TG2 and massive cross-linking of cellular proteins and apoptosis. In contrast, once the TG2 expression is turned on in tumor cells (probably in response to ROS- , hypoxia, chemotherapy, or radiation), there is no mechanism to turn it off. We have shown previously that in chemoresistant tumor cells, the activation of TG2, by increasing cytosolic calcium, is an extremely lethal event
has been implicated in constitutive activation of FAK/Akt and NF-κB, respectively (Mhaouty-Kodja 2004, Kim et al. 2006, Mann et al. 2006, Verma et al. 2006) and confers protection against stress-induced cell damage (ROS- , hormones, TNF, drugs) (Fig. 5.1). Under extreme stress or trauma conditions, Ca2+ homeostasis may be perturbed due to leaky membranes, resulting in the activation of cytosolic enzymes and cross-linking of intracellular proteins as observed during apoptosis (Fesus and Piacentini 2002) or necrosis (Nicholas et al. 2003). Interestingly, despite the wide range of functions in which TG2 participates, the TGM2 gene in mice showed no phenotype, and the mice were anatomically, developmentally, and reproductively normal (De Laurenzi and Melino 2001, Nanda et al. 2001).
5 TG2 and Chemoresistance
Integrins β1, β3, β5 (Akimov et al. 2001; Herman et al. 2006) Importin-α3 (Peng et al. 1999) HPV18E7 (Jeon et al. 2003)
99 Fibronectin (Akimov et al. 2000) Focal adhesion kinase (Verma et al. 2006) PTEN (Verma et al. 2008)
TG2
IkBα/p65 (Mann et al. 2006)
GRP56 Protein kinase A (Xu et al. 2006) (Lewis et al. 2005) C-Jun (Ahn et al. 2008) IGFBP-3 HIF-1β (Mishra et al. 2004) (Filiano et al. 2008)
Fig. 5.2 TG2 interacts with a large number of proteins and modulates their function and stability. The association of TG2 with various cellular proteins has been documented both biochemically and immunochemically. Such interaction with TG2, in general, has been shown to modulate the function, activity, or stability of the partner protein. For example, association of TG2 with IκBα could prevent its binding to NFκB, resulting in its constitutive activation. In contrast, association of TG2 with tumor-suppressor protein, PTEN, prevents its phosphorylation and promotes ubiquitination and proteasomal degradation. Association with cell surface integrins increases their stable interaction with the ECM proteins
TG2, Drug Resistance, and Metastasis Besides resistance to chemotherapy and radiation therapy, dissemination and metastasis of tumor cells in distant organs represent a significant clinical problem. Although studies of drug resistance and metastasis have generally proceeded along separate research pathways, there are several reasons to believe that the two phenotypes may have some common features. Evidence exits supporting the idea that expression of certain oncogenes or altered expression of suppressor genes can promote not only tumor cell growth and aggressiveness but also the relative expression of drug resistance (Fesik 2005). For example, advanced cancers, which might be expected to harbor a number of genetic alterations such as overexpression of bcl-2 and inactivation of p53, should also express an “apoptosis-resistant” phenotype. Not only would this property endow the tumor cells with an increased ability to grow and survive in foreign tissue sites but it would also allow the cells to express a drugresistant phenotype. Indeed, tumor cells selected for resistance to drugs in vitro are more malignant in vivo. Conversely, metastatic tumors generally exhibit higher resistance to drug and radiation therapies than their primary counterparts. In view of this information, it is tempting to speculate that overexpression of TG2 represents one such link between drug-resistant and metastatic tumor cells. Thus, a number of cancer cell lines, including breast carcinoma, malignant melanoma, pancreatic ductal adenocarcinoma, glioma, lung adenocarcinoma, ovarian carcinoma, prostate carcinoma, and colorectal carcinoma—when selected for resistance to drugs—expressed elevated levels of TG2 (Verma and Mehta 2007a, Mehta in
100
K. Mehta and J.Y. Fok
press). Similarly, metastatic tumors from patients with breast cancer (Mehta et al. 2004), malignant melanoma (Mehta et al. 2006, Fok et al. 2006), and ovarian carcinoma (Hwang et al. 2008) showed a more significant increase in TG2 than their primary counterparts. Importantly, downregulation or inhibition of TG2 in various cancer cell types is associated with their increased sensitivity to chemotherapeuticinduced cell death and inhibition of invasion (Herman et al. 2006, Kim et al. 2006, Hwang et al. 2008, Yuan et al. in press). In line with these observations, Satpathy et al. (2007) observed that increased expression of TG2 in ovarian cancer cells enhanced their adhesion to fibronectin and promoted directional cell migration. Accordingly, ovarian cancer cells with knockdown TG2 showed diminished tumor dissemination on the peritoneal surface and in mesentery in an intraperitoneal ovarian xenograft mouse model. Furthermore, in patients with ovarian cancer, overexpression of TG2 in tumor samples was associated with significantly worse overall patient survival in both univariate and multivariate analyses (Hwang et al. 2008). Similarly, overexpression of TG2 in pancreatic tumor samples was strongly associated with nodal metastasis and lymphovascular invasion (Verma et al. 2006). These results imply that expression of TG2 in cancer cells is aberrant and involved in promoting drug resistance and metastatic phenotype. It is generally believed that mechanisms responsible for promoting growth, survival, and invasion of cancer cells also operate in normal cells. The major difference is that in normal cells, these pathways are under tight control; once the stimulus or event that triggered these pathways dies down, cells revert to a quiescent state. In contrast, as a result of genetic or epigenetic changes, cancer cells generally become independent of the need for such stimuli to activate their growth and survival (Hanahan and Weinberg 2000). In this context, the significance of increased TG2 expression in normal cells is worth mentioning. Several years ago, we observed that macrophages collected from inflammatory sites accumulated large amounts of TG2 protein (Khera and Mehta 1989). In view of our current understanding on TG2 overexpression in highly malignant cancer cells, induction of TG2 in inflammatory macrophages may be related to their ability to migrate to the site of inflammation and the protection from cytotoxic mediators that they produce in response to infectious agents. Indeed, many recent reports have documented a direct role for TG2 in promoting migratory functions of normal cells. Expression of TG2 in T lymphocytes has been shown to play a role in their transmigration across the endothelial cells (Mohan et al. 2003). TGF β-induced expression of TG2 in retinal pigment epithelial cells has been linked to their increased migration on fibronectin-coated matrices (Priglinger et al. 2004). Retinoic acid-induced TG2 expression in neuroblastoma SH-SY5 cells augments their migration and invasion functions (Joshi et al. 2006). Similarly, ectopic expression of TG2 in mesenchymal stem cells (MSCs) promotes their adhesion on fibronectin and significantly increases phosphorylation of focal adhesion-related kinases FAK, Src, and PI3K (Song et al. 2007). Moreover, TG2-transfected MSCs can effectively restore the cardiac functions of infarcted myocardium (Song et al. 2007). In an attempt to identify metastasis-associated proteins by proteomic analysis, Jiang et al. (2003) observed that TG2 was 1 of the 11 proteins that were selectively
5 TG2 and Chemoresistance
101
amplified in metastatic human lung carcinoma. Similarly, comprehensive analysis of more than 30,000 genes by three different techniques revealed that TG2 was one of the most differentially expressed genes in pancreatic tumors (IacobuzioDonahue et al. 2003). Treatment of cancer cells with epidermal growth factor (EGF) induced the expression of TG2 and protected cells from doxorubicin-induced apoptosis (Antonyak et al. 2004). These observations imply that expression of TG2 promotes cell resistance to chemotherapeutic drugs and invasion. On the other hand, there have also been reports suggesting that in certain types of cancer, downregulation of TG2 expression is related to the onset of chemoresistance and to an altered ability of tumor cells to metastasize (Birckbichler et al. 2000, Jones et al. 2006). Given the known functions of TG2, reduced levels or activity of TG2 can confer resistance to apoptosis and less stable ECM, resulting in attenuated cell adhesion and increased migration, which facilitates the initial step in metastasis. Xu and Hyne (2007) recently identified GPR56 as a protein downregulated in metastatic melanoma cells and showed that TG2 was a binding partner for GPR56, suggesting that TG2 can act as a tumor-suppressor protein through its interaction with GPR56. These conflicting results of TG2 expression in cancer cells suggest that the relevance of TG2 to cancer biology may depend on the type, location, and possibly the stage of cancer. Therefore, a precise understanding of TG2 functions in the context of cancer stage and type is important for the implementation of TG2-based interventions to disrupt malignant invasion, growth, and survival.
TG2-Mediated Cell Signaling Integrins are one important class of molecules; TG2 can bind to them and modulate their activity (Fig. 5.2). Integrins are a family of cell-surface proteins that serve as receptors for the ECM proteins (fibronectin, vitronectin, laminin, collagen), and they influence several aspects of cancer cell behavior, including motility, invasion, growth, and survival in response to binding to the ECM ligands. In general, integrins are low-affinity receptors (106 –109 L/mol) and bind to their ligands only when they exceed certain critical numbers in the form of focal contacts or hemidesmosomes. In response to certain stimuli (growth factors, cytokines), integrins cluster together, and their combined weak affinities give rise to a spot on the cell surface (focal contact) that now has enough avidity to support stable interaction of cells with the ECM. Thus, under normal circumstances, the interaction of integrins with their ECM ligands is tightly regulated to ensure controlled growth, survival, and migration of cells. Interestingly, certain cellular proteins can selectively bind to integrins and promote their affinity for ECM. The first such interaction was identified between β3 integrin and integrin-associated protein (IAP), also referred to as CD47 (Brown and Frazier 2001). The signaling cues transmitted by a specific integrin inside the cells can be modulated as a result of such an interaction between the integrin and the protein. For example, the cytoplasmic protein, nischarin, was recently shown to promote the cell motility of fibroblasts as a result of its interaction with the
102
K. Mehta and J.Y. Fok
cytoplasmic domain of integrin α5β1 (Alahari et al. 2000). In view of these observations, the finding that TG2 can associate in a complex with β1 integrin (Akimov and Belkin 2001, Fok et al. 2006, Herman et al. 2006, Mangala et al. 2007) may have important implications in terms of TG2-mediated cell signaling to promote proliferation, survival, and migratory functions in cancer cells. Depending on the cell type, 20% to 30% of β integrin on the cell surface can exist in a complex with TG2 (Akimov and Belkin 2001). The association of TG2 with integrins is known to occur primarily at extracellular domains of integrins and promotes their interaction with the ECM ligands, such as fibronectin, collagen, and vitronectin (Akimov and Belkin 2001). Importantly, the interaction between TG2 and integrin is independent of the cross-linking activity of TG2 and results in increased cell adhesion, migration, and activation of the downstream survival signaling pathways (Akimov and Belkin 2001, Herman et al. 2006). More recently, syndecan-4 (S4) has been shown to interact with TG2-bound integrins, raising the possibility that TG2 contributes to cell adhesion via binding to S4. Indeed, S4-null fibroblasts showed a lower level of FAK (Y397) during the initial phase of cell adhesion to fibronectin than wild-type cells did. A similar defect was observed in early FAK (pY397) activation in TG2null mouse embryonic fibroblasts when compared with the wild-type fibroblasts; the early FAK activation was accompanied by hyperactivation of RhoA and decreased cell migration (Verderio et al. in press). TG2 is also known to regulate FAK activity. FAK is a 125-kDa nonreceptor protein tyrosine kinase that plays a significant role in cell survival, migration, and invasion (Sieg et al. 2000, Hsia et al. 2003). FAK-induced signaling pathways are initiated at sites of integrin-mediated cell adhesions—the so-called focal adhesions—and carry out protein–protein interaction adaptor functions at sites of cell attachment to the ECM. FAK is activated by integrin clustering and transmits adhesion and growth factor-dependent signals into the cell interior to promote cell growth, cell survival, and invasive functions (Schlaepfer et al. 1999, McLean et al. 2005). Overexpression and increased activity of FAK has been observed frequently during the advanced stages of a wide variety of human cancers. For example, increased levels of FAK were reported in 17 of 20 invasive tumors and in all 15 metastatic tumors of different origins but were reported in none of the six normal tissue samples (Owens et al. 1995). Given the important role of FAK in many processes involved in tumorigenesis and metastasis, FAK can be a potential target in the development of anticancer drugs. FAK itself can be regulated by a range of mechanisms, including tyrosine phosphorylation, serine or threonine phosphorylation, and protein–protein interactions. For example, association of TG2 with β1 integrin has been shown to promote the activation of FAK in response to fibronectin binding (Akimov and Belkin 2001, Herman et al. 2006). Our recent results suggested a direct role of TG2 in the activation of FAK and the activation of its downstream PI3K/Akt pathway in cancer cells (Verma et al. 2006). This activation of FAK is mediated by direct interaction between TG2 and FAK. Although the precise mechanism by which TG2 affects autophosphorylation of FAK is not yet understood, the observation that TG2 physically associates with FAK suggests that such interaction may induce a conformational change in FAK protein and lead to its autophosphorylation.
5 TG2 and Chemoresistance
103
Once phosphorylated, FAK can recruit Src kinase that phosphorylates other tyrosine sites on FAK (Y407 , Y576 , Y577 , Y861 , and Y925 ), leading to the recruitment and activation of several downstream signaling proteins such as RAS/ERK, PI3K/Akt, and Crk/Dock180/Rac, which can impact the growth, survival, and invasion of cancer cells (McLean et al. 2005). Adding further complexity to the role of TG2 in PI3K/Akt pathway regulation, we recently observed a novel function of TG2 in regulating PTEN expression. TG2 inversely regulates the expression of PTEN (Verma et al. 2008a). PTEN is known for its tumor-suppressive functions such as inhibition of cell growth, invasion, migration, and focal adhesions (Tamura et al. 1998), primarily by dephosphorylation and inactivation of signaling proteins Akt and FAK. Gene deletion and mutation of PTEN are observed frequently in various human cancers. These genetic changes, however, are not necessarily the only way to inactivate PTEN during tumorigenesis; some subtle changes induced by posttranslational modifications can also affect the stability and degradation of PTEN, which can profoundly affect tumorigenesis. Indeed, a recent report demonstrated that the oncogenic protein NEDD4-1 acts like E3 ubiquitin ligase for PTEN and promotes its degradation via ubiquitin-proteasomal pathway (Wang et al. 2007). Very little is known about the regulation and stability of PTEN, except that phosphorylation can affect its stability in certain cell types (Vazquez et al. 2001, Okahara et al. 2004). Published evidence suggests that phosphorylation of PTEN by casein kinase 2 (CK2) is important for the stability of PTEN protein in the face of proteasome-mediated degradation. In a separate study, phosphorylation of the PTEN tail was shown to negatively regulate PTEN stability (Vazquez et al. 2001). Phosphorylation of PTEN by CK2 prevents its interaction with MAGI-2 and its consequent recruitment into a high-molecularweight complex (PTEN-associated complex). In line with these reports, our results revealed that TG2 expression could affect the stability of PTEN protein by preventing its phosphorylation at ser380 (Torres and Pulido 2001, Vazquez et al. 2001) and promoting ubiquitination-mediated proteasomal degradation. Thus, TG2 can promote the activation of the FAK/PI3K/Akt pathway in two complementary ways: one by direct phosphorylation of FAK and second by inhibiting the phosphatase activity of PTEN, resulting in constitutively activating the PI3K/Akt pathway (Fig. 5.3).
TG2-Mediated NF-κB Activation The transcription factor NF-κB plays an important role in regulating genes that are involved in controlling cell growth, apoptosis, and metastatic functions (Baeuerle and Baltimore 1996, Bours et al. 2000, Karin et al. 2002). Constitutive activation of NF-κB has been observed in various cancers, and NF-κB’s role has been implicated in drug resistance and metastasis (Bours et al. 1994, Bargou et al. 1997, Mori et al. 1999, Pahl 1999, Mukhopadhyay et al. 2001). TG2 expression contributes to constitutive activation of NF-κB in a classical IKK-independent manner (Verma and Mehta 2007a). The expression of TG2 in various cancer cell types is associated
104
K. Mehta and J.Y. Fok Fn TG2
INTEGRIN
β α
FAK
siRNA inhibitors
Src
pY397
FAK
PI3K
TG2 inhibition
Ser473
autophagy apoptosis
Thr308
PDK1/2
AKT
PIP3
PIP2
PTEN Drug sensitivity
MDM2
κ NFκB
FKHR
TG2
BAD ΙκΒα
Cell Survival
NFκB
NFκB
Drug resistance Fig. 5.3 TG2-mediated signaling promotes cell survival and invasion. Association of TG2 with integrins (e.g., β1, β3, β4, β5) can increase their avidity for extracellular matrix proteins, such as fibronectin (FN), and result in the activation of downstream cell survival FAK/PI3K/Akt signaling pathways. TG2 can also affect FAK phosphorylation directly by associating with FAK or indirectly by promoting PTEN degradation via the ubiquitin-proteasomal pathway. Either collectively or individually, activation of these signaling molecules in the PI3K/Akt axis leads to the phosphorylation of various downstream substrates, activation of MDM2 and NF-κB, and the inhibition of FKHR and BAD proteins, resulting in increased cell survival and chemoresistance. On the other hand, TG2—by cross-linking IκBα (inhibitor of kappa B alpha)—can induce dissociation of the NF-κB/IκBα complex, resulting in constitutive activation NF-κB in a nonclassical IKK-independent manner
with constitutive activation of NF-κB. Cancer cells with high basal levels of TG2 or forced expression of TG2 in low TG2-expressing cancer cells are associated with high NF-κB activity. The NF-κB activation in these cells has been significantly inhibited by TG2 enzyme inhibitors but not by dominant-negative IκBα (Mann et al. 2006). Conversely, a knockdown of endogenous TG2 expression by siRNA resulted in strong inhibition of NF-κB. Interestingly, in situ activation of the TG2 transamidating activity by calcium ionophore A23187 treatment caused strong activation of NF-κB, while inhibition of the activity by enzyme-specific inhibitors such as 5-(biotinamido) pentylamine (BPA) and monodansylcadaverine (MDC) attenuated NF-κB activation. Thus, TG2 expression and its cross-linking function are critical for NF-κB activation. Indeed, IkBα has been shown to be a good substrate for TG2-catalyzed cross-linking reaction (Lee et al. 2004). Thus, in vitro incubation of IkBα protein with purified TG2 and calcium could effectively catalyze the crosslinking of IkBα into high-molecular-weight polymers. Importantly, the polymeric
5 TG2 and Chemoresistance
105
form of IκBα had much lower binding affinity for the p65:p50 complex, suggesting that TG2-mediated posttranslational modification of IkBα may hamper its ability to associate with the p65:p50 complex and consequently result in constitutive activation of NF-κB. In a recent report, Kim et al. (2006) observed that inhibition of TG2 activity attenuated NF-κB activation and reversed the sensitivity of drug-resistant breast cancer cells to doxorubicin. Based on these observations, these authors concluded that TG2 expression and its cross-linking function are critical for NF-κB activation and for conferring drug resistance phenotype to cancer cells. We observed a similar reversal in drug resistance of MCF-7/DOX cells in response to downregulation of endogenous TG2 by siRNA (Herman et al. 2006). Alternatively, TG2 can directly associate with the p65:p50 complex in the cytoplasm and with p65 in the nucleus. The significance of this association is still not clear. We speculate that such an association could mitigate the binding of IκBα to the NF-κB complex in the cytoplasm, leading to its constitutive activation. Under certain conditions, TG2 can also serve as a kinase, and its serine–threonine kinase activity can phosphorylate histones and p53 (Mishra et al. 2006). Because p65 undergoes phosphorylation by various kinases at the Ser536 site (Bohuslav et al. 2004, Douillette et al. 2006), it is likely that p65 serves as a substrate for TG2 kinase activity. In addition, since TG2 is a bulky protein (80 kDa), it could cause stearic hindrance or conformational changes when complexed with p65 and permit preferential binding of the NF-κB (p50:p65) complex only to high-affinity or selective promoters resulting in differential transcriptional regulation and expression of target proteins that are involved in drug resistance and metastasis. All these possibilities warrant further investigation to harness NF-κB as a target for cancer therapy.
TG2 Promotes Cell Survival and Chemoresistance While delivery of a drug to its target is critical to its therapeutic effect, the ability of a drug to successfully induce cancer cell death generally requires transduction of intrinsic signaling pathways to initiate the cellular program that causes the cancer cell to die. Therefore, novel therapeutic strategies that promote apoptosis and block pathways or proteins that inhibit apoptosis could significantly enhance cancer sensitivity to conventional therapies. In this regard, TG2 overexpression could offer a promising therapeutic target for enhancing the sensitivity of cancer cells to drugs. As discussed above, overexpresssion of TG2 in various cancer cell types is associated with constitutive activation of antiapoptotic signaling pathways (FAK, NF-κB, PI3K, etc). Indeed, Ai et al. (2008) recently concluded that epigenetic silencing of the TGM2 gene in breast cancer cells could serve as a marker for chemotherapeutic drug sensitivity. Moreover, downregulation of TG2 by siRNA, antisense, or ribozyme results in the reversal of chemoresistance, while ectopic expression conferred resistance to drugs in breast, melanoma, glioblastoma, and ovarian cancer cells (Herman et al. 2006, Kim et al. 2006, Verma and Mehta 2007a, Hwang et al. 2008, Yuan et al. in press).
106
K. Mehta and J.Y. Fok
In addition to apoptosis, TG2 expression can protect cancer cells from another type of cell death called autophagy. Autophagy is type II programmed cell death that plays a crucial role in various physiologic processes such as development, cell homeostasis, elimination of unwanted cells, and carcinogenesis. Cancer cells exhibit defective autophagic cell death compared with their normal counterparts (Edinger and Thompson 2003), which may contribute to chemoresistance. Autophagic cell death is caspase independent and is characterized by autophagosome formation that surrounds various cellular organelles such as Golgi complexes, polyribosomes, and endoplasmic reticulum (Kondo et al. 2005). Subsequently, autophagosomes merge with lysosomes and digest the organelles, leading to cell death (Kroemer and Jaattela 2005). A recent observation made by our research group showed that inhibition of TG2 expression by siRNA resulted in induction of autophagy in pancreatic cancer cells and eventual cell death (Akar et al. 2007). Notably, inhibition of PKCδ activity by rottlerin or its downregulation by PKCδ siRNA was associated with a parallel decrease in TG2 expression and induction of autophagy in pancreatic cancer cells. These observations suggest that PKCδ is an upstream regulator of TG2 expression, and therefore targeting PKCδ, TG2, or both may represent an effective approach to treat patients with pancreatic cancer.
Therapeutic Significance of TG2 Based on the information discussed in the preceding sections, we speculated that inhibition of TG2 could be a promising therapeutic target for reversing chemoresistance in cancer cells. Initially, we determined the significance of TG2 expression on growth and survival of pancreatic ductal adenocarcinoma (PDAC) in vivo by downregulating TG2 expression. TG2 knockdown PDAC cells were tested for their ability to grow in xenografts in a nude mouse model (Verma et al. 2008a). The MDAPanc28 subclone (Panc28/cl.10), which expressed 70% to 80% lower TG2 than the vector alone or parental MDA-Panc28 cells, was selected for stable transfection with TG2-shRNA. Xenografts were grown subcutaneously in athymic nude mice using MDA-Panc28/cl.10 or Panc-28/empty vector (control) cells. Panc28/cl.10 xenografts showed significantly more retarded growth than Panc28/empty vector controls (Verma et al. 2008a). The tumor growth was followed for 5 weeks, and mice were killed during the sixth week. The Panc28/cl.10 cells consistently produced xenografts with 60% to 80% lower tumor volumes than the empty vectorPanc28 xenografts (P = 0.017). The tumors were analyzed for TG2 expression to ascertain that TG2 expression remained suppressed in vivo in Panc28/cl.10 tumors. Indeed, TG2 expression in Panc28/cl.10 xenografts was significantly lower than in control tumors. Next we determined the therapeutic potential of elevated TG2 expression for treatment of orthotopically grown pancreatic and ovarian tumors. Using small (≤100 nm) neutrally charged liposomes (dioleoyl-phosphatidylcholine, DOPC) as the delivery system, we found that TG2 siRNA could effectively downregulate TG2
5 TG2 and Chemoresistance
107
expression in orthotopically growing tumors. Thus, inhibition of TG2 by siRNADOPC retarded growth and rendered PDAC tumors sensitive to gemcitabine. Importantly, the number of metastatic foci that was recovered from mice treated with DOPC-TG2 siRNA alone or in combination with gemcitabine was more dramatically reduced (>80%) than was that for mice treated with DOPC control siRNA or gemcitabine alone (Verma et al. 2008b). Similarly, treatment of mice with TG2 siRNA-DOPC alone or in combination with docetaxel demonstrated significant antitumor activity against orthotopically growing chemotherapy-sensitive (HeyA8) and resistant (HeyA8-MDR) ovarian tumors (Hwang et al. 2008). To determine potential mechanisms underlying the antitumor effect of TG2 siRNA-DOPC, we examined its effect on several biological endpoints, including cell proliferation (Ki-67), angiogenesis (CD31), and apoptosis (TUNEL). More than 90% reduction in Ki-67 expression was evident (P < 0.001) in tumors obtained from mice given TG2 siRNA-DOPC alone or in combination with chemotherapy. Tumors obtained from mice treated with chemotherapy alone or with control siRNA-DOPC consistently showed high levels of Ki-67 staining. We also evaluated the blood vessel density in tumors obtained from mice treated with control siRNA, chemotherapy alone, TG2 siRNA, or a combination of chemotherapy plus TG2 siRNA. The results obtained revealed a significant decrease in the mean blood vessel density in tumors recovered from mice that received TG2 siRNA-DOPC or chemotherapy alone (Verma et al. 2008b, Hwang et al. 2008). Densitometric analysis showed a significant difference in the mean microvascular density (P < 0.0013) in the mice that received TG2 siRNA-DOPC plus chemotherapy. Finally, we evaluated apoptosis in orthotopic tumors using TUNEL staining. In ovarian tumors, minimal cell apoptosis was apparent in empty liposome, control siRNA-DOPC, or control siRNA-DOPC with docetaxel treatment groups. However, treatment with TG2 siRNA-DOPC alone and TG2 siRNA-DOPC plus docetaxel resulted in a significant increase in apoptosis (P = 0.027 and P = 0.001, respectively). Interestingly, the increase in apoptosis in the TG2 siRNA-DOPC plus docetaxel group was greater than in the TG2 siRNADOPC alone group (P = 0.004). In summary, targeted therapy with TG2 siRNA in combination with chemotherapy significantly reduces tumor growth and metastasis in chemotherapy-sensitive and chemotherapy-resistant models. Given the clinical relationship between TG2 expression and poor prognosis of patients with cancer, our findings raise the possibility that TG2 silencing combined with chemotherapy could be a promising therapeutic option for treatment of these lethal cancers. In this regard, the use of siRNA to silence TG2 expression holds great promise for the development of therapeutics directed against drug-resistant and metastatic cancer cells. The use of siRNA as a method of gene silencing has rapidly become a powerful tool for determining protein function and gene discovery (Stenvang and Kauppinen 2008). The sequence specificity of siRNA makes it an attractive tool for cancer therapy. Moreover, siRNA-based therapeutics have the potential to inhibit molecular targets that are not treatable with conventional small molecules, antibodies, or other biological agents. However, a major challenge in using siRNA-based drugs in humans is the effective delivery to the target tissue. Naked siRNA is unstable in plasma. Chemically modified siRNA are thought to be relatively stable when
108
K. Mehta and J.Y. Fok
administered systemically in mice but they must be administered in large doses (30–50 mg/kg). Such large doses of siRNA may not be practical for therapeutic applications in humans because of the costs and safety issues (Morrissey et al. 2005). However, encapsulation of siRNA in lipid-based nanoparticles of ≤100 nm in diameter provide effective dosing in mice and monkeys at far lower amounts (0.2– 2 mg/kg). For example, the use of DOPC nanoliposomes for delivering TG2 siRNA to orthotopically growing pancreatic (Verma et al. 2008b) and ovarian (Hwang et al. 2008) tumors in mice was effective in silencing the target gene and inhibiting tumor growth. Similarly, two recent reports further documented the effective delivery of siRNA for silencing the oncoprotein EphA2 (Landen et al. 2005) and FAK (Halder et al. 2006) using DOPC nanoliposomes. More recently, Gray et al. (2008) reported that DOPC nanolipsomes were effective in delivering the siRNA to silence neurophilin proteins, which then inhibits metastasis of colorectal cancer in mice. The same group observed that this delivery system was equally effective in silencing the expression of interleukin-8 in orthotopically growing ovarian tumors (Merritt et al. 2008). From these studies, it is apparent that the effectiveness of DOPC liposomes for delivering TG2 siRNA can be rapidly translated into the clinical setting for treatment of chemoresistant cancers.
Conclusions The observations of elevated TG2 expression in drug-resistant cancer cells have raised great interest in terms of understanding its contributions to the development of drug resistance. TG2 expression results in a constitutive activation of FAK/PI3K/AKT and NF-κB cell-survival signaling pathways as outlined in Fig. 5.3. Either collectively or individually, these pathways confer resistance to chemotherapeutic drugs by preventing apoptotic or autophagic death. Increased threshold of cancer cells to undergo apoptosis enables them not only to display resistance against many anticancer drugs but also to proliferate and survive successfully in stressful environments of foreign tissues (metastasis). Therefore, TG2 may represent an attractive target to investigate for overcoming drug resistance in cancer cells.
References Adjei, A. A. 2006. Novel combinations based on epidermal growth factor receptor inhibition, Clin. Cancer Res. 12:4446–4450. Ahn, J.-S., Kim, M.-K., Hahn, H.-H., Park, J.-H., Park, K.-H., Cho, B.-R., Park, S. B., Kim, D.-J. 2008. Tissue transglutaminase-induced down regulation of matrix metalloprotease-9. Biochem. Biophys. Res Commun. 376:743–747. Akar, U., Ozpolat, B., Mehta, K., Fok, J. Y., Kondo Y., and Berestein, G. L. 2007. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol. Cancer Res. 5:241–249. Akimov, S. S., Krylov, D., Fleischman, L. F., and Belkin, A. M. 2000. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell. Biol. 148:825–838. Akimov, S. S., and Belkin, A. M. 2001. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98:1567–1576.
5 TG2 and Chemoresistance
109
Alahari, S. K., Lee, J. W., and Julaino, R. L. 2000. Nischarin, a novel protein that interacts with the integrin a5 subunit and inhibits cell migration. J. Cell Biol. 151:1141–1154. Ai, L., Kim, W. J., Demircan, B., Dyer, L. M., Bray, K. J., Skehan, R. R., Massoll, N. A., and Brown, K. D. 2008. The transglutaminase 2 gene, a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29: 510–518. Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., Balkman, C. E., Wakshlag, J. J., Page, R. L., Cerione, R. A. 2004. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 40:41461–41467. Baeuerle, P. A., and Baltimore, D. 1996. NF-kB: ten years after. Cell 87:13–20. Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dorken, B. 1997. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J. Clin. Invest. 100:2961–2969. Birckbichler, P. J., Bonner, R. B., Hurst, R. E., Bane, B. L., Pitha, J. V., and Hemstreet, G. P. III. 2000. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer. 89:412–423. Bloom, R. and Kloog, Y. 2005. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist. Updates 8: 369–380. Boehm, J. E., Singh, U., Combs, C., Antonyak, M. A., and Cerione, R. A. 2002. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J. Biol. Chem. 277:20127–20130. Bohuslav, J., Chen, L. F., Kwon, H., Mu, Y., and Greene, W. C. 2004. p53 induces NF-kB activation by an IkB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase. J. Biol. Chem. 279:26115–26125. Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M. P., and Castronovo, V. 1994. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa Brelated proteins in tumor cell lines. Biochem. Pharmacol. 47:145–149. Bours, V., Bonizzi, G., Bentires-Alj, M., Bureau, F., Piette, J., Lekeux, P., and Merville. M. 2000. NF-kB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology 153:27–38. Brown, E. J., Frazier, W. A. 2001. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11:130–135. Broxterman H. J., and Georgopapadakou, N. H. 2005. Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist. Updat. 8:183–197. Chen, J., Nikolovska-Coleska, Z., Wang, G., Qiu, S., and Wang, S. 2006. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg. Med. Chem. Lett. 16:5805–5808. Datta, S., Antonyak, M. A., and Cerione, R. A. 2006. Importance of Ca(2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry 45:13163–13174 De Laurenzi, V., and Melino, G. 2001. Gene disruption of tissue transglutaminase. Mol. Cell. Biol. 21:148–155. Demarchi, F., and Brancolini, C. 2005. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist. Updat. 8:359–368. Douillette, A., Bibeau-Poirier, A., Gravel, S. P., Clement, J. F., Chenard, V., Moreau, P., and Servant M. J. 2006. The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkB kinase complex. J. Biol. Chem. 281:13275–13284. Edinger, A. L., and Thompson, C. B. 2003. Defective autophagy leads to cancer. Cancer Cell 4:422–424. Fesik, S. W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5:876–885.
110
K. Mehta and J.Y. Fok
Fesus, L., and Piacentini, M. 2002. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem. Sci. 27:534–539. Filiano, A. J., Bailey, C. D., Tucholski, J., Gundemir, S., and Johnson, G. V. 2008. Transglutaminase 2 protects against ischemic insult, interacts with HIF1{beta}, and attenuates HIF1 signaling. FASEB J. 22:2662–2675. Fok, J., Ekmekcioglu, S., and Mehta, K. 2006. Tissue transglutaminase expression in melanomas: a potential target for intervention. Mol. Cancer Therapeut. 5:1493–1503. Gottesman, M. M., Fojo, T., and Bates, S. E. 2002. Multidrug resistance in cancer: role of ATPdependent transporters. Nat. Rev. Cancer 2:48–58. Gray, M. J., Buren, G. V., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., Mangala, L.S., Arumugam, T., Logsdon, C. D., Lopez-Berestein. G., Sood, A. K., and Ellis, L. M. 2008. Therapeutic targeting of Neurophilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl. Cancer Inst. 100:109–120. Green, S. K., Frankel, A., and Kerbel, R. S. 1999. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des. 14:153–168. Griffin, M., Casadio, R., and Bergamini, C. M. 2002. Transglutaminases: nature’s biological glues. Biochem. J. 368:377–396. Halder, J., Kamat, A. A., Landen, C. N., Jr., Han, L.Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., Gershenson, D. M., Schmandt, R., Cole, S. W., Lopez-Berestein, G., and Sood, A. K. 2006. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12:4916–4924. Hanahan, D., Weinberg, R. A. 2000. The hallmarks of cancer. Cell 100:57–70. Herman, J. F., Mangala, L. S., and Mehta, K. 2006. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25: 3049–3058. Horton, T. M., Gannavarapu, A. S., Blaney, S. M., D’Argenio, D. Z., Plon, S. E., and Berg, S. L. 2006. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 58:13–23 Hsia, D. A., Mitra, S. K., Hauck, C. R., Streblow, D. N., Nelson, J. A., Llic, D., Huang, S., Li, E., Nemerow, G. R., Leng, J., Spencer, K. S., Cheresh, D. A., and Schlaepfer, D. D. 2003. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160:753–767. Hwang, J. Y., Mangala, L. S., Fok, J. Y., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Nick, A. M., Fiterman, D. J., Vivas-Mejia, P. E., Deavers, M. T., Coleman, R. L., Lopez-Berestein, G., Mehta, K., and Sood, A. K. 2008. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 68:5849–5858. Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V., Shen-Ong, G. L., Berg, K., Hollingsworth, M. A., Cameron, J. L., Yeo, C. J., Kern, S. E., Goggins, M., and Hruban, R. H. 2003. Highly expressed genes in pancreatic ductal adenocarcinoma: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63:8614–8622. Jeon, J. H., Choi, K. H., Cho, S. Y., Kim, C. W., Shin, D. M., Kwon, J. C., Song, K. Y., Park, S. C., and Kim, I. G. 2003.Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J. 22:5273–82. Jiang, D., Ying, W., Lu, Y., Wan, J., Zhai, Y., Liu, W., Zhu, Y., Qiu, Z., Qian, X., and He, F. 2003. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 3:724–737. Jones, R. A., Kotsakis, P., Johnson, T. S., Chau, D. Y., Ali, S., Melino, G., and Griffin, M . 2006. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ. 13:1442–1453. Joshi, S., Guleria, R., Pan, J., DiPette, D., and Singh, U. S. 2006. Retinoic acid receptors and tissue transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25:240–247.
5 TG2 and Chemoresistance
111
Karin, M., Cao, Y., Greten, F., and Li, Z. 2002. NF-kB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2:301–310. Khera, V., and Mehta, K. 1989. Tissue transglutaminase and immunologic functions of BCGelicited mouse peritoneal macrophages isolated by centrifugal elutriation. J. Leukoc. Biol. 45:434–443. Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H., and Kim, S. Y. 2006. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappa B inactivation. Cancer Res. 66:10936–10943. Kondo, Y., Kanzawa, T., Sawaya, R., and Kondo, S. 2005. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5:726–734. Kroemer, G., and Jaattela, M. 2005. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5:886–897. Lai, T. S., Slaughter, T. F., Peoples, K. A., Hettqasch, J. M., and Greenberg, C. S. 1998. Regulation of human tissue transglutaminase function by magnesium nucleotide complexes. J. Biol. Chem. 273:1776–1781 Landen, C. N., Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein. G., and Sood, A. K. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910–6918. Lee, J., Kim, Y. S., Choi, D. H., Bang, M. S., Han, T. R., Joh, T. H., and Kim, S. Y. 2004. Transglutaminase 2 induces nuclear factor-kB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 279:53725–53735. Lewis, T. E., Milam, T. D., Klingler, D.W., Rao, P. S., Jaggi, M., Smith, D. J., Hemstreet, G. P., and Balaji, K. C. 2005. Tissue transglutaminase interacts with proteins kinase A anchor protein 13 in prostate cancer. Urol. Oncol. 23:407–412. Lorand, L., and Graham, R. M. 2003. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell. Biol. 4:140–156. Mashima, T., and Tsuruo, T. 2005. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist. Updat 8:339–343. Mangala, L. S., Fok. J. Y., Zorrilla-Calancha, I. R., Verma, A., and Mehta, K. 2007. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459–2470. Mann, A. P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J. Y., Kunnumakkara, A. B., Kumar, R., Aggarwal, B. B., and Mehta, K., 2006. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-{kappa}B in cancer cells: delineation of a novel pathway. Cancer Res. 66:8788–8795. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., and Frame, M. C. 2005. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat. Rev. Cancer 5:505–515. Mehta, K., Fok, J., Miller, F. R., Koul, D., and Sahin, A. A. 2004. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin. Cancer Res. 10: 8068–8076. Mehta, K. 2005. Mammalian TGase: A family portrait. Prog. Exp. Tumor Res. 38:1–18. Mehta, K., Fok, J. Y., and Mangala, L. S. 2006. Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci. 11:173–185. Mehta, K. 2008. Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer. Amino Acids In press. DOI-10-1007/s00726-008-0128-4 Merritt, W. M., Lin, Y., G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., Villares, G., Sanguino, A., Lutgendorf, S. K., Lopez-Berestein, G., Bar-Eli, M. M., and Sood, A. K. 2008. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100:359–372. Mhaouty-Kodja, S. 2004. Ghalpha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 96:363–367.
112
K. Mehta and J.Y. Fok
Milakovic, T., Tucholski, J., McCoy, E., and Johnson, G. V. 2004. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J. Biol. Chem. 279:8715–8722. Mishra, S., Saleh, A., Espino, P. S., Davie, J. R., and Murphy, L. J. 2006. Phosphorylation of histones by tissue transglutaminase. J. Biol. Chem. 281:5532–5538. Mohan, K., Pinto, D., and Issekutz, T. B. 2003. Identification of tissue transglutaminase as a novel molecules involved in human CD8+ T cell transendothelial migration. J. Immunol. 171:3179– 3186. Morabito, A., De Maio, E., Di Maio, M., Normanno, N., and Perrone, F. 2006. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753–764. Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D. W., and Yamamoto, N. 1999. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 93:2360– 2368. Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C. S., Jeffs, L. B., Judge, A., MacLachlan, I., and Polisky, B. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23: 1002–1007. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., and Aggarwal, B. B. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:7597–7609. Nanda, N., Iismaa, S. E., Owens, W., Husain, A. A., Mackay F., and Graham, R. M. 2001. Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem. 276:20673–20678. Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Dunner, K. Jr., Huang, P., Abbruzzese, J. L., and McConkey, D. J. 2005. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65:11658–11666. Nicholas, B., Smethurst, P., Verderio, E., Jones, R., and Griffin, M. 2003. Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. Biochem. J. 371:413–422. Okahara, F., Ikawa, H., Kanaho, Y., and Maehama, T. 2004. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J. Biol. Chem. 79:45300–45303. Owens, L. V., Xu, L., Craven, R. J., Dent, G. A., Weiner, T. M., Kornberg, L., Liu, E. T., and Cance, W. G. 1995 Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 55:2752–2755. Pahl, H. L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853–6866. Peng, X., Zhang, Y., Zhang, H, Graner, S., Williams, J. F., Levitt, M. L., Lokshin, A. 1999. Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. FEBS Lett. 446:35–39. Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., Jain, R. K. 2001. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U S A 98, 4628–4633. Priglinger, S. G., Alge, C. S., Neubauer, A. S., Haritoglou, C., Kampik, A., Welge-Luessen, U. 2004. TGF-beta2- induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. Invest. Ophthalmol Vis. Sci. 45:955–963. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2609–2617.
5 TG2 and Chemoresistance
113
Richardson, A., and Kaye, S.B. 2005. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updat. 8: 311–321. Rodolfo, C., Mormone, E., Matarrese, P., Ciccosanti, F., Farrace, M. G., Garofano, E., Piredda, L., Fimia, G. M., Malorni, W., and Piacentini, M. 2004. Tissue Transglutaminase is a multifunctional BH3-only protein. J. Biol. Chem. 279:54783–54792. Satpathy, M., Cao, L., Pincheira, R., Emerson, R., Bigsby, R., Nakshatri, H., and Matei, D. 2007 Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 67:7194–202. Schlaepfer, D. D., Hauck, C. R., and Sieg, D. J. 1999. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 71:435–478. Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., Schlaepfer, D. D. 2000. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2:249–256. Sierra, A., 2005. Metastases and their microenvironment: linking pathogenesis and therapy. Drug Resist. Updat. 8:247–257. Song, H., Woochul, C., Lim, S., Seo, H. S., Shim, C. Y., Park, S., Yoo, K. J., Kim, B. S., Min, B. H., Lee, H., Jang, Y., Chung, N., Hwang, K. C. 2007 Tissue transglutaminase is essential for integrin-mediated survival of bone marrow derived mesenchymal stem cells. Stem Cells 25:1431–138. Stenvang, J., Kauppinen, S. 2008. MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 8:59–81. Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R., and Yamada, K. M. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614–1617. Torres, J., and Pulido, R. 2001. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276:993–998. Vazquez, F., Takahashi, Y., Rokas, M. V., Nakamura, N., and Sellers, W. R. 2001. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276:48627–48630. Verderio, E. A., Johnson, T. S., and Griffin, M. 2005. Transglutaminase in wound healing and inflammation. Prog. Exp. Tumor Res. 38:89–114. Verderio, E. A., Scarpellini, A., and Johnson, T. S. 2008. Novel interactions of TG2 with heparan sulfate proteoglycans: reflection on physiological implications. Amino Acids In press. DOI-10-1007/s00726-008-0134-6 Verma, A., Wang, H., Manavathi, B., Fok, J. Y., Mann, A. P., Kumar, R., and Mehta, K. 2006. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 66, 10525–10533. Verma, A., and Mehta, K. 2007a. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Res. Update. 10:144–151. Verma, A., and Mehta, K. 2007b. Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr. Cancer Drug Targets 7: 559–565. Verma, A., Guha, S., Wang, H., Fok, J. Y., Koul, D., Abbruzzese, J., Mehta, K. 2008a. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin. Cancer Res. 14:1997–2005. Verma, A., Guha, S., Diagaladjane, P., Kunnumakkara, A. B., Sanguino, A. M., Lopez-Berestein, G., Sood, A. K., Aggarwal, B. B., Krishnan, S., Gelovani, J. G., Mehta, K. 2008b. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin. Cancer Res. 14:2476–2483. Yuan, L., Behdad, A., Siegel, M., Khosla, C., Higashikubo, R., Rich, K. M. 2008. Tissue transglutaminase 2 expression in meningiomas. J Neurooncol. 90:125–132.
114
K. Mehta and J.Y. Fok
Wang, X., Trotman, L. C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, J., ErdjumentBromage, H., Tempst, P., Cordon-Cardo, C., Pandolfi, P. P., Jiang, X. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128:129–139. Xu, L., and Hyne, R. O. 2007. GPR56 and TG2 – possible role in suppression of tumor growth by the microenvironment. Cell Cycle 6:160–165. Yamaguchi, H., and Wang, H. G. 2006. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol. Cell Biol. 26:569–579.
Chapter 6
Extracellular Matrix-Mediated Drug Resistance P.S. Hodkinson and Tariq Sethi
Abstract The prognosis from cancer remains poor largely due to the resistance of tumour cells to drug therapy. Single cell studies of drug-resistant clones have revealed important mechanisms of acquired chemoresistance but have failed to take into account the contribution of host factors. The tumour microenvironment plays a crucial role in cancer growth and spread. Extracellular matrix (ECM) proteins have been identified within the tumour stroma and have been shown to promote tumour growth in vivo. Initial work by our group and others clearly demonstrated that ECM could protect cancer cells from the pro-apoptotic effects of several diverse chemotherapy agents in vitro. Subsequent research has elucidated the mechanisms by which ECM mediates these effects. This chapter will review these pathways in detail giving particular mention to the role of ECM–integrin interactions. The challenge for the future will be in applying these advances to develop effective therapeutic strategies for drug resistance. Keywords Extracellular matrix · Drug resistance and cancer Abbreviations ECM, extracellular matrix; PI3-K, phosphoinositide-3-OH kinase; SCLC, small cell lung cancer; GMCSF, granulocyte macrophage colony stimulating factor; GSK-3β, glycogen synthase-3β; CDK, cyclin-dependent kinase; ILK, integrin-linked kinase; FAK, focal adhesion kinase; PDK, PI3-K-dependent kinase; IgG, immunoglobulin G
T. Sethi (B) Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK e-mail:
[email protected]
K. Mehta, Z.H. Siddik (eds.), Drug Resistance in Cancer Cells, C Springer Science+Business Media, LLC 2009 DOI 10.1007/978-0-387-89445-4 6,
115
116
P.S. Hodkinson and T. Sethi
Introduction The discovery of cytotoxic drug therapy as an effective treatment modality for cancer more than five decades ago heralded a new era for the management of malignant disease (Goodman et al. 1984). Subsequently, chemotherapy has become the mainstay of treatment for many patients with metastatic solid organ tumours and haematological malignancies (Joensuu 2008). In addition, cytotoxic drug therapy has replaced surgery as the primary treatment option for some solid malignancies (e.g. small cell lung cancer (SCLC)), and adjuvant chemotherapy has been shown to provide additional survival benefit following the surgical removal of locally advanced cancer (Osterlind 2001, Molina et al. 2006) . In haematological malignancies, combination chemotherapeutic regimes can frequently produce sustained objective tumour remission, resulting in long-term survival (Savarese et al. 1997). Unfortunately, this situation is not reflected in solid organ cancers. Here, although chemotherapy can induce significant initial tumour responses, residual or recurrent disease resistant to further drug treatment results in cancer progression and ultimately death (Tannock 2001). It is estimated that intrinsic or acquired resistance of cancer cells to cytotoxic drug therapy accounts for 90% of treatment failure. This is highlighted in SCLC, where an initial objective response rate (ORR) of up to 95% can be achieved in limited disease with a combination of etoposide and a platinum-based agent (Bunn and Carney 1997). Unfortunately, the response duration is short (1–2 years) and trials of second-line chemotherapy have been disappointing (ORR 20%) resulting in poor 5-year survival (less than 5%) (Lally et al. 2007). It is clear that understanding the mechanisms of drug resistance is of paramount importance. Multiple factors can affect the sensitivity of cancer cells to cytotoxic drugs. Early studies have investigated ‘genetic’ drug resistance by exposing cancer cells to cytotoxic agents and studying single surviving cells (unicellular model). This field of research has revealed several important drug resistance mechanisms including drug-efflux pumps (e.g. P-glycoprotein pump), drug inactivation systems (e.g. glutathione-S-transferase) and altered drug targets (e.g. topoisomerase II mutations) (Kartner et al. 1983, Cole et al. 1992, Goto et al. 2001, de Jong et al. 1990, Lage et al. 2000). Although these mechanisms operate in vitro to protect cancer cells from cytotoxic drugs and may contribute to acquired chemoresistance in recurrent tumours following first-line cytotoxic therapy, their role in initial drug resistance is unclear (Desoize and Jardillier 2000). The failure of unicellular models to account for drug resistance has prompted investigation of other mechanisms. Unicellular models do not take into account host–tumour interactions. The importance of the host in the development of drug resistance has been indicated from studies of mouse mammary tumours, in which drug resistance induced in vivo was not apparent in cell culture in vitro (Teicher et al. 1990). Furthermore, the recurrence of some solid organ malignancies (e.g. SCLC) at the primary tumour site following first-line chemotherapy has suggested the presence of local factors that promote cancer cell survival (Rintoul and Sethi 2001). It is now widely accepted that tumours exist not in isolation, but within a specialised microenvironment that has properties
6 Extracellular Matrix and Drug Resistance
117
similar to a chronic wounding reaction, containing cytokines and growth factors, which may affect cytotoxic drug responses (Mueller 2006). Examples include IL-6 and granulocyte macrophage colony stimulating factor (GMCSF), inhibiting the cytotoxicity of vincristine, adriamycin and cyclophosphamide (Lotem and Sachs 1992). Host–tumour interactions can also occur between stromal cells (leukocytes and fibroblasts) and with extracellular matrix (ECM) proteins. Data collected over the past 15 years strongly suggests that cancer cell–ECM interactions may be important in cytotoxic drug resistance. This chapter will review the evidence for the role of ECM in drug resistance and consider the cellular mechanisms involved.
ECM Proteins Promote Drug Resistance The ECM is produced by stromal cells (e.g. fibroblasts) and secreted to form an interstitial matrix or basement membrane, which provides structural support for cells and regulates cell–cell interactions. ECM consists of a network of carbohydrates (glycosaminoglycans) and proteins existing as either proteoglycans or nonproteoglycans (Iozzo 1998). Collagen, fibronectin, tenascin and laminin comprise a significant portion of non-proteoglycan matrix components (Iozzo 1998). Immunohistochemical studies of sections from human cancers have demonstrated the presence of these non-proteoglycan matrix proteins within the tumour microenvironment. Our group investigated the matrix composition of SCLC primary tumours (n = 23) (Sethi et al. 1999). We observed high levels of fibronectin, collagen IV and tenascin staining in all samples, which was localized to the stroma infiltrated by tumour cells but not surrounding normal lung tissue. In addition, fibronectin and laminin staining was visible within tumour cells (∼25% of tumours), suggesting that SCLC cells may produce some components of the local ECM. Several other groups have demonstrated the presence of ECM proteins within both the primary and metastatic tumour microenvironment of breast, ovarian, head and neck and gastrointestinal tract cancers (Bergamaschi et al. 2008, Chin et al. 2005, Aishima et al. 2003, Grigioni et al. 1991, Sherman-Baust et al. 2003). Furthermore, these studies have demonstrated that the presence or expression profile of ECM components correlates with poorer patient prognosis, suggesting an important role for ECM in cancer pathogenesis. Cellular adhesion is essential for untransformed epithelial cells to survive in vitro and if detached cells undergo apoptosis, a process known as anoikis (Frisch and Francis 1994). In contrast, cancer cells display a key feature of tumourigenicity, anchorage-independent growth (Shin et al. 1975). This ability to escape anoikis is an important feature that allows malignant cells to survive and metastasise. Therefore, it would seem unlikely that tumour cells would derive important survival signals from interaction with ECM components. However, data collected in the early 1990s suggested that despite this, ECM proteins could promote malignant transformation and cancer cell growth. In 1990, Fridman et al. demonstrated that reconstituted basement membrane proteins (in the form of matrigel) could enhance SCLC
118
P.S. Hodkinson and T. Sethi
cell line growth in vivo (Fridman et al. 1990). Subsequently, matrigel has been shown to enhance the in vivo and in vitro growth of several diverse tumour cell lines (Vukicevic et al. 1992, Passaniti et al. 1992, Albini et al. 1992). Furthermore, Fridman et al. (1992) demonstrated that subcutaneous injection of athymic mice with untransformed NIH-3T3 cells mixed with matrigel resulted in the formation of invasive tumours, but without matrigel the cells were non-tumorigenic (Fridman et al. 1992). These initial data, suggesting an important role for ECM proteins in the tumour microenvironment, have prompted experiments investigating the effect of cancer cell–ECM interaction on cytotoxic drug sensitivity. In addition to demonstrating enhanced tumour growth with matrigel, Fridman et al. (1990) demonstrated that SCLC cells could adhere to laminin in vitro, protecting the cells from cytotoxic drug-induced growth inhibition (Fridman et al. 1990). Many chemotherapeutic agents exert their cytotoxic effects by inducing apoptosis (Hannun 1997). Developing Fridman’s initial observation, our group investigated the effects of ECM proteins on apoptosis induced in SCLC cells by cytotoxic drugs used clinically to treat this aggressive cancer (Sethi et al. 1999). We employed an in vitro model of drug resistance in which SCLC cells were allowed to adhere to purified ECM proteins (laminin and fibronectin) and then treated with chemotherapeutic agents including etoposide, adriamycin and cyclophosphamide. This allowed the effects of individual ECM proteins to be examined without other contaminating factors (e.g. growth factors) that may be present in matrigel. Crucially, we found that adhesion to laminin or fibronectin strongly protected SCLC cells from apoptosis induced by chemotherapeutic agents, with diverse mechanisms of action (Sethi et al. 1999). Subsequently, other groups have demonstrated that ECM proteins can protect a variety of cancer cell lines from cytotoxic drug therapy in vitro. Chronic myeloid leukaemia and myeloma cell lines have been shown to bind to fibronectin and consequently display increased resistance to diverse genotoxic drugs (Hazlehurst et al. 2000, Damiano et al. 2001). Breast cancer, fibrosarcoma and glioma cell lines have all been shown to be more resistant to the apoptotic effects of cytotoxic drugs in the presence of ECM proteins or basement membrane extracts (Aoudjit and Vuori 2001, Pogany et al. 2001). Furthermore, data from a clinical study has suggested that the presence of ECM proteins in the tumour microenvironment prior to treatment can predict response to chemotherapy (Jayne et al. 2002). However, the role of ECM as a mechanism of drug resistance in vivo remains to be defined definitively. Despite these limitations, the current in vitro data suggests that ECM proteins promote drug resistance, and that this may represent an important mechanism by which cancer cells can survive an initial cytotoxic insult allowing tumour relapse.
Mechanisms of ECM-Mediated Drug Resistance It is clear from our data, and that of other groups, that ECM proteins protect cancer cells from the effects of mechanistically diverse cytotoxic drugs. This has led to the proposal of several mechanisms to explain ECM-mediated drug resistance. These
6 Extracellular Matrix and Drug Resistance
119
include altered drug penetration, reduced DNA damage, effects on cell proliferation and interaction with cell-surface integrins. This section will review the evidence for each of these potential pathways.
Altered Drug Penetration It has been hypothesised that ECM surrounding cancer cells may form a physical barrier to chemotherapeutic drug entry thus promoting drug resistance. In 2002, Tannock et al. demonstrated that penetration of chemotherapeutic agents through a 200-μM thick multi-cellular layer of mouse mammary tumour or human bladder cancer cells containing ECM proteins was reduced in comparison to a control Teflon membrane (Tannock et al. 2002). They concluded that drug entry into areas of tumour without blood vessels could be impaired, explaining why some cancer cells escape initial cytotoxic therapy. In support of this theory, Netti et al. showed inhibition of macromolecule (IgG) diffusion through tumour tissue by an extensive collagen network, which could be circumvented by collagenase treatment (Netti et al. 2000). Furthermore, pre-clinical and preliminary clinical trials using hyaluronidase, an enzyme that lowers the viscosity of hyaluronic acid and aids tissue permeability, have demonstrated an additive effect to cytotoxic drug therapy (Beckenlehner et al. 1992, Spruss et al. 1995, Smith et al. 1997, Baumgartner et al. 1998). Unfortunately, these effects have not been reproduced in larger randomised controlled trials (Baumgartner et al. 1998). In addition, ECM-mediated drug resistance can be demonstrated in monolayer cell culture systems in vitro, where the matrix is unlikely to prevent drug penetration. In support of this, we have clearly demonstrated that adhesion of SCLC cells to fibronectin does not prevent etoposide from inhibiting its intracellular target, topoisomerase (Sethi et al. 1999). Therefore, it seems unlikely that reduced drug entry into cancer cells is solely responsible for ECM-mediated drug resistance.
Reduced DNA Damage Many cytotoxic agents cause damage to cellular DNA promoting cell cycle arrest and apoptosis (Helleday et al. 2008). It has been proposed that ECM modulates DNA damage or repair thus conferring drug resistance. This was initially suggested from in vitro experiments in untransformed lung endothelial cells, which demonstrated that adhesion to collagen and laminin caused a reduction in bleomycininduced DNA damage (Hoyt et al. 1997). The role of this mechanism in cancer was supported by experiments using topoisomerase II inhibitors in haemopoietic cancer cell lines. In 2001, Hazlehurst et al. demonstrated that mitoxantrone- and etoposideinduced DNA double-strand breaks in U937 cells were significantly reduced by adhesion to fibronectin, and this correlated with altered nuclear distribution of topoisomerase II beta (Hazlehurst et al. 2001). The cellular pathways involved in
120
P.S. Hodkinson and T. Sethi
ECM-mediated protection from DNA damage have not yet been elucidated. In addition, this mechanism of drug resistance may not be widely applicable. For example, we have demonstrated in SCLC cells that adhesion to ECM proteins (collagen IV, laminin and fibronectin) protects against etoposide-induced apoptosis but does not alter topoisomerase inhibition or DNA damage (Sethi et al. 1999).
Effects on Cell Proliferation It is generally accepted that the development of cancer requires escape from the normal controls of cellular proliferation (Rozengurt 1999). DNA damage induced by cytotoxic drugs promotes cell cycle arrest thus preventing cancer cell proliferation (Schwartz and Shah 2005). Adhesion of untransformed epithelial cells to ECM typically results in cycle progression and increased cellular proliferation (Lin and Bissell 1993). Therefore, it has been proposed that ECM may override chemotherapy-induced inhibition of cellular proliferation, promoting drug resistance. This is supported by our data demonstrating that adhesion of SCLC cell lines to fibronectin prevents G2/M cell cycle arrest induced by etoposide treatment (Hodkinson et al. 2006). It is generally accepted that cancer cells can promote cellular proliferation by secreting growth factors that act on the same tumour cells (autocrine growth loops) (Rozengurt 1999). We have demonstrated that SCLC cells in vivo stain intracellularly for ECM proteins (Sethi et al. 1999). Other groups have also demonstrated ECM expression by cancer cells (Gladson et al. 1995, van Riet et al. 1994). This data suggests the possibility of an autocrine growth loop involving cancer cell production of ECM proteins, which promote cell cycle progression and drug resistance. However, this may not be a generally applicable mechanism, as research in haemopoietic cancer cell lines has indicated that adhesion to ECM may inhibit cellular proliferation possibly allowing greater time for DNA repair (Lundell et al. 1996, Hazlehurst et al. 2000).
Interaction with Cell-Surface Integrins Adhesion to ECM components, such as collagen and fibronectin, is mediated by a family of cell-surface proteins called integrins. Structurally, integrins are composed of α and β subunits that are non-covalently linked as heterodimers (Humphries 2000). Each subunit is a type I transmembrane protein that consists of a large extracellular domain, linked by a single-pass transmembrane segment to a smaller intracellular domain or tail (Hynes 2002). Eighteen α and eight β subunits have been identified. Extensive research has demonstrated that integrins are central to many of the cellular processes important in cancer, including survival, proliferation and migration (Moschos et al. 2007). A wide range of integrin heterodimers have been demonstrated to play a role in many types of cancer, including haematopoietic, breast, lung and colon (Mizejewski 1999). Clinical studies have shown that increased integrin expression independently correlates with poorer patient survival
6 Extracellular Matrix and Drug Resistance
121
(Oshita et al. 2002, Hazelbag et al. 2007, Yao et al. 2007). Furthermore, in vitro research has indicated that several diverse cancer cell lines can adhere to ECM proteins via specific surface integrins (Mizejewski 1999). These studies strongly suggest that integrins are important in the pathogenesis of cancer, prompting the investigation of ECM–integrin interactions in drug resistance. In 1999, we published important data demonstrating for the first time that SCLC cells could bind to ECM proteins in vitro via cell-surface integrins and that this interaction provided protection from chemotherapy-induced apoptosis (Sethi et al. 1999). We found that SCLC cell lines derived from human patients expressed predominantly α2β1, α3β1, α6β1 and αvβ1 integrins. These integrins have been shown to mediate cell binding to collagen, fibronectin and laminin (Hynes 2002). We demonstrated that adhesion to these ECM proteins conferred resistance to apoptosis induced by etoposide, cis-platinum and doxorubicin and that this effect was completely abrogated by a function-blocking β1 integrin antibody (4B4) (Sethi et al. 1999). Subsequently, we have confirmed that a β1 integrin-activating antibody (TS2/16) can also reproduce the chemoprotective effect of ECM, strongly implicating β1 integrins in ECM-mediated drug resistance (Hodkinson et al. 2006). Further to this research, other groups have demonstrated that this phenomenon is applicable to other cancer cells. Damiano et al. showed that adhesion of K562 chronic myeloid leukaemia cells to fibronectin protected against chemotherapy-induced apoptosis, a mechanism mediated via α5β1 integrins (Damiano et al. 2001). Aoudjit and Vuori (2001) demonstrated that β1 integrin ligation by ECM proteins significantly protects breast cancer cell lines from apoptosis induced by paclitaxel and vincristine (Aoudjit and Vuori 2001). In addition, β1 integrins have been shown to confer resistance to drug-induced apoptosis in hepatoma and lymphoma cell lines (Zhang et al. 2002, Hazlehurst et al. 2001). Drug resistance has also been observed with other integrin subunits. In 1999, Uhm et al. showed that vitronectin, through αvβ3 and αvβ5 integrins, could protect glioma cells from apoptosis induced by the inhibition of topoisomerase (Uhm et al. 1999). Data collected over the last decade has indicated that ECM–integrin interactions can modulate the effects of cytotoxic drug therapy on apoptotic pathways. It has been shown that integrin ligation protects breast cancer cell lines from paclitaxel-induced apoptosis through reduction in mitochondrial cytochrome c release, a key intermediate in apoptosis (Aoudjit and Vuori 2001). Indirect evidence has also implicated the Bax/Bcl-2 system in integrin-mediated drug resistance. A study in B-lymphoma cells demonstrated that α4β1 integrin ligation by vascular cellular adhesion molecule-1 (VCAM-1) promoted Bcl-X(L) gene transcription and prevented etoposide from disrupting Bax-Bcl-X(L) binding (Taylor et al. 2000). Furthermore, vitronectin-induced chemoresistance in glioma cell lines has been shown to be associated with an increase in expression of Bcl-2 and Bcl-X(L) proteins (Uhm et al. 1999). Despite the clear role of integrins in cell cycle control and proliferation, data regarding the role of cell cycle effectors in ECM-mediated drug resistance is sparse. DNA damage by cytotoxic drugs frequently results in cell cycle arrest and escape from this is a crucial mechanism by which cancer cells may resist drug therapy and continue to proliferate with DNA damage. The key regulators of the cell cycle
122
P.S. Hodkinson and T. Sethi
have been defined and include cyclins A, B, D and E and their associated cyclindependent kinases (CDK) (Boonstra 2003, Woo and Poon 2003). Cell arrest can occur at two main checkpoint, G1/S and G2/M, mediated by factors including p53, p21 and p27 (Schwartz and Shah 2005, Vidal and Koff 2000). In 2000, Hazelhurst demonstrated that ligation of β1 integrins by fibronectin on myeloma cells promoted drug resistance and that this was associated with increased p27 levels and cell cycle arrest at the G1 checkpoint (Hazlehurst et al. 2000). Subsequently, we have demonstrated a contradictory mechanism in SCLC cells, showing that ECM–β1 integrin interaction prevents etoposide-induced G2/M cell cycle arrest (Hodkinson et al. 2006). This discrepancy suggests cell context dependent differences in the response to integrin ligation. The collected data clearly demonstrates an important role for ECM components in the initial resistance to a diverse array of chemotherapeutic drugs. Although it is possible that ECM may alter drug effects or provide a physical barrier to drug penetration, it is clear that the interaction of ECM with integrins represents the most widely applicable mechanism of cancer cell resistance to cytotoxic injury. An obvious extrapolation of this conclusion is that disruption of ECM–integrin interaction could prove to be a novel therapeutic strategy to circumvent drug resistance. It has been proposed that integrin-blocking antibodies or peptides could be used to prevent cancer cell–ECM binding. In support of this hypothesis, data from 3-dimensional breast cancer cell line cultures has indicated that β1 integrin inhibition promotes cancer cell loss without affecting normal cells (Park et al. 2006). Specific studies addressing the efficacy of β1 integrin blockade as a strategy for preventing drug resistance in vivo are lacking. However, β1 integrin-blocking antibodies inhibit tumour growth in vivo without toxicity to the animals (Park et al. 2006). Although this initial data is encouraging, global integrin blockade is likely to have complex effects on the host. This can be appreciated by considering cells commonly found in the tumour microenvironment. Fibroblasts, leukocytes and endothelial cells all utilise integrins for essential cellular functions, e.g. leukocyte migration and activation, fibroblast viability and matrix assembly or endothelial cell survival and angiogenesis (Sixt et al. 2006, Tian et al. 2002, Mettouchi and Meneguzzi 2006, Luscinskas and Lawler 1994). Therefore, integrin blockade could prevent an effective immune response or alter tumour blood vessel formation, facilitating cancer growth rather than promoting effective drug therapy. It is clear that prior to the development of novel therapeutic strategies, we require a better understanding of the integrin signalling mechanisms activated by ECM that promote drug resistance in cancer cells.
Integrin Signalling Pathways and Drug Resistance Integrins do not simply function as cell adhesion molecules. Extensive research has demonstrated that matrix binding to the extracellular domain of integrin subunits promotes integrin clustering, leading to the recruitment of multiple intracellular
6 Extracellular Matrix and Drug Resistance
123
proteins to localised cell membrane areas called focal adhesions (Zaidel-Bar et al. 2004). These macromolecular complexes form an essential mechanical link between integrins and the cytoskeleton. Many adaptor proteins are involved and their role in regulation of integrin function is beyond the scope of this chapter. Geiger et al. have published an excellent review of this topic (Geiger et al. 2001). In addition to adaptor molecules, several proteins with intrinsic kinase activity are recruited to focal adhesion complexes, including focal adhesion kinase (FAK) and integrin-linked kinase (ILK) (Wozniak et al. 2004, Legate et al. 2006). Subsequently, ECM–integrin interaction is translated into intracellular effects involving other signalling molecules (e.g. Akt, glycogen-synthase-3β (GSK-3β), phosphoinositide-3-kinase (PI3-K) and Src) (Schaller 2001, Klinghoffer et al. 1999, Khwaja et al. 1997). The contribution of these signalling pathways to ECM-mediated drug resistance has been the focus of considerable research over the past 5 years and will be reviewed in this section.
The Role of FAK as a Mediator of Drug Resistance Following its description over 15 years ago in v-Src transformed chick embryo cells, the 125-kDa non-receptor tyrosine kinase FAK has been shown to regulate downstream signalling by integrins and growth factor receptors (Schaller et al. 1992, Hanks et al. 2003, Sieg et al. 2000). Structurally, FAK possess several important regions: an N-terminal FERM domain which mediates interaction with growth factor receptors; a central kinase domain; two proline-rich regions that act as binding sites for Src homology 3 (SH3) domains in other proteins (e.g. p130Cas); and a C-terminal focal adhesion targeting domain (FAT) that is necessary for localisation of FAK to focal adhesion complexes and also facilitates binding of integrinassociated proteins (e.g. talin, paxillin) (Dunty et al. 2004, Hildebrand et al. 1993, Schaller et al. 1994, Polte and Hanks 1995). Integrin or growth factor receptor interaction results in FAK autophosphorylation at tyrosine 397, which promotes the binding and activation of Src kinase, to form the FAK–Src complex (Schaller et al. 1994, Calalb et al. 1995). Subsequently, FAK is further phosphorylated promoting the binding and/or phosphorylation of several important focal adhesion molecules (e.g. the p85 subunit of PI3-K, p130Cas and Grb2) (Xia et al. 2004, Polte and Hanks 1995, Schlaepfer et al. 1994). As a result, crucial cell signalling pathways are activated including Akt, JNK and Ras/ERK that promote cell survival, proliferation and motility. Thus FAK would appear to be a key regulator of many processes important to cancer pathogenesis and in particular integrin-mediated drug resistance. Extensive research, both in vitro and in vivo, has suggested a central role for FAK signalling in cancer. Gene expression analysis has demonstrated increased FAK expression in human tumours (Bhattacharjee et al. 2001, Yeoh et al. 2002). Furthermore, increased FAK phosphorylation has been shown in some transformed cells (Datta et al. 2001). Work investigating the development of skin tumours following chemical carcinogen exposure has demonstrated an important role for FAK in tumorigenesis, although FAK overexpression has not been shown to promote
124
P.S. Hodkinson and T. Sethi
malignant transformation in vitro (McLean et al. 2001). FAK is critical for normal cell survival, and overexpression of FAK in epithelial cells has been shown to be sufficient to prevent anoikis (Frisch et al. 1996). Furthermore, expression of the C-terminal portion of FAK (FRNK), which inhibits FAK signalling, has been shown to suppress tumour cell proliferation in vitro and suppress tumour growth in vivo, suggesting a central role for FAK in cancer cell proliferation (van Nimwegen et al. 2005). Interestingly, stable FRNK expression in v-Src transformed NIH-3T3 fibroblasts reduced tumour cell metastasis but not growth in nude mice (Hauck et al. 2002). This data clearly implicates FAK in cancer cell survival, growth and spread. Several recent studies have also addressed the influence of FAK on cytotoxic drug sensitivity. In 2005, Halder et al. demonstrated that docetaxel induced cleavage of FAK in drug-sensitive but not drug-resistant ovarian cancer cell lines, indicating that FAK degradation may play a role in docetaxel resistance (Halder et al. 2005). To confirm this, they used siRNA and demonstrated increased docetaxel sensitivity in cells with reduced FAK expression. Following this, van Nimwegen et al. (2006) demonstrated that expression of FRNK sensitised a rat mammary adenocarcinoma cell line (MTLn3) to doxorubicin-induced cell death (van Nimwegen et al. 2006). In addition, Duxbury et al. (2003) demonstrated that reduction in FAK expression using siRNA promoted gemcitabine sensitivity in a nude mouse xenograft model of human pancreatic adenocarinoma (Duxbury et al. 2003). These studies have also suggested that FAK-mediated drug resistance relies in part on PI3-K/Akt signalling. However, the exact mechanisms by which FAK regulates drug resistance remain to be elucidated.
The Role of ILK in Drug Resistance ILK, which was first described in 1996, is a non-receptor-bound serine/threonine kinase that has been shown to directly interact with the cytoplasmic tail of β1 integrins (Hannigan et al. 1996). This 59-kDa protein has three distinct regions: four N-terminal ankyrin repeats that are required for localisation to focal adhesion complexes and binding adaptor proteins (e.g. particularly interesting new cysteine histidine rich protein (PINCH)); a central pleckstrin homology (PH) domain; and a C-terminal domain that is also required for localisation to focal adhesions and mediates interactions with β integrin subunits and cytoplasmic adaptor proteins (e.g. paxillin and actopaxin) providing connection to the actin cytoskeleton. In addition to its structural interactions, ILK possesses a C-terminal kinase catalytic domain (Tu et al., 1999 Delcommenne et al. 1998, Nikolopoulos and Turner 2001, Nikolopoulos and Turner 2002). The serine/threonine kinase activity of ILK is stimulated by ECM–integrin interaction in a PI3-K-dependent manner, resulting in phosphorylation of Akt and GSK-3β (Lynch et al. 1999, Troussard et al. 1999). Furthermore, through interaction with PINCH and its interacting protein Nck-2, ILK provides a connection between integrins and growth factor receptor signalling (Tu et al. 1999).
6 Extracellular Matrix and Drug Resistance
125
These important downstream signalling pathways regulate cell survival, proliferation and motility suggesting that ILK may be important in cancer. Knockout experiments have demonstrated that ILK is essential for embryonic viability (Sakai et al. 2003). Furthermore, constitutive activation or overexpression of ILK has been shown in vitro to protect mammalian cells from anoikis, effects that are mediated by activation of Akt, suggesting a central role for ILK in cell survival (Attwell et al. 2000). ILK has also been shown to promote cell invasion in vitro (Troussard et al. 2000). Analysis of human tumours, including melanoma and prostate cancer, has demonstrated an increased expression of ILK, which correlates with cancer stage and progression (Dai et al. 2003, Graff et al. 2001). Importantly, specific expression of ILK in mammary epithelial cells has been shown to result in mammary tumour development in transgenic mice, and inhibition of ILK using a small molecule inhibitor has been shown to suppress thyroid cancer cell growth in vivo (White et al. 2001, Younes et al. 2005). Despite the clear role of ILK signalling in cell survival and oncogenesis, the role in drug resistance has received relatively little attention. In 2005, Duxbury et al. demonstrated that human pancreatic adenocarcinoma cells were sensitised to the pro-apoptotic effects of gemcitabine by suppression of ILK expression using siRNA and protected by overexpression of ILK (Duxbury et al. 2005). Furthermore, they showed that constitutively activated Akt could promote gemcitabine resistance in the presence of ILK knockdown. In contrast to this data, Cordes (2004) demonstrated that overexpression of ILK could sensitise cells to the cytotoxic effects of radiation, a finding also supported in A549 lung cancer cells (Cordes 2004). It is proposed that this discrepancy relates to differences in the cell death pathways activated by different cytotoxic agents. Further experimentation is required to determine the exact role of ILK in drug resistance and which key signalling events are responsible for the effects.
The Role of PI3-K Signalling in Integrin-Mediated Drug Resistance Cross-linking of integrins by ECM results in activation of PI3-K, both in a FAK-dependent and FAK-independent manner (Xia et al. 2004, Velling et al. 2004). Subsequently, through PI3-K-dependent kinases, PDK1 and PDK2, downstream signalling molecules Akt and GSK-3β are phosphorylated (Fresno Vara et al. 2004). Akt has been shown to promote cell survival by phosphorylating proteins involved in apoptosis including Bad and pro-caspase 9 (Cardone et al. 1998). Furthermore, activated Akt has been demonstrated to reduce expression levels or activity of cell cycle inhibitors p21 and p27 (Sun et al. 1999, Zhou et al. 2001). GSK-3β promotes degradation of cyclin D1, which is crucial for cell cycle progression (Diehl et al. 1998). Akt phosphorylates and inactivates GSK-3β thus stabilising cyclin D1 promoting cell proliferation. Thus integrin-mediated activation of PI3-kinase may represent an important mechanism by which ECM proteins protect cancer cells from chemotherapy.
126
P.S. Hodkinson and T. Sethi
We have recently demonstrated that the PI3-K pathway is a key regulator of integrin-mediated drug resistance in SCLC cells (Hodkinson et al. 2006). Initially we observed that adhesion of human SCLC cell lines to ECM proteins or ligation of β1 integrins on SCLC cells with activating antibodies (TS2/16) increased PI3K activity resulting in phosphorylation of downstream Akt and GSK-3β. Subsequently, we investigated the role of PI3-K in ECM-mediated chemoprotection using two separate strategies: pharmacological inhibition of PI3-K with LY294002 and genetic manipulation of PI3-K signalling by overexpression of constitutively active or dominant negative Akt. Crucially we found that inhibition of PI3-K signalling prevented β1 integrin-mediated resistance to etoposide in SCLC cells. Furthermore, we demonstrated that adhesion to ECM via β1 integrins phosphorylated Bad protein and prevented etoposide activation of the caspase cascade in a PI3-K-dependent manner. Thus we have defined an intracellular pathway mechanism by which ECM can promote drug resistance. The importance of this pathway is supported by research in other types of cancer. Auodjit and Vuori (2001) demonstrated that ECM-mediated drug resistance in breast cancer correlated with an increase in Akt and that inhibition of PI3-K reversed the chemoresistance (Aoudjit and Vuori 2001). In 2006, Cordes et al. demonstrated that integrin/PI3-K/Akt signalling was central to glioma cell survival in the context of radiation-induced cytotoxic injury (Cordes et al. 2006). Estrugo et al. (2007) showed that HL60 human leukaemia cells were protected from chemotherapyinduced procaspase-8-mediated apoptosis by a β1 integrins/PI3K-dependent pathway (Estrugo et al. 2007). It has been suggested by some authors that this data should be interpreted with caution as alteration of PI3-K signals may lower integrin affinity for ECM. This has not been reported, and we have found that mutants of the small GTPase H-Ras, which preferentially activate PI3-K, do not suppress integrins (Lad et al. 2006). In addition to determining the effect of PI3-K inhibition on integrin-mediated resistance to apoptosis, we have also investigated the effect on etoposide-induced cell cycle arrest (Hodkinson et al. 2006). We have shown that etoposide (and ionising radiation) promoted G2/M cell cycle arrest in SCLC cells and that adhesion to ECM via β1 integrins prevented this, driving cell cycle progression. This correlated with reduced expression of p21 and p27, reduced phosphorylation of CDK1 and maintained expression of cyclins D, E, A and B and phosphorylation of CDK2. These effects were abrogated by chemical and genetic inhibition of PI3-K signalling. Furthermore, we observed that SCLC cells displayed similar degrees of DNA damage and repair whether adhered to ECM or not. This suggests that ECM via β1 integrin/PI3-K signalling can prevent etoposide-induced cell cycle arrest and subsequent apoptosis, allowing the cells to survive with persistent DNA damage, which could promote the development of acquired drug resistance mechanisms (e.g. altered drug targets). Therapeutic strategies designed to selectively inhibit PI3-K may therefore enhance the efficacy of traditional drug regimes improving anticancer treatment. The data presented here clearly indicates a central role for downstream integrin signalling pathways in drug resistance. It is also apparent that considerable overlap
6 Extracellular Matrix and Drug Resistance
127
exists between the pathways activated by ECM–integrin interaction and that several molecules recruited to the focal adhesion complex allow binding to growth factor receptors introducing a further layer of complexity. In addition, some of these mechanisms are cell context dependent demonstrating that no single pathway will be applicable to all cancer cells and many of these cascades are active in normal cells. Further work is needed to define the mechanisms activated in cancer cells in vivo and to determine the best strategies for inhibition to limit toxicity to normal cells.
ECM-Mediated Drug Resistance in the Context of Metastatic Cancer The mechanisms described here by which adhesion to ECM proteins within the tumour microenvironment protect cancer cells from drug-induced apoptosis do not conform to our concept of cancer as a highly invasive and metastatic disease. Furthermore, malignant tumours frequently show high expression levels of matrix metalloproteinases (MMP). These proteolytic enzymes facilitate tumour invasion and metastasis by degrading ECM (Bonomi 2002). Inhibitors of MMP have also been shown to reduce tumour growth and metastasis in animal models of cancer, including breast, colon and pancreatic cancer, suggesting a central role for matrix degradation in cancer pathogenesis (Lozonschi et al. 1999, Naglich et al. 2001, Lein et al. 2002). Thus, it would seem unlikely that cancer cells would use their surrounding ECM as a pro-survival signal if they actively produce enzymes to degrade it. SCLC is highly metastatic, and MMP expression has been demonstrated in SCLC tumour sections from patients (Michael et al. 1999, Ylisirnio et al. 2000). On the basis of this, a phase III trial of an MMP inhibitor, Marimastat, in SCLC was conducted. Unfortunately, Marimastat treatment demonstrated no survival advantage over placebo (Shepherd et al. 2002). The reasons for the poor efficacy of MMP inhibitors are complex but one suggestion is that the majority of trials were conducted in patients with widespread metastatic disease and thus MMP inhibitor treatment to this group of patients could not be expected to alter this process. Interestingly, data supporting the role of ECM in drug resistance suggests that MMP inhibition may actually enhance matrix stability, promoting cancer cell survival and growth, a situation deleterious to patient survival. The affinity of integrin for ligand binding is a dynamic process regulated by intracellular signals. This allows cellular adhesion to ECM to vary in strength, facilitating changes in cell behaviour e.g. migration or mitosis. Thus, it seems likely that cancer cells would also modulate their integrin affinity, utilising ECM-derived survival signals when strongly adherent and being more motile and invasive when less adherent. In this later setting, the cancer cells, unlike untransformed cells would survive anoikis due to intracellular pro-survival signals and autocrine growth loops. In the context of chemotherapy, a small number of cancer cells with high integrin affinity and thus strongly adherent would survive cell cycle arrest and apoptosis despite
128
P.S. Hodkinson and T. Sethi
DNA damage. The result would be recurrence of tumour at the original site of disease, as is often seen in SCLC, with the potential development of acquired multidrug resistance. Implicit in this concept is that new therapies designed to disrupt ECM–integrin survival mechanisms should be appropriately timed with chemotherapy. Furthermore, modulators of integrin affinity may prove to be more important targets for anti-cancer therapy.
Conclusions and Future Directions Cancer continues to be a significant health burden, in part due to initial and subsequently acquired drug resistance. This chapter has outlined several important areas of research that have demonstrated a key role for ECM in cancer cell drug resistance. Furthermore, mechanisms underpinning this have been described with particular reference to the role of integrin signalling. It seems most likely that cancer cells have a dynamic relationship with the surrounding ECM, allowing escape from chemotherapy, and also metastasis. At a simple level, interruption of ECM–integrin interaction could increase the sensitivity of many cancers to initial chemotherapy, improving patient survival. However, non-specific integrin inhibition is likely to have widespread and possibly toxic effects on the host’s normal cells. This could prevent an adequate anti-tumour response or may promote cancer cell growth. The future challenges faced by researchers in this field are not easy to surmount. Crucial to the successful development of real therapeutic strategies is the description of an in vivo model that will allow study and manipulation of integrin signalling in cancer development and treatment. Furthermore, we need to understand the complex interactions of the downstream signalling events initiated by ECM binding to integrins and the signals that modulate integrin affinity. The ultimate hurdle will be to develop a rationale therapy that has minimal host side effects and will reduce cancer drug resistance without promoting undesirable cancer cell behaviour (e.g. metastatic invasion). Realistically, no single approach will be applicable to all cancers. It is predictable that definition of the molecular signature of a patient’s tumour cells will allow rational application of several targeted therapies to compliment traditional chemotherapy and thus improve patient survival.
References Aishima, S., Taguchi, K., Terashi, T., Matsuura, S., Shimada, M. & Tsuneyoshi, M. (2003) Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod Pathol, 16,1019–27. Albini, A., Melchiori, A., Garofalo, A., Noonan, D. M., Basolo, F., Taraboletti, G., Chader, G. J. & Gavazzi, R. (1992) Matrigel promotes retinoblastoma cell growth in vitro and in vivo. Int J Cancer, 52,234–40. Aoudjit, F. & Vuori, K. (2001) Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene, 20,4995–5004.
6 Extracellular Matrix and Drug Resistance
129
Attwell, S., Roskelley, C. & Dedhar, S. (2000) The integrin-linked kinase (ILK) suppresses anoikis. Oncogene, 19,3811–5. Baumgartner, G., Gomar-Hoss, C., Sakr, L., Ulsperger, E. & Wogritsch, C. (1998) The impact of extracellular matrix on the chemoresistance of solid tumors–experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett, 131,85–99. Beckenlehner, K., Bannke, S., Spruss, T., Bernhardt, G., Schonenberg, H. & Schiess, W. (1992) Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J Cancer Res Clin Oncol, 118,591–6. Bergamaschi, A., Tagliabue, E., Sorlie, T., Naume, B., Triulzi, T., Orlandi, R., Russnes, H. G., Nesland, J. M., Tammi, R., Auvinen, P., Kosma, V. M., Menard, S. & Borresen-Dale, A. L. (2008) Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol, 214,357–67. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sugarbaker, D. J. & Meyerson, M. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 98,13790–5. Bonomi, P. (2002) Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol, 29,78–86. Boonstra, J. (2003) Progression through the G1-phase of the on-going cell cycle. J Cell Biochem, 90,244–52. Bunn, P. A., JR. & Carney, D. N. (1997) Overview of chemotherapy for small cell lung cancer. Semin Oncol, 24,S7-69–S7-74. Calalb, M. B., Polte, T. R. & Hanks, S. K. (1995) Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol, 15,954–63. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S. & Reed, J. C. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science, 282,1318–21. Chin, D., Boyle, G. M., Williams, R. M., Ferguson, K., Pandeya, N., Pedley, J., Campbell, C. M., Theile, D. R., Parsons, P. G. & Coman, W. B. (2005) Novel markers for poor prognosis in head and neck cancer. Int J Cancer, 113,789–97. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. & Deeley, R. G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258,1650–4. Cordes, N. (2004) Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Res, 64,5683–92. Cordes, N., Seidler, J., Durzok, R., Geinitz, H. & Brakebusch, C. (2006) beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene, 25,1378–90. Dai, D. L., Makretsov, N., Campos, E. I., Huang, C., Zhou, Y., Huntsman, D., Martinka, M. & Li, G. (2003) Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res, 9,4409–14. Damiano, J. S., Hazlehurst, L. A. & Dalton, W. S. (2001) Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia, 15, 1232–9. Datta, A., Shi, Q. & Boettiger, D. E. (2001) Transformation of chicken embryo fibroblasts by v-src uncouples beta1 integrin-mediated outside-in but not inside-out signaling. Mol Cell Biol, 21,7295–306. De Jong, S., Zijlstra, J. G., De Vries, E. G. & Mulder, N. H. (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res, 50,304–9.
130
P.S. Hodkinson and T. Sethi
Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J. & Dedhar, S. (1998) Phosphoinositide3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A, 95,11211–6. Desoize, B. & Jardillier, J. (2000) Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol, 36,193–207. Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev, 12,3499–511. Dunty, J. M., Gabarra-Niecko, V., King, M. L., Ceccarelli, D. F., Eck, M. J. & Schaller, M. D. (2004) FERM domain interaction promotes FAK signaling. Mol Cell Biol, 24,5353–68. Duxbury, M. S., Ito, H., Benoit, E., Waseem, T., Ashley, S. W. & Whang, E. E. (2005) RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res, 11,3433–8. Duxbury, M. S., Ito, H., Benoit, E., Zinner, M. J., Ashley, S. W. & Whang, E. E. (2003) RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun, 311,786–92. Estrugo, D., Fischer, A., Hess, F., Scherthan, H., Belka, C. & Cordes, N. (2007) Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One, 2,e269. Fresno Vara, J. A., Casado, E., De Castro, J., Cejas, P., Belda-Iniesta, C. & gonzalez-Baron, M. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev, 30,193–204. Fridman, R., Giaccone, G., Kanemoto, T., Martin, G. R., Gazdar, A. F. & Mulshine, J. L. (1990) Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A, 87,6698–702. Fridman, R., Sweeney, T. M., Zain, M., Martin, G. R. & Kleinman, H. K. (1992) Malignant transformation of NIH-3T3 cells after subcutaneous co-injection with a reconstituted basement membrane (matrigel). Int J Cancer, 51,740–4. Frisch, S. M. & Francis, H. (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol, 124,619–26. Frisch, S. M., Vuori, K., Ruoslahti, E. & Chan-Hui, P. Y. (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol, 134,793–9. Geiger, B., Bershadsky, A., Pankov, R. & Yamada, K. M. (2001) Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. Nat Rev Mol Cell Biol, 2,793–805. Gladson, C. L., Wilcox, J. N., Sanders, L., Gillespie, G. Y. & Cheresh, D. A. (1995) Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci, 108 ( Pt 3),947–56. Goodman, L. S., Wintrobe, M. M., Dameshek, W., Goodman, M. J., Gilman, A. & Mclennan, M. T. (1984) Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(betachloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. Jama, 251,2255–61. Goto, S., Ihara, Y., Urata, Y., Izumi, S., Abe, K., Koji, T. & Kondo, T. (2001) Doxorubicininduced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. Faseb J, 15, 2702–14. Graff, J. R., Deddens, J. A., Konicek, B. W., Colligan, B. M., Hurst, B. M., Carter, H. W. & Carter, J. H. (2001) Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res, 7,1987–91. Grigioni, W. F., Garbisa, S., D’errico, A., Baccarini, P., Stetler-Stevenson, W. G., Liotta, L. A. & Mancini, A. M. (1991) Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol, 138,647–54. Halder, J., Landen, C. N., JR., Lutgendorf, S. K., Li, Y., Jennings, N. B., Fan, D., Nelkin, G. M., Schmandt, R., Schaller, M. D. & Sood, A. K. (2005) Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res, 11,8829–36.
6 Extracellular Matrix and Drug Resistance
131
Hanks, S. K., Ryzhova, L., Shin, N. Y. & Brabek, J. (2003) Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci, 8,d982–96. Hannigan, G. E., Leung-Hagesteijn, C., Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, J. C. & Dedhar, S. (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature, 379,91–6. Hannun, Y. A. (1997) Apoptosis and the dilemma of cancer chemotherapy. Blood, 89,1845–53. Hauck, C. R., Hsia, D. A., Puente, X. S., Cheresh, D. A. & Schlaepfer, D. D. (2002) FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. Embo J, 21,6289–302. Hazelbag, S., Kenter, G. G., Gorter, A., Dreef, E. J., Koopman, L. A., Violette, S. M., Weinreb, P. H. & Fleuren, G. J. (2007) Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol, 212,316–24. Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J. & Dalton, W. S. (2000) Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 19,4319–27. Hazlehurst, L. A., Valkov, N., Wisner, L., Storey, J. A., Boulware, D., Sullivan, D. M. & Dalton, W. S. (2001) Reduction in drug-induced DNA double-strand breaks associated with beta1 integrinmediated adhesion correlates with drug resistance in U937 cells. Blood, 98,1897–903. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8,193–204. Hildebrand, J. D., Schaller, M. D. & parsons, J. T. (1993) Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions. J Cell Biol, 123,993–1005. Hodkinson, P. S., Elliott, T., Wong, W. S., Rintoul, R. C., Mackinnon, A. C., Haslett, C. & Sethi, T. (2006) ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ, 13,1776–88. Hoyt, D. G., Rizzo, M., Gerritsen, M. E., Pitt, B. R. & Lazo, J. S. (1997) Integrin activation protects pulmonary endothelial cells from the genotoxic effects of bleomycin. Am J Physiol, 273, L612–7. Humphries, M. J. (2000) Integrin structure. Biochem Soc Trans, 28,311–39. Hynes, R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell, 110,673–87. Iozzo, R. V. (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem, 67,609–52. Jayne, D. G., Heath, R. M., Dewhurst, O., Scott, N. & Guillou, P. J. (2002) Extracellular matrix proteins and chemoradiotherapy: alpha5beta1 integrin as a predictive marker in rectal cancer. Eur J Surg Oncol, 28,30–6. Joensuu, H. (2008) Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol, 9,304. Kartner, N., Riordan, J. R. & Ling, V. (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science, 221,1285–8. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. Embo J, 16,2783–93. Klinghoffer, R. A., Sachsenmaier, C., Cooper, J. A. & Soriano, P. (1999) Src family kinases are required for integrin but not PDGFR signal transduction. Embo J, 18,2459–71. Lad, Y., Mchugh, B., Hodkinson, P. S., Mackinnon, A. C., Haslett, C., Ginsberg, M. H. & Sethi, T. (2006) Phospholipase C epsilon suppresses integrin activation. J Biol Chem, 281,29501–12. Lage, H., Helmbach, H., Dietel, M. & Schadendorf, D. (2000) Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer, 82,488–91. Lally, B. E., Urbanic, J. J., Blackstock, A. W., Miller, A. A. & Perry, M. C. (2007) Small cell lung cancer: have we made any progress over the last 25 years? Oncologist, 12,1096–104.
132
P.S. Hodkinson and T. Sethi
Legate, K. R., Montanez, E., Kudlacek, O. & Fassler, R. (2006) Ilk, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol, 7,20–31. Lein, M., Jung, K., Ortel, B., Stephan, C., Rothaug, W., Juchem, R., Johannsen, M., Deger, S., Schnorr, D., Loening, S. & Krell, H. W. (2002) The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene, 21,2089–96. Lin, C. Q. & Bissell, M. J. (1993) Multi-faceted regulation of cell differentiation by extracellular matrix. Faseb J, 7,737–43. Lotem, J. & Sachs, L. (1992) Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood, 80,1750–7. Lozonschi, L., Sunamura, M., Kobari, M., Egawa, S., Ding, L. & Matsuno, S. (1999) Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res, 59,1252–8. Lundell, B. I., Mccarthy, J. B., Kovach, N. L. & Verfaillie, C. M. (1996) Activation-dependent alpha5beta1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells. Blood, 87,2450–8. Luscinskas, F. W. & Lawler, J. (1994) Integrins as dynamic regulators of vascular function. Faseb J, 8,929–38. Lynch, D. K., Ellis, C. A., Edwards, P. A. & Hiles, I. D. (1999) Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene, 18,8024–32. Mclean, G. W., Brown, K., Arbuckle, M. I., Wyke, A. W., Pikkarainen, T., Ruoslahti, E. & Frame, M. C. (2001) Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis. Cancer Res, 61,8385–9. Mettouchi, A. & Meneguzzi, G. (2006) Distinct roles of beta1 integrins during angiogenesis. Eur J Cell Biol, 85,243–7. Michael, M., Babic, B., Khokha, R., Tsao, M., Ho, J., Pintilie, M., Leco, K., Chamberlain, D. & Shepherd, F. A. (1999) Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol, 17,1802–8. Mizejewski, G. J. (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med, 222,124–38. Molina, J. R., Adjei, A. A. & Jett, J. R. (2006) Advances in chemotherapy of non-small cell lung cancer. Chest, 130,1211–9. Moschos, S. J., Drogowski, L. M., Reppert, S. L. & Kirkwood, J. M. (2007) Integrins and cancer. Oncology (Williston Park), 21,13–20. Mueller, M. M. (2006) Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer, 42,735–44. Naglich, J. G., Jure-Kunkel, M., Gupta, E., Fargnoli, J., Henderson, A. J., Lewin, A. C., Talbott, R., Baxter, A., Bird, J., Savopoulos, R., Wills, R., Kramer, R. A. & Trail, P. A. (2001) Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res, 61,8480–5. Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J. & Jain, R. K. (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res, 60,2497–503. Nikolopoulos, S. N. & Turner, C. E. (2001) Integrin-linked kinase (ILK) binding to paxillin LD1 motif regulates ILK localization to focal adhesions. J Biol Chem, 276,23499–505. Nikolopoulos, S. N. & Turner, C. E. (2002) Molecular dissection of actopaxin-integrin-linked kinase-Paxillin interactions and their role in subcellular localization. J Biol Chem, 277, 1568–75. Oshita, F., Kameda, Y., Ikehara, M., Tanaka, G., Yamada, K., Nomura, I., Noda, K., Shotsu, A., Fujita, A., Arai, H., Ito, H., Nakayama, H. & Mitsuda, A. (2002) Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res, 22,1065–70. Osterlind, K. (2001) Chemotherapy in small cell lung cancer. Eur Respir J, 18,1026–43.
6 Extracellular Matrix and Drug Resistance
133
Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J. & Bissell, M. J. (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res, 66,1526–35. Passaniti, A., Isaacs, J. T., Haney, J. A., Adler, S. W., Cujdik, T. J., Long, P. V. & Kleinman, H. K. (1992) Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J Cancer, 51,318–24. Pogany, G., Timar, F., Olah, J., Harisi, R., Polony, G., Paku, S., Bocsi, J., Jeney, A. & Laurie, G. W. (2001) Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology, 60,274–81. Polte, T. R. & Hanks, S. K. (1995) Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Proc Natl Acad Sci U S A, 92,10678–82. Rintoul, R. C. & Sethi, T. (2001) The role of extracellular matrix in small-cell lung cancer. Lancet Oncol, 2,437–42. Rozengurt, E. (1999) Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin Oncol, 11,116–22. Sakai, T., Li, S., Docheva, D., Grashoff, C., Sakai, K., Kostka, G., Braun, A., Pfeifer, A., Yurchenco, P. D. & Fassler, R. (2003) Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev, 17,926–40. Savarese, D. M., Hsieh, C. & Stewart, F. M. (1997) Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol, 15,2981–95. Schaller, M. D. (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta, 1540,1–21. Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B. & Parsons, J. T. (1992) pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A, 89,5192–6. Schaller, M. D., Hildebrand, J. D., Shannon, J. D., Fox, J. W., Vines, R. R. & Parsons, J. T. (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol, 14,1680–8. Schlaepfer, D. D., Hanks, S. K., Hunter, T. & VAN DER Geer, P. (1994) Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 372,786–91. Schwartz, G. K. & Shah, M. A. (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol, 23,9408–21. Sethi, T., Rintoul, R. C., Moore, S. M., Mackinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R. & Haslett, C. (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med, 5,662–8. Shepherd, F. A., Giaccone, G., Seymour, L., Debruyne, C., Bezjak, A., Hirsh, V., Smylie, M., Rubin, S., Martins, H., Lamont, A., Krzakowski, M., Sadura, A. & Zee, B. (2002) Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol, 20,4434–9. Sherman-Baust, C. A., Weeraratna, A. T., Rangel, L. B., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T. & Morin, P. J. (2003) Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell, 3,377–86. Shin, S. I., Freedman, V. H., Risser, R. & Pollack, R. (1975) Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A, 72,4435–9. Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H. & Schlaepfer, D. D. (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol, 2,249–56.
134
P.S. Hodkinson and T. Sethi
Sixt, M., Bauer, M., Lammermann, T. & Fassler, R. (2006) Beta1 integrins: zip codes and signaling relay for blood cells. Curr Opin Cell Biol, 18,482–90. Smith, K. J., Skelton, H. G., Turiansky, G. & Wagner, K. F. (1997) Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi’s sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol, 36,239–42. Spruss, T., Bernhardt, G., Schonenberger, H. & Schiess, W. (1995) Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol, 121,193–202. Sun, H., Lesche, R., Li, D. M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X. & Wu, H. (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A, 96,6199–204. Tannock, I. F. (2001) Tumor physiology and drug resistance. Cancer Metastasis Rev, 20,123–32. Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S. & Egorin, M. J. (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res, 8,878–84. Taylor, S. T., Hickman, J. A. & Dive, C. (2000) Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst, 92,18–23. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W. & Frei, E., 3RD (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 247,1457–61. Tian, B., Lessan, K., Kahm, J., Kleidon, J. & Henke, C. (2002) beta 1 integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3kinase/Akt/protein kinase B signaling pathway. J Biol Chem, 277,24667–75. Troussard, A. A., Costello, P., Yoganathan, T. N., Kumagai, S., Roskelley, C. D. & Dedhar, S. (2000) The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene, 19, 5444–52. Troussard, A. A., Tan, C., Yoganathan, T. N. & Dedhar, S. (1999) Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol Cell Biol, 19,7420–7. Tu, Y., Li, F., Goicoechea, S. & Wu, C. (1999) The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol, 19,2425–34. Uhm, J. H., Dooley, N. P., Kyritsis, A. P., Rao, J. S. & Gladson, C. L. (1999) Vitronectin, a gliomaderived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res, 5,1587–94. Van Nimwegen, M. J., Huigsloot, M., Camier, A., Tijdens, I. B. & Van De Water, B. (2006) Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol, 70,1330–9. Van Nimwegen, M. J., Verkoeijen, S., Van Buren, L., Burg, D. & Van De Water, B. (2005) Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res, 65,4698–706. Van Riet, I., De Greef, C., Del Favero, H., Demanet, C. & Van Camp, B. (1994) Production of fibronectin and adherence to fibronectin by human myeloma cell lines. Br J Haematol, 87, 258–65. Velling, T., Nilsson, S., Stefansson, A. & Johansson, S. (2004) beta1-Integrins induce phosphorylation of Akt on serine 473 independently of focal adhesion kinase and Src family kinases. EMBO Rep, 5,901–5. Vidal, A. & Koff, A. (2000) Cell-cycle inhibitors: three families united by a common cause. Gene, 247,1–15.
6 Extracellular Matrix and Drug Resistance
135
Vukicevic, S., Somogyi, L., Martinovic, I., Zic, R., Kleinman, H. K. & Marusic, M. (1992) Reconstituted basement membrane (Matrigel) promotes the survival and influences the growth of murine tumors. Int J Cancer, 50,791–5. White, D. E., Cardiff, R. D., Dedhar, S. & Muller, W. J. (2001) Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene, 20,7064–72. Woo, R. A. & Poon, R. Y. (2003) Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle, 2,316–24. Wozniak, M. A., Modzelewska, K., Kwong, L. & Keely, P. J. (2004) Focal adhesion regulation of cell behavior. Biochim Biophys Acta, 1692,103–19. Xia, H., Nho, R. S., Kahm, J., Kleidon, J. & Henke, C. A. (2004) Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem, 279,33024–34. Yao, E. S., Zhang, H., Chen, Y. Y., Lee, B., Chew, K., Moore, D. & Park, C. (2007) Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res, 67,659–64. Yeoh, E. J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., Cheng, C., Campana, D., Wilkins, D., Zhou, X., Li, J., Liu, H., Pui, C. H., Evans, W. E., Naeve, C., Wong, L. & Downing, J. R. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, 1,133–43. Ylisirnio, S., Hoyhtya, M. & Turpeenniemi-Hujanen, T. (2000) Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer–TIMP-1 as a prognostic marker. Anticancer Res, 20,1311–6. Younes, M. N., Kim, S., Yigitbasi, O. G., Mandal, M., Jasser, S. A., Dakak Yazici, Y., Schiff, B. A., EL-Naggar, A., Bekele, B. N., Mills, G. B. & Myers, J. N. (2005) Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther, 4,1146–56. Zaidel-Bar, R., Cohen, M., Addadi, L. & Geiger, B. (2004) Hierarchical assembly of cell-matrix adhesion complexes. Biochem Soc Trans, 32,416–20. Zhang, H., Ozaki, I., Mizuta, T., Matsuhashi, S., Yoshimura, T., Hisatomi, A., Tadano, J., Sakai, T. & Yamamoto, K. (2002) Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer, 95, 896–906. Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M. H. & Hung, M. C. (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol, 3,245–52.
Chapter 7
Oxidative Stress and Drug Resistance in Cancer Dunyaporn Trachootham, Wan Zhang, and Peng Huang
Abstract Increased generation of reactive oxygen species (ROS) is observed in many types of cancer cells. Besides the well-recognized effect of ROS in causing mutations and promoting cancer cell growth, recent evidence further suggests the involvement of oxidative stress in anticancer drug resistance. Consistent with the tumor-promoting effect of ROS, many in vitro studies have reported tumorsuppressing properties of ROS-scavenging enzymes. However, enhancement of those enzymes in tumor cells in vivo has been implicated in chemoresistance and seems to be associated with poor prognosis. In this chapter, we summarized the relevant observations in the field and discuss evidences that may explain these seemingly paradoxical findings. Malignant transformation is often associated with a moderate increase in cellular ROS content as a result of evelvated ROS production and/or decreased ROS-scavenging capacity. Because the increase in ROS stress may induce oxidative damage of cellular components leading to cell dea